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OXIDATIVE METABOLISM AND CALCIUM HANDLING IN HUNTINGTON’S DISEASE 
 Huntington’s disease (HD) is an autosomal dominantly inherited, fatal 
neurodegenerative disorder for which there is no cure. HD is clinically characterized by 
progressively worsening motor, cognitive, and psychiatric disturbances. Currently 
available therapeutics for HD only treat symptoms, but do not address underlying 
disease pathology. HD pathogenesis is linked to a mutation in the huntingtin gene, which 
encodes a protein called huntingtin (Htt) that is normally involved in a variety of cellular 
processes. In healthy individuals, the N-terminus of huntingtin possesses a 
polyglutamine stretch containing less than 35 glutamines, however, the mutated 
huntingtin protein (mHtt) has an elongated polyglutamine tract that correlates with the 
development of HD. The mechanism of deleterious action by mHtt is unknown, but a 
major hypothesis postulates that mHtt may cause mitochondrial dysfunction. However, 
the data regarding involvement of mitochondrial impairment in HD pathology are 
contradictory. Some investigators previously reported, for example, that mHtt 
suppresses mitochondrial respiratory activity and decreases mitochondrial Ca2+ uptake 
capacity. However, other investigators found increased respiratory activity and 
augmented mitochondrial Ca2+ uptake capacity.  
   We used transgenic mouse models of HD to investigate the effect of full-length 
and fragments of mHtt on oxidative metabolism and Ca2+ handling using a combination 
of isolated mitochondria, primary neurons, and whole-animal metabolic measurements.  
We evaluated the effect of full-length mHtt on isolated mitochondria and primary neurons 
from YAC128 mice. We found no alteration in respiratory activity or Ca2+ uptake 
capacity, indicative of mitochondrial damage, between mitochondria or neurons from  
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YAC128 mice compared to wild-type (WT) mice. Furthermore, we measured whole-
animal oxidative metabolism and physical activity level and found that YAC128 mice do 
not display any decline in metabolic and physical activity. Although full-length mHtt-
expressing YAC128 mice may be a more faithful genetic recapitulation of HD, data 
suggests mHtt fragments may be more toxic. To assess the effect of mHtt fragments, we 
used isolated brain mitochondria and primary striatal neurons from the R6/2 mouse 
model and found no significant impairment in respiration or Ca2+ handling. Thus, our 
data strongly support the hypothesis that mHtt does not alter mitochondrial functions 
assessed either with isolated mitochondria, primary neurons, or whole animals.  
 
 Nickolay Brustovetsky, Ph.D., Chair 
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I. Introduction 
A. Huntington’s Disease 
Huntington’s disease (HD) was first described in detail by George Huntington in 
1872, lending his name to the eponymous disease. Huntington, a 22-year-old physician 
living in Long Island, NY at the time of publication of his seminal report, “On Chorea”, 
had aggregated not only his own clinical observations but those of his father and 
grandfather, also physicians, to generate the most concise and clinically accurate 
account of the disease to that point. Although written descriptions of the disease predate 
Huntington’s account, his was the first to describe the hereditary nature and 
comprehensively discuss symptoms of HD (Huntington 1872;Roos 2010). Indeed, the 
most discerning symptom of HD is the abrupt, irregular, spontaneous, and uncontrolled 
movements described as chorea. In addition to motor symptoms, psychiatric 
disturbances and cognitive abnormalities are the two other components of a classically 
evoked triad of symptoms which are commonly used to describe the overt presentation 
of the disease (Bates et al. 2015). Specific psychiatric aberrations associated with HD 
include personality changes, anxiety, and depression and cognitive impairments are 
most commonly marked by a decline in abstract thinking and loss of executive function. 
Recent evidence suggests that alterations in mental state and cognition may precede 
onset of motor symptoms, leading to the designation of the so-called prodromal stage of 
HD. The stage of HD that is typically referred to as symptomatic HD is characterized by 
the initiation of motor symptoms. Memory loss also manifests as the disease advances 
(Govert and Schneider 2013). By virtue of the progressive nature of HD, patients will 
gradually lose the ability to perform the most basic of tasks, including walking, talking, 
swallowing, and ultimately the ability to take care of themselves. Complications from 
some of these diminished capabilities are life-threatening. The most common cause of 
death for HD patients is complications from aspiration pneumonia, due to difficulty or 
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inability to swallow food, drink, and sputum (Haines and Conneally 1986;Bates et al. 
2002;Heemskerk and Roos 2012). 
Huntington’s disease is an autosomal dominantly inherited neurodegenerative 
disorder affecting approximately 1 in 10,000 people, with variable incidence among 
different ethnic groups (Shoulson and Young 2011;Pringsheim et al. 2012). Among 
individuals of European ancestry the prevalence rate is estimated to be 11-14 per 
100,000 people, whereas some east Asian populations have a prevalence rate of only 1 
per 100,000 (Roos 2010;Bates et al. 2015). In the United States, it is estimated that 
30,000 individuals have manifest HD (Shoulson and Young 2011). Approximations of HD 
prevalence are generally considered to be underestimates due to the late onset of the 
disease and resultant inaccurately low rate of diagnosis among young, asymptomatic 
individuals (Bates et al. 2015). Commencement of motor symptoms typically occurs at 
midlife, with an average age of onset of 38 years (Govert and Schneider 2013). 
However, the age of motor symptom onset varies widely, with symptom onset recorded 
to have occurred as early as 2 years and as late as 80 years of age (Myers 2004). 
Historically, the term “manifest HD” was used to indicate the period of HD at which motor 
symptoms become apparent, and it was believed that the onset of chorea represented 
the earliest symptoms of HD. Although not solely confined to the context of Huntington’s 
disease, “chorea” is the term frequently used to describe the irregular, abrupt, 
spontaneous, and involuntary movements associated with HD. More recently, however, 
it has been shown that measurable but only slightly perceptible cognitive, motor, and 
psychiatric changes precede the onset of overt motor symptoms (Biglan et al. 
2009;Biglan 2010). This finding led to a change in the naming convention to describe HD 
symptom progression. Currently, “prodromal HD” is considered the stage of the disease 
at which subtle changes in cognition or psychiatric state can be measured before the 
onset of manifest motor symptoms (Reilmann et al. 2014). 
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Since HD can be definitively diagnosed with a genetic test and symptom 
progression is delayed, the potential exists for pre-symptomatic therapy. However, the 
treatments currently in use only act to mitigate symptoms, but do not address underlying 
causes of neuropathology. The dearth of disease-modifying therapeutics may be 
partially due to an incomplete understanding of the mechanisms of neuronal dysfunction 
and death in HD. Currently, the only FDA-approved treatment for HD is tetrabenazine 
(TBZ), which is indicated for the treatment of chorea associated with HD (Kaur et al. 
2016). TBZ is an inhibitor of vesicular monoamine transferase 2 (VMAT2), preventing 
the reuptake of monoamines into intracellular vesicles and effectively hindering the 
release of dopamine (Zheng et al. 2006). Unfortunately, the adverse effects of TBZ 
administration can be severe with side effects including insomnia, fatigue, akathisia, 
anxiety, and increased suicidal ideation (Chen et al. 2012). Moreover, the beneficial 
effect of TBZ may decline over time (Fasano and Bentivoglio 2009). Thus, the 
development of new therapies for treating and curing HD borne from a deeper 
understanding of the molecular mechanisms of disease is critical for individuals suffering 
with HD. 
Degeneration associated with HD is localized to the brain. The brain region that 
is most vulnerable to the effects of the disease is the striatum, and the most salient 
symptoms of HD have been correlated with and are consistent with striatal loss 
(Vonsattel and DiFiglia 1998;Bates et al. 2002;Walker and Raymond 2004). At more 
advanced stages of the disease, cortical loss has also been observed, but cortical 
pathology occurs to a lesser extent than striatal loss (Rosas et al. 2003). Diminution of 
striatal volume has been detected before symptom onset via magnetic resonance 
imaging, and in some cases striatal volume loss has been observed up to 10 years 
before the onset of motor symptoms (Rosas et al. 2003;Aylward et al. 2013). The 
mechanism by which striatal neurons are differentially vulnerable is unclear. Comprising 
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about 95% of all neurons in the striatum are the gamma-aminobutyric acid (GABA)ergic 
medium spiny neurons (MSNs) (Vonsattel and DiFiglia 1998;Han et al. 2010). MSNs, the 
major inhibitory neurons of the striatum, are the most vulnerable and earliest affected 
cell type in HD (Reiner et al. 1988;Walker and Raymond 2004;Ehrlich 2012). The 
mechanism of increased vulnerability of MSNs in HD is not clear, but may include an 
inherently lower metabolic activity of MSNs. (Nishino et al. 2000).  
In 1993, a consortium called the Huntington’s Disease Collaborative Research 
Group found that HD is linked to a gene that had previously only been known as IT15 
(“interesting transcript 15”) (MacDonald et al. 1993). Prior to this discovery, researchers 
had merely managed to identify the chromosome upon which the gene resided using 
genetic linkage (Bird et al. 1986). Following the study by MacDonald et al., the gene was 
renamed huntingtin (HTT) and found to be located on the p arm of chromosome 4 at 
position 16.3 (MacDonald et al. 1993). In most healthy individuals HTT contains a stretch 
of 16-20 CAG repeats encoding a poly-glutamine (polyQ) stretch near the NH2 terminus 
of the huntingtin protein (Htt). However, a lower percentage of healthy individuals may 
have slightly longer CAG repeat tracts of 21-26 repeats. An expansion mutation in HTT 
leading to the elongation of the CAG repeat tract to more than 35 repeats will result in 
HD with 100% penetrance. Individuals who possess a CAG stretch in the HTT gene of 
27-34 repeats have a possibility of developing HD, but the likelihood is less than 100% 
(Myers 2004;Paulson and Albin 2011). Such individuals, even if they do not develop 
symptoms of HD, are still at risk of passing HD to their offspring, especially if the 
expansion is being passed from the father (Ridley et al. 1988;Ashizawa et al. 1994). The 
mechanism for this increased likelihood of a father passing an expansion that could lead 
to HD remains unresolved, but may be related to instability of the CAG repeat during 
spermatogenesis (Wheeler et al. 2007). If the HTT gene is expanded to possess greater 
than 35 repeats, the resultant pathogenic protein product is dubbed mutant huntingtin 
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(mHtt) (MacDonald et al. 1993). Genetic anticipation has been observed in HD, possibly 
due to increased genetic instability during replication as the expanded CAG tract 
becomes longer (Bates et al. 2002). Greater number of repeats has been correlated with 
earlier age of onset of motor symptoms and more severe symptom progression (Roze et 
al. 2010). 
 
a. Huntingtin Protein Function 
HTT encodes a 350 kDa protein, called huntingtin (Htt), that is ubiquitously 
expressed throughout all tissues (MacDonald et al. 1993). Wild-type (WT) Htt is localized 
to the cytoplasm and loosely associated with the outer mitochondrial membrane since 
the protein can be removed from the membrane just by washing mitochondria with NaCl 
(Sharp et al. 1995). The protein possesses a polyQ stretch of varying length near the N-
terminus (Zuccato et al. 2010). The wild-type Htt protein has a polyQ stretch that is not 
more than 35 glutamines, but is typically only 16-20 glutamines in most humans 
(MacDonald et al. 1993). Although wild-type Htt is known to be expressed ubiquitously, it 
is most highly expressed in neurons of the central nervous systems (CNS) (Sharp et al. 
1995). However, the level of expression of wild-type Htt does not differ between various 
regions of the brain nor is Htt more highly expressed in MSNs, the most vulnerable cell 
type in HD (Sharp et al. 1995;Schilling et al. 1995). Moreover, the level of wild-type Htt 
expression is not correlated with vulnerability to HD (Trottier et al. 1995;Fusco et al. 
1999). 
Htt expression is essential for development and lack of Htt results in embryonic 
lethality (DiFiglia et al. 1995). Without Htt expression, the developing embryo cannot 
undergo proper gastrulation (Woda et al. 2005). A later study indicated that the mutated 
form of Htt, mHtt, is alone sufficient to mediate proper embryonic development. Leavitt et 
al. demonstrated that introducing mHtt to an endogenous Htt knock-out precludes 
6 
embryonic lethality, indicating that at least some of the normal functions of Htt are 
retained by mHtt (Leavitt et al. 2001). Another study using Cre/loxP excision strategy to 
conditionally inactivate Htt in adult mice resulted in the acquisition of motor deficits 
similar to those seen in HD mice as well as cerebral atrophy in these mice (Reddy et al. 
1999;Dragatsis et al. 2000). These studies not only indicate that Htt is critical for 
embryonic development and maintenance of neuronal viability, but also suggest that the 
expanded polyQ mutation in mHtt does not necessarily eliminate normal protein 
functions inherent to wild-type Htt.  
Since Htt is a large protein of 350 kDa with several functional domains, it has the 
capacity to be involved in numerous processes and functions. The best-described 
functions of Htt include regulation of brain derived neurotrophic factor (BDNF) production 
(Zuccato et al. 2001;Gauthier et al. 2004), vesicle transport (Brandstaetter et al. 2014), 
endocytosis (Velier et al. 1998), transcriptional regulation (Li and Li 2004), and anti-
apoptotic function (Rigamonti et al. 2000).   
Wild-type Htt is known to interact with over 100 proteins, primarily facilitated by 
the presence of 36 HEAT (huntingtin, elongation factor 3, protein phosphatase 2A, and 
TOR1) consensus sequences, each about 40 amino acids in length, within Htt (Neuwald 
and Hirano 2000). These domains mediate interactions with proteins that are involved in 
various processes including pre- and post-synaptic signaling, cytoskeletal organization, 
calcium signaling, and mitochondrial functions (Shirasaki et al. 2012). The strength of 
interaction of Htt with some proteins has been observed to be dependent on polyQ 
length. Indeed, certain proteins interact more strongly with either Htt or mHtt (Harjes and 
Wanker 2003;Li and Li 2004). Among the many hypotheses regarding the effect of the 
expanded polyQ in mHtt is the proposition that the expansion mutation may promote 
interaction with a different suite of binding partners thus leading to either the loss of 
7 
certain functions, the gaining of new functions, or both. Some groups have reported that 
both gain- and loss-of-function are involved in HD pathology (Zuccato et al. 2010). 
Although Htt does not have a DNA binding domain that would allow direct binding 
to nucleic acids, it does interact with proteins that are known to bind to DNA. Thus wild-
type Htt has the capacity to influence transcription (Cha 2007). Mutant Htt was found to 
bind p53 and increase its expression and transcriptional activity, leading to the 
upregulation of certain nuclear-encoded mitochondrial proteins and altered membrane 
potential (Bae et al. 2005). Additionally, mHtt has been shown to repress transcription of 
PGC-1α, a gene encoding a transcriptional co-activator that regulates expression for 
genes involved in mitochondrial respiration and mitochondrial biogenesis (Cui et al. 
2006). Moreover, the knock-out of PGC-1α in mice results in mitochondrial defects, 
altered motor functions, and striatal degeneration (Cui et al. 2006). These findings 
suggest that Htt and mHtt are involved in the regulation of mitochondrial functions. 
 
b. Models of HD 
Prior to the discovery of the genetic mutation linked to HD, researchers relied on 
chemical models to study HD. Use of such models was justified by the observation that 
certain neurotoxins recapitulated the striatal degeneration that is the hallmark of HD 
pathology (McGeer and McGeer 1976). Compounds used in these early studies could be 
categorized into one of two categories: excitotoxic chemicals and mitochondrial toxins. 
Quinolinic acid and kainic acid, compounds responsible for inducing excitotoxicity, when 
injected into the brains of mice caused striatal lesions that were reminiscent of the 
atrophy observed in HD patients (Beal et al. 1986). Inhibitors of Complex II of the 
mitochondrial electron transport chain such as malonic acid and 3-nitropropionic acid 
were likewise used to generate chemical models of HD because, when administered to 
mice, these toxins produced striatal lesions and motor disturbances similar to HD 
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patients (Borlongan et al. 1995;Brouillet et al. 1999). Although these chemicals produced 
HD-like motor disturbances and striatal degeneration, they only served as an 
approximation of disease pathology because they neglected to account for the genetic 
underpinnings of the disease. However, these models provide some insight into potential 
deleterious mechanisms in HD because they served as some of the first pieces of 
evidence to indicate that HD pathology may be linked to either abnormal cytosolic Ca2+ 
dynamics or mitochondrial dysfunction (McGeer and McGeer 1976;Borlongan et al. 
1995). However, such extrapolations should be made with caution because the 
mechanisms that underlie chemically induced motor abnormalities and striatal loss could 
be distinct from the mechanisms involved in HD pathology. 
Following the identification of the mutation linked to HD, the first rodent models of 
HD were developed based on genetic manipulation of the HTT gene (Ramaswamy et al. 
2007;Pouladi et al. 2013). The genetic rodent models of HD that express an elongated 
polyQ stretch can be broadly classified into three categories with respect to the 
characteristics of the protein expression in each: (i) N-terminal (polyQ-containing) 
truncated fragment of human mutant Htt; (ii) full-length human mutant Htt protein; and 
(iii) full-length mouse mutant Htt protein. Table 1 summarizes the three types of HD 
rodent models, citing specific examples, and provides detail about relevant findings from 
each model.  
One of the first genetic mouse models of HD to be generated was the R6/2 
mouse, which expresses an N-terminal fragment of human mHtt with an expanded 
polyQ region (Mangiarini et al. 1996). The R6/2 mice are notable for their accelerated 
symptom progression, which results in a more severe phenotype that afflicts mice at a 
younger age compared to full-length mHtt models (Ramaswamy et al. 2007). Though not 
the most genetically accurate models, N-terminal fragment-expressing mice are used by 
researchers to study HD symptom progression or the potential mechanisms of fragment-
9 
induced HD pathology. Mice such as the YAC128 model express full-length human mHtt 
and are considered a more accurate genetic representation of the human disease due to 
the presence of a motor and cognitive phenotype. YAC128 mice exhibit neuronal 
degeneration and motor deficits similar to fragment HD models albeit on a more 
protracted time course (Slow et al. 2003). A shared caveat for all transgenic mouse 
models, whether expressing full-length or fragment of human mHtt, is that they possess 
more than two alleles of Htt or mHtt. In addition to endogenous mouse Htt gene, the 
human mHtt transgene (which in some cases has integrated multiple times into the 
genome) is expressed. Obviously, this is a departure from the genetics of human HD 
patients who typically have one normal copy of HTT and one mutant copy.  
Models of HD that have an expanded CAG repeat introduced into normal 
endogenous mouse HTT (so-called “knock-in models”) are considered the most 
genetically faithful representation of the genetics of human disease. The mutant protein 
is expressed in every tissue and has been observed in both the cytosolic and nuclear 
compartments (Menalled 2005). However, these models possess a very mild disease 
phenotype, typically live the full lifespan of a normal mouse, and, in some cases, striatal 
atrophy never occurs (Wheeler et al. 1999;Wheeler et al. 2000). For these reasons, 
knock-in models have received only tepid attention from many researchers because 
these models may not closely recapitulate the symptoms and pathology of the disease. 
The selection of a rodent model for the study of disease mechanisms in HD requires 
pensive consideration to choose the best model based on which aspects of the disease 
are to be investigated.  
In the initial studies described herein, the YAC128 mouse model was used to 
assess various aspects of mitochondrial function and Ca2+ handling in neurons. As the 
name suggests, this model takes advantage of a yeast artificial chromosome (YAC) to 
allow for expression of the relatively large human mutant HTT gene in its entirety. The 
10 
full-length human mutant HTT gene expressed by this mouse possesses a 128 CAG 
repeat expansion with the gene under control of human HTT promoter as well as 
upstream and downstream cis-regulatory elements (Slow et al. 2003). Mutant Htt is 
expressed in all tissues of the mouse where full-length protein is localized to the cytosol, 
and fragments of mHtt reside in both the cytosol and nucleus (Slow et al. 2003). Full-
length mHtt transgenic models typically display delayed symptom onset, allowing for the 
study of HD mechanisms in pre-symptomatic animals. This advantage provides 
researchers with the opportunity to investigate the primary causes of disease without the 
potentially confounding impediment of studying animals that already display an HD 
phenotype (Fan and Raymond 2007). The YAC128 mouse was developed as an 
improvement upon previous YAC models that had shorter polyQ stretches (Hodgson et 
al. 1999). The longer glutamine expansion leads to a decrease in the age at which motor 
phenotypes are first observed, making these animals more convenient for use in some 
studies. The correlation between increased polyQ length and decreased age of symptom 
development is also a characteristic of the human disease (Roze et al. 2010). In 
YAC128 mice, motor symptoms are visible by 12 weeks and significant striatal atrophy 
can be observed by 9 months (Bates et al. 2002;Slow et al. 2003;Ramaswamy et al. 
2007). These findings indicate that striatal loss may not be necessary for the onset of 
motor symptoms, and may suggest that neuronal dysfunction occurs well before striatal 
atrophy. The YAC128 model was initially chosen for use in this study because, although 
it is not the most genetically faithful model, it does express full-length human mHtt and it 
displays motor symptoms and striatal atrophy, unlike many knock-in models. 
Additionally, the slowed progression of symptom onset in YAC128 mice compared to 
R6/2 mice, a mHtt fragment model, allows for the pre-symptomatic study of adult 
animals.  
11 
The R6/2 mouse model is one of the first-developed and the most well-studied 
mHtt fragment transgenic mouse model of HD (Mangiarini et al. 1996). In contrast to full-
length mHtt models, such as YAC128, these mice express the N-terminal fragment of 
human mHtt with a 144-glutamine stretch. The fragment contains only exon 1 of the 
human HTT gene in addition to the human HTT promoter (Mangiarini et al. 1996). In this 
model, mHtt is expressed in all tissues and the protein has been observed in the 
cytoplasm as well as the nucleus (Sathasivam et al. 2010). R6/2 mice display overt and 
severe behavioral abnormalities by 6 weeks and significant striatal atrophy can be 
observed by 11 weeks (Stack et al. 2005). Whereas full-length transgenic mouse models 
can live for more than one year, the average lifespan of R6/2 mice is only about 13 
weeks (Mangiarini et al. 1996;Van Raamsdonk et al. 2006). The large number of repeats 
in the R6/2 model corresponds to juvenile onset HD, which only occurs in about 10% of 
human cases, but this model provides an opportunity for researchers to assess the 
potential deleterious effect of mHtt fragments (Mangiarini et al. 1996;Nance and Myers 
2001). In our study, symptomatic 6- to 8-week-old R6/2 mice were utilized to probe the 
effect of mHtt fragments on the pathogenesis of HD.    
In addition to mouse models, other animals have been used as HD models, 
including rats, song birds, pigs, sheep, and non-human primates (Yang et al. 
2008;Jacobsen et al. 2010;Yang et al. 2010;Yu-Taeger et al. 2012). Cell lines that model 
HD have also been generated. One of the most commonly used cell lines is derived from 
knock-in mice that possess a 111 glutamine stretch (Trettel et al. 2000). These aptly 
named STHdhQ111/Q111, conditionally immortalized, striatal progenitor cells have been 
used to study oxidative metabolism and Ca2+ handling and display phenotypes 
reminiscent of primary striatal neurons from knock-in mice, including increased 
propensity to cell death (Trettel et al. 2000;Gines et al. 2003;Milakovic et al. 2006). 
12 
 
Ta
bl
e 
1:
 G
en
et
ic
 R
od
en
t H
D
 M
od
el
s 
R
od
en
t M
od
el
 
C
on
st
ru
ct
 
N
ot
ab
le
 F
ea
tu
re
s 
Tr
an
sg
en
ic
 tr
un
ca
te
d 
N
-te
rm
in
al
 fr
ag
m
en
t m
od
el
s 
Tr
an
sg
en
ic
 R
6/
2 
m
ic
e 
(M
an
gi
ar
in
i e
t a
l.,
 1
99
6)
 
N
-te
rm
in
al
 fr
ag
m
en
t (
67
 a
a)
 o
f h
um
an
 
H
TT
 w
ith
 1
15
-1
50
 o
r 1
95
 C
A
G
 re
pe
at
s 
N
eu
ro
na
l a
tro
ph
y 
by
 3
 m
on
th
s 
(S
ta
ck
 e
t a
l.,
 2
00
5)
 
D
ea
th
 a
t 1
0-
13
 w
ee
ks
 (M
an
gi
ar
in
i e
t a
l.,
 1
99
6)
 
D
ec
re
as
ed
 re
sp
ira
to
ry
 ra
te
s 
in
 s
tri
at
al
 
ho
m
og
en
at
e 
(A
id
t e
t a
l.,
 2
01
3)
 
A
ug
m
en
te
d 
C
a2
+  u
pt
ak
e 
ca
pa
ci
ty
 in
 b
ra
in
 
no
ns
yn
ap
tic
 m
ito
ch
on
dr
ia
 (O
liv
ei
ra
 e
t a
l.,
 2
00
7)
 
Tr
an
sg
en
ic
 N
17
1-
82
Q
 
m
ic
e 
(S
ch
ill
in
g 
et
 a
l.,
 1
99
9)
 
N
-te
rm
in
al
 fr
ag
m
en
t (
17
1,
 1
18
, o
r 5
86
 
aa
) o
f h
um
an
 H
TT
 w
ith
 8
2 
C
A
G
 re
pe
at
s 
N
eu
ro
na
l a
tro
ph
y 
by
 1
6 
w
ee
ks
 (M
cB
rid
e 
et
 a
l.,
 
20
06
) 
Tr
an
sg
en
ic
 D
9-
N
17
1-
98
Q
 
m
ic
e,
 a
ls
o 
kn
ow
n 
as
 D
E
5 
m
ic
e 
(B
ro
w
n 
et
 a
l.,
 2
00
8)
 
N
-te
rm
in
al
 fr
ag
m
en
t o
f h
um
an
 H
TT
 w
ith
 
98
 C
A
G
 re
pe
at
s 
ex
pr
es
se
d 
on
ly
 in
 
m
ed
iu
m
 s
pi
ny
 n
eu
ro
ns
 o
f t
he
 s
tri
at
um
 
N
o 
st
ria
ta
l a
tro
ph
y 
(K
im
 e
t a
l.,
 2
01
1)
 
M
ild
 m
ot
or
 a
bn
or
m
al
iti
es
 (B
ro
w
n 
et
 a
l.,
 2
00
8)
 
Tr
an
sg
en
ic
 S
ho
rt 
S
to
p 
m
ic
e 
(S
lo
w
 e
t a
l.,
 2
00
5)
  
N
-te
rm
in
al
 fr
ag
m
en
t (
17
1 
aa
) o
f h
um
an
 
H
TT
 w
ith
 1
28
 C
A
G
 re
pe
at
s 
P
re
se
nc
e 
of
 m
H
tt 
ag
gr
eg
at
es
; 
N
o 
be
ha
vi
or
al
 d
ys
fu
nc
tio
n 
or
 n
eu
ro
na
l l
os
s 
(S
lo
w
 
et
 a
l.,
 2
00
5)
 
Tr
an
sg
en
ic
 H
D
 ra
ts
 (v
on
 
H
or
st
en
 e
t a
l.,
 2
00
3)
 
E
xp
re
ss
 7
27
 a
m
in
o 
ac
id
s 
of
 th
e 
H
TT
51
Q
 
ge
ne
, c
or
re
sp
on
di
ng
 to
 2
2%
 o
f t
he
 fu
ll-
le
ng
th
 g
en
e 
R
ed
uc
ed
 m
ito
ch
on
dr
ia
l m
em
br
an
e 
po
te
nt
ia
l 
st
ab
ili
ty
 in
 re
sp
on
se
 to
 C
a2
+ , 
de
cr
ea
se
d 
C
a2
+  
up
ta
ke
 c
ap
ac
ity
, i
nc
re
as
ed
 p
ro
pe
ns
ity
 to
 P
TP
 
in
du
ct
io
n 
(G
el
le
ric
h 
et
 a
l.,
 2
00
8)
 
Tr
an
sg
en
ic
 fu
ll-
le
ng
th
 m
od
el
s 
Tr
an
sg
en
ic
 B
A
C
H
D
 m
ic
e 
(G
ra
y 
et
 a
l.,
 2
00
8)
 
Fu
ll-
le
ng
th
 h
um
an
 H
TT
 g
en
e 
w
ith
 9
7 
m
ix
ed
 C
A
A
-C
A
G
 re
pe
at
s 
S
tri
at
al
 a
tro
ph
y 
by
 1
2 
m
on
th
s 
S
ym
pt
om
s 
by
 6
 m
on
th
s 
(G
ra
y 
et
 a
l.,
 2
00
8)
 
D
ec
re
as
e 
in
 m
ax
im
al
 re
sp
ira
to
ry
 c
ap
ac
ity
 o
f 
pr
im
ar
y 
ne
ur
on
s 
(G
ou
ar
ne
 e
t a
l.,
 2
01
3)
 
Tr
an
sg
en
ic
 Y
A
C
46
 o
r 
Y
A
C
72
 m
ic
e 
(H
od
gs
on
 e
t 
al
., 
19
99
) 
Fu
ll-
le
ng
th
 h
um
an
 H
TT
 g
en
e 
w
ith
 4
6 
or
 
72
 C
A
G
 re
pe
at
s 
D
ec
re
as
ed
 C
a2
+  u
pt
ak
e 
ca
pa
ci
ty
 (P
an
ov
 e
t a
l.,
 
20
02
) 
 
13 
 
  
Ta
bl
e 
1:
 G
en
et
ic
 R
od
en
t H
D
 M
od
el
s 
(c
on
tin
ue
d)
 
R
od
en
t M
od
el
 
C
on
st
ru
ct
 
N
ot
ab
le
 F
ea
tu
re
s 
Tr
an
sg
en
ic
 Y
A
C
12
8 
m
ic
e 
(S
lo
w
 e
t a
l.,
 2
00
3)
 
Fu
ll-
le
ng
th
 h
um
an
 H
TT
 g
en
e 
w
ith
 1
28
 
C
A
G
 re
pe
at
s 
N
eu
ro
na
l a
tro
ph
y 
by
 9
 m
on
th
s 
(S
lo
w
 e
t a
l.,
 2
00
3)
 
A
ug
m
en
te
d 
m
ito
ch
on
dr
ia
l d
ep
ol
ar
iz
at
io
n 
in
 
re
sp
on
se
 to
 e
ne
rg
y-
de
m
an
di
ng
 s
tim
ul
i i
n 
m
ed
iu
m
 
sp
in
y 
ne
ur
on
s 
(F
er
na
nd
es
 e
t a
l.,
 2
00
7)
 
A
ug
m
en
te
d 
C
a2
+  u
pt
ak
e 
ca
pa
ci
ty
 in
 b
ra
in
 
no
ns
yn
ap
tic
 m
ito
ch
on
dr
ia
 (O
liv
ei
ra
 e
t a
l.,
 2
00
7)
 
Tr
an
sg
en
ic
 B
A
C
H
D
 ra
ts
 
(Y
u-
Ta
eg
er
 e
t a
l.,
 2
01
2)
 
Fu
ll-
le
ng
th
 h
um
an
 H
TT
 g
en
e 
w
ith
 9
7 
m
ix
ed
 C
A
A
-C
A
G
 re
pe
at
s 
E
ar
ly
 o
ns
et
 m
ot
or
 d
ef
ic
its
 
m
H
tt 
ag
gr
eg
at
es
 (Y
u-
Ta
eg
er
 e
t a
l.,
 2
01
2)
 
K
no
ck
-in
 fu
ll-
le
ng
th
 m
od
el
s 
K
no
ck
-in
 H
dh
Q
50
, Q
92
, 
an
d 
Q
11
1 
m
ic
e 
(W
he
el
er
 
et
 a
l.,
 1
99
9)
 
M
ou
se
 H
TT
 g
en
e 
w
ith
 in
se
rte
d 
50
, 9
2,
 o
r 
11
1 
C
A
G
 re
pe
at
s 
in
 e
xo
n 
1 
N
o 
st
ria
ta
l d
eg
en
er
at
io
n 
(W
he
el
er
 e
t a
l.,
 1
99
9)
 
N
o 
co
gn
iti
ve
 p
he
no
ty
pe
s 
(W
he
el
er
 e
t a
l.,
 2
00
0)
 
G
ai
t a
bn
or
m
al
iti
es
 a
t 2
4 
m
on
th
s 
in
 Q
11
1 
(W
he
el
er
 
et
 a
l.,
 2
00
0)
 
N
o 
ch
an
ge
 in
 th
e 
ac
tiv
iti
es
 o
f m
ito
ch
on
dr
ia
l 
co
m
pl
ex
es
 I-
IV
 (M
ila
ko
vi
c 
an
d 
Jo
hn
so
n,
 2
00
5)
 
K
no
ck
-in
 H
dh
15
0Q
 a
nd
 
H
dh
q2
00
 m
ic
e 
(L
in
 e
t a
l.,
 
20
01
; Y
u 
et
 a
l.,
 2
00
3)
 
M
ou
se
 H
TT
 g
en
e 
w
ith
 in
se
rte
d 
15
0 
an
d 
20
0 
C
A
G
 re
pe
at
s 
in
 e
xo
n 
1 
in
 a
 s
in
gl
e 
al
le
le
 (H
dh
15
0/
+ )
 o
r b
ot
h 
al
le
le
s 
(H
dh
15
0/
15
0 )
 
N
o 
co
gn
iti
ve
 s
ym
pt
om
s 
R
es
pi
ra
to
ry
 a
ct
iv
ity
 o
f s
tri
at
al
 n
eu
ro
ns
 fr
om
 
H
dh
15
0Q
 is
 s
im
ila
r t
o 
W
T 
(O
liv
ei
ra
 e
t a
l.,
 2
00
7)
 
N
o 
ch
an
ge
 in
 C
a2
+  u
pt
ak
e 
ca
pa
ci
ty
 in
 b
ra
in
 
no
ns
yn
ap
tic
 m
ito
ch
on
dr
ia
 (O
liv
ei
ra
 e
t a
l.,
 2
00
7)
 
 
14 
c. Proposed Mechanisms of Neurodegeneration in HD 
Huntingtin is a protein composed of over 3100 amino acids and has a molecular 
weight of 350 kDa (MacDonald et al. 1993). It has been observed to interact with a large 
number of proteins, potentially interfering with a wide array of cellular functions. For this 
reason, the mutation of huntingtin could potentially affect different processes by either 
causing loss of certain normal Htt functions or leading to the acquisition of new functions 
by mHtt. These dichotomic components, gain-of-function and loss-of-function alterations, 
are not necessarily mutually exclusive, but form the foundation by which hypotheses are 
generated regarding the mechanisms of mHtt effects in HD. Therefore, the overall 
pathology of HD may be the result of a convergence of many deleteriously altered 
cellular mechanisms. Although this dissertation focuses on the possible effects of mHtt 
on mitochondrial functions, other hypotheses provide alternative explanations for HD 
pathogenesis. Some of these alternative hypotheses will be briefly described below.  
Although mHtt does not possess a DNA binding domain, it has been shown to 
interact with transcription factors and indirectly influence transcription (Zuccato et al., 
2010). Reports indicate that both WT and mHtt are cleaved into N-terminal fragments by 
caspases, and fragments of mHtt have been found in the nucleus (Warby et al. 2008). 
Initial studies suggesting that mHtt may interfere with transcriptional regulation showed 
the direct binding of mHtt with transcription factors cAMP-responsive element (CRE) 
binding protein (CREB) and with TATA box-binding protein (TBP)-associated factor 
TAF4/TAFII130, thereby altering transcription (Steffan et al. 2000;Dunah et al. 
2002;Shimohata et al. 2005). Additionally, evidence suggests that mHtt interacts with the 
peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α), which is 
involved in regulation of mitochondrial functions such as mitochondrial biogenesis, 
respiration, energy metabolism, and thermogenesis (Houten and Auwerx 2004). Data 
show that PGC-1α expression is reduced in various models of HD (Cui et al. 2006). 
15 
Moreover, exogenous expression of PGC-1α protects primary striatal neurons derived 
from HD models and direct delivery of PGC-1α into the striatum of HD mice decreases 
striatal atrophy (Cui et al. 2006). The modes by which the polyQ stretch of mHtt may 
precipitate transcriptional dysregulation may include binding to transcription factors or 
other coactivators and preventing their normal function (Cha 2007). Indeed, altered 
localization of mHtt may mediate this process since mHtt has shown increased nuclear 
localization compared to WT Htt, which is primarily a cytosolic protein (Kegel et al. 
2002;Sugars and Rubinsztein 2003).      
Another potential consequence of alterations in transcription induced by mHtt 
could be a decrease of brain-derived neurotrophic factor (BDNF) expression in the 
brains of HD patients. Medium spiny neurons (MSNs) of the striatum depend on the 
production and release of BDNF by the cerebral cortex for survival (Baquet et al. 2004). 
Previous studies have established that cortical BDNF is decreased about 50% in brains 
from HD patients and it has been proposed that the loss of BDNF at MSNs may be a 
contributor to striatal degeneration in HD (Zuccato and Cattaneo 2007;Zuccato and 
Cattaneo 2009). Additional quantitative studies using brains from postmortem HD 
patients have indicated that not only BDNF protein, but also BDNF mRNA levels are 
decreased in the cortex of patients (Zuccato et al. 2008). Likewise, a decrease in BDNF 
levels has been reported in the brains of various mouse models of HD and the 
overexpression of BDNF is neuroprotective in a model of HD (Zuccato and Cattaneo 
2009;Kells et al. 2004). The mechanism leading to decreased BDNF production may 
involve changes in the localization of a protein complex, REST/NRSF, when mHtt is 
expressed. Wild-type Htt interacts with REST/NRSF as part of a cytosolic complex; 
however, mHtt is unable to form this complex, allowing for translocation of REST/NRSF, 
a silencing factor, to the nucleus (Zuccato et al. 2007). Once in the nucleus, 
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REST/NRSF interacts with a silencer element in the promoter of the gene encoding 
BDNF, leading to a decrease in transcription (Zuccato et al. 2003). 
Alterations in autophagy have been proposed to contribute to HD pathogenesis. 
The purpose of autophagy is to promote cell survival by recycling cell components. 
During this process, the components of the cytosol are degraded in bulk by being first 
engulfed by a double membrane bound structure called an autophagosome, then 
degraded through fusion of the autophagosomes with lysosomes (Menzies et al. 2017). 
Impairment of autophagy could lead to potentially harmful buildup of free mHtt and mHtt 
aggregates, possibly contributing to cell death (Ventruti and Cuervo 2007). 
Administration of chemicals to induce autophagy or overexpression of genes involved in 
autophagy enhances mHtt clearance and improves HD behavior phenotype (Ravikumar 
et al. 2004;Jia et al. 2007). Conversely, inhibition of the autophagosome/lysosomal 
pathway increases mHtt levels in cells and increases cellular toxicity (Ravikumar et al. 
2002). Early studies using the postmortem brains of HD patients showed an increase in 
autophagosome-like structures in neurons of patients compared to neurons from the 
brains of controls, suggesting that autophagy may actually be enhanced in HD (Petersen 
et al. 2001;Qin et al. 2003). However, more recent findings suggest that the increased 
generation of autophagosomes may be due to an inability of autophagosomes to 
properly recognize and load cytosolic cargo in HD cells (Martinez-Vicente et al. 2010). 
Both Htt and mHtt are subject to proteolytic cleavage by caspases, including 
caspases-2, 3, 6, and 7 (Goldberg et al. 1996). This discovery lead to the development 
of the toxic fragment hypothesis, which suggests that cleavage of mHtt produces polyQ 
containing N-terminal fragments of the protein that may be more toxic than full-length 
mHtt (Wellington et al. 2000;Wellington et al. 2002). Evidence to support this assertion is 
derived from experiments showing that inhibition of caspase-mediated mHtt cleavage 
can ameliorate symptoms of HD in mouse models and the observation that mHtt 
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fragment models of HD have an accelerated and more severe symptom progression 
(Mangiarini et al. 1996;Chen et al. 2000;Graham et al. 2006). Mutant Htt fragments exert 
deleterious effect by having a higher propensity for aggregation compared to Htt. The 
extent of mHtt aggregation is dependent on the length of the fragment and the length of 
the polyQ tract (Chen et al. 2002). Additionally, accumulation of these polyQ-containing 
fragments may drive further caspase activity, ultimately leading to cell death (Goldberg 
et al. 1996).  
Aggregates of mHtt have been found in both human brains from postmortem HD 
patients and brains from mouse models of HD (DiFiglia et al. 1997;Davies et al. 1997). In 
humans, aggregates have been found in neurons of the striatum and have been 
observed to occur more frequently in neurons from juvenile patients, suggesting that the 
increased number of aggregates correlates with an accelerated disease progression 
(DiFiglia et al. 1997). Aggregates have been found both in the nucleus and in the 
cytosol, with the aggregates within the nucleus containing most the NH2 terminus 
fragment of mHtt, whereas cytosolic aggregates contain both full-length and truncated 
mHtt as well as Htt (Cooper et al. 1998). The harmful effects of mHtt aggregation may 
stem from either the ability of aggregates to bind to and prevent the normal function of 
other nearby proteins or the difficulty they present to cellular machinery responsible for 
the degradation and clearance of the aggregates from the cell (Tydlacka et al. 
2008;Bates et al. 2015). An alternative hypothesis suggests that aggregates may 
actually be beneficial to mHtt-expressing cells by reducing the levels of free mHtt, thus 
decreasing neuronal death (Arrasate et al. 2004). Additional research is required to more 
fully explore the effect of mHtt aggregation in HD pathology and the role of fragments in 
this process.  
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B. Mitochondrial Dysfunction in HD 
In addition to the putative detrimental mechanisms described above, there are 
numerous reports suggesting that mitochondrial bioenergetic deficiency and 
mitochondrial Ca2+ handling defects may be important contributors to neuronal 
dysfunction in HD. However, there is also growing body of evidence indicating the lack of 
direct detrimental effect of mHtt on mitochondrial functions. Thus, despite numerous 
studies, the effect of mHtt on oxidative metabolism and mitochondrial Ca2+ handling 
remains controversial. Indeed, a previous study using electron microscopy to view 
immunolabeled mHtt demonstrated the presence of mHtt at the outer membrane, but not 
inside of mitochondria (Orr et al. 2008). Additionally, immunoblotting studies with 
isolated mitochondria probed for mHtt and Htt show that both mutant and WT protein are 
lost from the mitochondrial fraction following treatment with trypsin or alkaline conditions 
(Pellman et al. 2015). Despite the loss of mHtt and Htt in these experiments, treated 
mitochondria show no loss of matrix, IMM, or intermembrane space proteins (Pellman et 
al. 2015). Therefore, since mHtt cannot access the inner compartments of mitochondria 
the mechanism by which mHtt may induce mitochondrial dysfunction, if it exists, remains 
unclear. In the following sections is a description of the current experimental data 
regarding the role of mHtt in oxidative metabolism and mitochondrial Ca2+ handling. 
In many previous studies, assessment of mitochondrial dysfunction has involved 
the use of isolated brain mitochondria to evaluate respiration, membrane potential, Ca2+ 
uptake, and combinations thereof (Oliveira 2010a;Oliveira 2010b). Major mitochondrial 
functions include generation of ATP through oxidative phosphorylation, of elevated 
cytosolic Ca2+ due to Ca2+ influx into mitochondria mediated by mitochondrial calcium 
uniporter (MCU), generation of reactive oxygen species (ROS), and regulation of 
apoptosis (Lehninger et al. 1993;Wang and Youle 2009). Figure 1 highlights the basic 
molecular components of oxidative phosphorylation and mitochondrial Ca2+ uptake. 
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Through the oxidation of pyruvate and malate, the Complex I substrates, or succinate, 
the Complex II substrate, electrons are donated to the electron transport chain (ETC). 
Transport of electrons is coupled to the transfer of protons from the mitochondrial matrix 
to the intermembrane space, generating electrical membrane potential (negative inside) 
and a chemical gradient of protons (more alkaline inside) across the inner mitochondrial 
membrane. Protons may then return to the mitochondrial matrix through ATP synthase, 
generating ATP at the expense of membrane potential and proton gradient (Mitchell 
1961). Additionally, Ca2+ is taken into the mitochondrial matrix through the MCU in a 
process that is driven by membrane potential (Pan et al. 2013). Accumulation of Ca2+ by 
mitochondria is limited by induction of the permeability transition pore (PTP), a 
nonspecific pore of still debatable molecular composition whose induction leads to 
mitochondrial depolarization, Ca2+ release from mitochondria, and swelling of the 
organelles (Bernardi et al. 1999).  
In isolated mitochondria, these processes can be evaluated by measuring 
mitochondrial respiration, Ca2+ uptake capacity, and membrane potential. In our study, 
we routinely measured mitochondrial respiration, mitochondrial membrane potential, and 
Ca2+ uptake capacity of mitochondria from HD and WT mice.  Measurements of 
respiration and membrane potential can be done simultaneously or separately using 
tightly closed, thermostated chamber equipped with Clark-type oxygen electrode and 
tetraphenylphopshonium (TPP+)-sensitive electrode. TPP+ is a hydrophobic cation that 
easily crosses mitochondrial inner membrane according to membrane potential. 
Measurements of TPP+ concentration outside of mitochondria ([TPP+]ext) allow for 
assessment of the amount of TPP+ accumulated in mitochondria, which is indicative of 
membrane potential: the more TPP+ that is accumulated, the higher the membrane 
potential. A typical experiment with isolated mitochondria (Fig. 2) includes the 
measurements of respiration in the presence of only oxidative substrates (e.g. pyruvate 
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plus malate), called State 2 respiration, which is accompanied by generation of high 
membrane potential and denoted “V2” (Brand and Nicholls 2011;Brustovetsky and 
Brustovetsky 2017). Adding ADP to mitochondria leads to transient depolarization and 
an increased respiratory rate as ADP is converted to ATP in the process of oxidative 
phosphorylation (State 3, V3). This ADP-stimulated respiratory rate allows for 
assessment of the activity of the oxidative phosphorylation system. After all added ADP 
is consumed, respiration spontaneously reverts to a slower rate called State 4 (V4) and 
simultaneously high membrane potential is restored. The rate of respiration under these 
conditions is determined predominately by proton leaks across the inner mitochondrial 
membrane, which could be used to evaluate mitochondrial damage. The addition of 2,4-
dinitrophenol (2,4-DNP), a molecule that increases proton permeability of the inner 
membrane and uncouples oxidative phosphorylation, strongly depolarizes mitochondria 
and induces the maximal respiratory rate, which is denoted “VDNP”. The maximal 
respiratory rate allows assessment of ETC activity.  
Analysis of Ca2+ uptake capacity is achieved by administering Ca2+ pulses to 
mitochondria while tracking the Ca2+ concentration in the external medium ([Ca2+]ext) 
outside of mitochondria. Eventually, the permeability transition pore will be induced, 
mitochondrial will be depolarized and unable to accumulate additional Ca2+, and 
previously accumulated Ca2+ will be released from mitochondria (Bernardi et al. 1999).           
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Figure 1. Electron Transport Chain (ETC), ATP Synthase, and Mitochondrial 
Calcium Uniporter. Electrons from the substrates pyruvate and malate (pyr, mal, 
respectively) enter the ETC through Complex I (CI), whereas the substrate succinate 
(succ) provides electrons through Complex II (CII). Electrons are then transferred 
through Complexes III and IV (CIII, CIV, respectively). Transport of electrons is coupled 
to proton extrusion, generating an electrochemical proton gradient across the inner 
mitochondrial membrane. Protons passing through ATP Synthase (ATP Syn) drive ATP 
generation. Ca2+ is transported into the mitochondrial matrix through the mitochondrial 
calcium uniporter (MCU) at the expense of membrane potential.    
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Figure 2. Representative measurements of respiration (blue trace) and 
mitochondrial membrane potential (red trace) in isolated synaptic mitochondria.  
Where indicated, 50 µg mitochondria (Mito), 300 µM ADP, and 60 µM 2,4-dinitrophenol 
(2,4-DNP) were added to the chamber. Respiration and membrane potential were 
measured simultaneously. Respiration was measured with a Clark-type oxygen 
electrode. Membrane potential was monitored by following distribution of 
tetraphenylphosphonium (TPP+) across the inner mitochondrial membrane with TPP+-
sensitive electrode. Prior to addition of mitochondria, five pulses of 30 µM TPP+ were 
added to the chamber to calibrate the system for later membrane potential calculations. 
The incubation medium contained 125 mM KCl, 3 mM KH2PO4, 0.5 mM MgCl2, 3 mM 
pyruvate, 1 mM malate,10 mM Hepes, pH 7.4, 10 µM EGTA, 0.1% BSA (free from fatty 
acids). The measurements were performed under continuous stirring at 37ºC in a 0.4 mL 
chamber. (From: Brustovetsky, N., and Brustovetsky, T. Monitoring of permeability 
transition pore in isolated individual brain mitochondria. Stefan Strack and Yuriy M. 
Usachev (eds.), Techniques to Investigate Mitochondrial Function in Neurons, 
Neuromethods, Humana Press, vol. 123, 199-210, 2017)  
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a. Defects in Oxidative Metabolism  
In early papers concerning HD-associated alterations in bioenergetics, even 
before the discovery of the mutation in Htt, investigators reported some defects in 
mitochondrial respiratory activity. In postmortem brain tissues from HD patients, 
decreased respiratory activity of caudate mitochondria was found (Brennan, Jr. et al. 
1985), and defects in mitochondrial Complexes II, III, and IV were described (Gu et al. 
1996;Browne et al. 1997). However, it was not obvious whether these respiratory defects 
contributed to HD pathogenesis or if they were a result of the late stage of HD pathology. 
To resolve this issue, various experimental models of HD have been developed and 
utilized in search of a mechanistic link between mutation in Htt and HD pathology 
(Pouladi et al. 2013). The effects of mHtt on oxidative metabolism have been examined 
with polyglutamine–glutathione S-transferase (polyQ-GST) fusion proteins as surrogates 
for mHtt (Puranam et al. 2006;Rockabrand et al. 2007), with cell models expressing mHtt 
(Trettel et al. 2000) as well as with numerous HD rodent models that express full-length 
or fragments of endogenous or human mHtt with different lengths of polyQ stretch (Heng 
et al. 2007;Ramaswamy et al. 2007). 
 
i. Evidence Supporting Oxidative Metabolism Defects in HD 
 The polyQ-GST fusion proteins were generated and tested in experiments with 
isolated mitochondria from wild-type (WT) animals. In experiments with Q62-GST fusion 
protein applied to liver mitochondria isolated from WT mice, investigators found a slight 
inhibition of ADP-stimulated respiration, but no inhibition of respiratory Complexes, ATP 
synthase, or adenine nucleotide translocase (Puranam et al. 2006). Another mHtt 
substitute, GST-51Q exon 1 fusion protein, resulted in depolarization in isolated rat brain 
cortical mitochondria accompanied by a significant increase in oxygen consumption by 
the organelles, suggesting mitochondrial uncoupling but not inhibition of mitochondrial 
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respiratory Complexes (Rockabrand et al. 2007). Interestingly, in this study, GST-20 
exon 1 fusion protein with an unexpanded polyQ stretch produced similar effects, 
arguing against the role of an expanded polyQ stretch in the observed mitochondrial 
defects and suggesting non-polyQ dependent effects of the GST fusion proteins in this 
study. 
 The opportunities to investigate the effects of mHtt on cell physiology and 
biochemistry were significantly expanded with the advent of conditionally immortalized, 
mutant STHdhQ111/Q111 striatal neuronal progenitor cells (Trettel et al. 2000). Although 
Milakovic and Johnson observed reduced respiration and ATP production using these 
cells, they found no difference in activities of mitochondrial Complex I–IV in mutant 
STHdhQ111/Q111 cells compared with STHdhQ7/Q7 cells (Milakovic and Johnson 2005). The 
authors concluded that mHtt may impair mitochondrial bioenergetics via different 
mechanisms that do not directly affect respiratory Complexes. In line with this 
conclusion, Seong et al. found lower cellular ATP in STHdhQ111/Q111 cells compared with 
STHdhQ7/Q7 cells potentially indicating decreased energy production (Seong et al. 2005). 
The authors found inhibition of ADP uptake by mitochondria from mutant cells; however, 
activity of adenine nucleotide translocase that catalyzes ADP/ATP exchange across the 
inner membrane remained unchanged. Mitochondrial membrane potential was 
decreased whereas intracellular Ca2+ was elevated in mutant cells. The elevated 
intracellular Ca2+ was proposed to be responsible for inhibition of ADP transport into 
mitochondria. Indeed, inhibition of Ca2+ influx into STHdhQ111/Q111 cells with EGTA in the 
bath solution or NMDA receptor antagonist MK-801 significantly increased ATP/ADP 
ratio in these cells, suggesting improvement in ADP translocation into mitochondria 
(Seong et al. 2005). Recently, in experiments with STHdhQ111/Q111 cells, Siddiqui et al. 
found slightly reduced maximal respiratory activity without any difference in basal 
respiration (Siddiqui et al. 2012). The authors obtained a similar result with primary 
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cultures of HD diploid skin fibroblasts. Consistent with these findings, in experiments 
with heterozygous and homozygous STHdhQ111/Q7 and STHdhQ111/Q111 striatal neuronal 
progenitor cells, Napoli et al. found deficient oxidative phosphorylation and decreased 
Complex I and IV activities as well as a decrease in F0F1-ATPase activity (Napoli et al., 
2013). It has to be noted, however, that immortalized neuronal progenitor cells may differ 
functionally and morphologically from primary neurons and, therefore, mHtt effects on 
oxidative metabolism in these cells should be taken cautiously, especially, bearing in 
mind negative results produced in numerous experiments with primary neurons, brain 
slices, and whole HD animals.  
 In addition to experiments with polyQ-GST fusion proteins and immortalized 
neuronal progenitor cells, experiments with isolated mitochondria and cells in culture 
derived from HD animal models provided important information about the possible 
effects of mHtt on oxidative metabolism. Tabrizi et al., using biochemical assays, found a 
significant decrease in activities of Complex IV and aconitase in the striatum of R6/2 
mice (Tabrizi et al. 2000). In line with these findings, Bae et al., using the same 
methodology, reported decreased activity of Complex IV in striatum of N171-82Q 
transgenic mice (Bae et al. 2005). Later, Kim et al. found significant reduction in States 3 
and 4 respiration of succinate-fueled striatal mitochondria from pre-symptomatic 
transgenic D9-N171-98Q mice, also known as DE5 mice, compared with their age-
matched controls, suggesting Complex II impairment (Kim et al. 2011). On the other 
hand, Complex I and IV activities as well as activity of ATP synthase were not altered in 
the striatum of young and old DE5 mice compared with WT littermates. Interestingly, 
succinate-supported respiration in States 3 and 4 as well as maximal carbonylcyanide-p-
trifluorometh-oxyphenylhydrazone (FCCP)-stimulated respiration were found to be 
increased in symptomatic DE5 mice compared with pre-symptomatic animals (Kim et al. 
2011). Damiano et al. also reported defects in respiration of mitochondria isolated from 
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forebrains of N171-82Q transgenic mice (Damiano et al. 2013). With malate/glutamate 
(Complex I substrates) or succinate (Complex II substrate) supplemented with 
glutamate, ADP-stimulated respiration of mitochondria from 2–3-month-old N171-82Q 
transgenic mice was lower compared to respiration of mitochondria from control N171-
Q18 mice. Recently, Aidt et al. measured respiration of striatum homogenates from 12-
week-old R6/2 mice and found a slight but statistically significant decrease in Complex II 
and Complex IV flux control ratios defined as respiratory rates normalized to the 
maximal uncoupled respiration (Aidt et al. 2013). The authors interpreted these data as 
an indication of respiratory impairment in striatal mitochondria of R6/2 mice. However, 
how mHtt, a 350-kDa cytosolic protein that binds to the outer mitochondrial membrane 
but cannot cross it (Choo et al. 2004), impairs the respiratory chain in the inner 
mitochondrial membrane remains not completely understood. One possibility is that mHtt 
might decrease expression and/or mitochondrial import of proteins, involved in oxidative 
metabolism. Indeed, loss of Complex II activity was found in the postmortem striatum of 
HD patients and associated with a decreased expression of two subunits of Complex II, 
iron-sulfur subunit Ip (30 kDa) and FAD subunit Fp (70 kDa) (Benchoua et al. 2006). 
Similarly, Damiano et al. demonstrated preferential loss of Complex II in mitochondria 
isolated from forebrains of N171-82Q transgenic mice (Damiano et al. 2013). Recently, 
Yano et al. reported mHtt-mediated inhibition of mitochondrial protein import (Yano et al. 
2014). On the other hand, no decrease in Complex II levels (judged by the levels of 30- 
and 70-kDa subunits of Complex II) was found in brain mitochondria isolated from 
Hdh150Q knock-in mice (Orr et al. 2008) and in mitochondria of STHdhQ111/Q111 cells 
(Milakovic and Johnson 2005). Possible alterations in oxidative metabolism could 
decrease ATP production in cells expressing mHtt. Indeed, Lim et al. reported a 
significant decrease in ATP level in cortex of R6/1 mice compared with WT control (Lim 
et al. 2014). However, although in HD striatum is considered the most vulnerable region 
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of the brain (Zuccato et al. 2010), a decrease of ATP in striatum was much less 
pronounced and was not statistically significant suggesting ATP deficiency may not be 
involved in striatal degeneration (Lim et al. 2014).  
 
ii. Evidence Against Oxidative Metabolism Defects in HD 
In addition to studies reporting mHtt-induced impairment of oxidative metabolism, 
there are numerous studies that demonstrate the lack thereof. Trushina et al. discovered 
a reduction in mitochondrial motility due to sequestration of trafficking motor components 
by mHtt aggregates but did not find signs of mitochondrial dysfunction in striatal neurons 
derived from YAC72 mice (Trushina et al. 2004). Mitochondrial morphology was not 
altered in these neurons, and the levels of ATP and lactate (an indicator of glycolytic 
activity) were similar in neurons from WT and YAC72 mice. Olah et al. reported that the 
activities of Complexes I–IV in brain mitochondria from 20-week-old transgenic N171-
82Q mice were not decreased compared with mitochondria from WT animals (Olah et al. 
2008). Interestingly, the authors found that ATP levels in the homogenate of the 
posterior brain regions of N171-82Q mice were significantly higher than in brains from 
WT mice. In addition, the authors noticed an increased glycolytic rate in cytosolic 
extracts from brain tissue of N171-82Q mice (Olah et al. 2008). Based on these 
observations, the authors concluded that expression of the N-terminal fragment of mHtt 
is not accompanied by decreased activity of the mitochondrial respiratory chain or 
decline in glycolytic rate. Consistent with this, Guidetti et al. did not find any changes in 
mitochondrial electron transport through Complexes I–IV in the striatum and cerebral 
cortex of HD48 and HD89 mice, expressing full-length mHtt with either 48 or 89 Qs in 
polyQ stretches, compared with WT animals (Guidetti et al. 2001). Moreover, these 
investigators failed to find changes in the activity of Complexes I–IV in the neostriatum 
and cerebral cortex in pre-symptomatic and pathological grade 1 HD cases. Oliveira et 
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al. reported that respiration of cultured striatal neurons derived from heterozygous 
knock-in Hdh150/+ mice and their WT littermates was similar (Oliveira et al. 2007). Later, 
Gouarne et al. measured respiration of cultured striatal neurons from heterozygous 
transgenic BACHD rats and found no difference compared with WT neurons, when cells 
were incubated in the presence of 25 mM glucose and 1 mM pyruvate (Gouarne et al. 
2013). However, when neurons were incubated in a low-glucose (2.5 mM) medium, the 
authors observed a modest decrease in maximal, FCCP-stimulated respiration of mHtt-
expressing cells. Interestingly, this difference between mutant and WT cells was 
observed only with striatal but not cortical neurons. The authors proposed that mHtt 
expression results in a dysfunction in glycolysis that might precede defects in 
mitochondrial respiration (Gouarne et al. 2013). Yano et al. reported that respiration of 
synaptic and nonsynaptic mitochondria from forebrains of pre-symptomatic and mid-
stage disease R6/2 mice (the authors used two distinct R6/2 strains: 150 CAG R6/2 and 
195 CAG R6/2) was not different from that of mitochondria from WT littermates (Yano et 
al. 2014). Consistent with this, in a recent study with neurons and astrocytes from 
BACHD mice, Boussicault et al. found no evidence for direct effect of mHtt with 97 Qs on 
oxidative metabolism in these cells in vitro (Boussicault et al. 2014). In this study, mHtt 
did not affect the glycolytic rate in single cells as measured by FRET and did not 
decrease mitochondrial membrane potential in neurons assessed with fluorescent dye 
Rhodamine 123. Taken together, these data obtained with isolated mitochondria and 
cells in culture argue against mHtt-induced impairment of oxidative metabolism in animal 
models of HD.  
 In addition to isolated mitochondria and cells in culture, experiments with animal 
brain slices and whole animals in vivo provided further insights into the possible effect of 
mHtt on respiratory activity. Weydt et al. reported that oxygen consumption measured by 
indirect calorimetry of the whole animals was slightly increased in transgenic HD N171-
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82Q mice at baseline, especially during fasting (Weydt et al. 2006). The oxygen 
consumption rates (OCRs) in brain slices from 11-week-old, pre-symptomatic N171-82Q 
mice incubated with 20 mM glucose were similar. However, when brain slices were 
incubated with 5 mM lactate and 1 mM pyruvate, OCRs for HD slices were significantly 
lower (Weydt et al. 2006). Thus, the ability of lactate to be converted to pyruvate and 
subsequently undergo oxidative metabolism in the citric acid cycle appeared to be 
impaired in brains of N171-82Q mice. At the same time, respiration of brain slices fueled 
by succinate was normal, indicating no impairment of Complex II and the rest of 
respiratory chain. Goodman et al. reported that 8-week-old R6/2 mice had oxygen 
consumption, energy expenditure, and respiratory exchange ratio (RER, defined as CO2 
release rate/O2 consumption rate) similar to WT animals (Goodman et al. 2008). With 
14-week-old R6/2 mice, the authors found significantly increased oxygen consumption 
and energy expenditure, while RER was not significantly different. Van der Burg et al. 
found elevated oxygen consumption in 6- to 12-week-old R6/2 mice compared with WT 
littermates (van der Burg et al. 2008). In elegant in vivo experiments with magnetic 
resonance spectroscopy (31PMRS), Tkac et al. found no significant change in ATP 
concentration in the brain of knock-in Q111 mice (Tkac et al. 2012). ADP concentration 
was increased in brain of Q111 mice at 6 weeks but returned to nearly normal level at 13 
weeks. In R6/2 mice, however, these parameters remained normal (Tkac et al. 2012). 
The authors proposed that brain energy homeostasis in these HD mouse models is 
maintained from early ages until the pathological symptoms become apparent. Overall, 
these data argue against an overt inhibitory effect of mHtt on oxidative energy 
metabolism. 
 The experiments with cell and animal models generate important information 
about HD, but only studies with human tissues and HD patients provide an ultimate test 
of the hypotheses tested in animal studies. Severe reduction in the activity of 
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mitochondrial respiratory chain complexes was found in caudate/putamen from human 
postmortem brain tissue, suggesting that these abnormalities may underlie HD 
pathology (Brennan, Jr. et al. 1985;Gu et al. 1996;Browne et al. 1997). However, in vivo 
measurements of oxygen consumption and glucose metabolism with positron emission 
tomography in early-stage HD patients demonstrated that, while glucose consumption 
was somewhat reduced in striatum, its respiratory capacity was not significantly altered 
(Powers et al. 2007b). Consistent with this, the mid-stage HD patients do not show 
energy imbalance in vivo compared to age-matched healthy individuals as judged by 
indirect calorimetry in a human respiratory chamber (Gaba et al. 2005). Anecdotal 
evidence indicates that pre-symptomatic individuals who tested positive for the mutation 
in HTT do not experience any energy deficit and are able to, for example, participate in 
high-level athletic competition, supporting the lack of mHtt-triggered mitochondrial 
dysfunction. As an example, British rower Sarah Winckless, who carries the mutation in 
Htt, has competed in multiple Olympic games (English 2014). Turner et al. studied the 
respiratory chain function in skeletal muscle biopsies from HD patients and also failed to 
find a significant difference in the activities of Complexes I–IV compared with age-
matched controls (Turner et al. 2007). Powers et al. investigated platelet mitochondrial 
citrate synthase and Complex I and I/III activities in HD patients and found no difference 
compared with healthy controls, whereas striatal volume was already significantly 
reduced in patients with HD (Powers et al. 2007a). Because HD pathology was already 
manifested by striatal atrophy, the authors concluded that a deficit in energy production 
due to impairment of mitochondrial respiratory chain is not important for the mechanism 
of neuronal death in early HD. 
 Thus, the existing literature supports two different views on the interaction of 
mHtt with oxidative metabolism system. One group of investigators reports detrimental 
effects of mHtt on oxidative metabolism, whereas another group does not find evidence 
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for such effects. This contradiction limits our understanding of HD pathogenesis and 
impedes the development of new treatment approaches for HD. Consequently, this 
contradiction has to be resolved in order to provide explicit answers to the questions of 
whether mHtt results in defects in oxidative metabolism and whether these defects 
contribute to HD pathogenesis and therefore represent a valid target for the 
development of effective HD therapies. 
 
b. Defects in Mitochondrial Calcium Handling and Calcium Uptake 
 One of the main hypotheses regarding HD pathology postulates that expression 
of mHtt results in defects in Ca2+ signaling in neurons (Bezprozvanny and Hayden 2004) 
most likely due to augmented activity of NMDA subtype of ionotropic glutamate 
receptors (Zhang et al. 2008), abnormalities in IP3 receptor function (Tang et al. 2003), 
and aberrations in mitochondrial Ca2+ handling (Panov et al. 2002). The inner 
mitochondrial membrane has a Ca2+ channel (Baughman et al. 2011;De et al. 2011), 
historically called “the mitochondrial Ca2+ uniporter” (MCU) (Bernardi et al. 1999), that 
mediates Ca2+ influx into the mitochondrial matrix driven by large membrane potential 
(160-180 mV) negative inside of mitochondria. The magnitude of mitochondrial Ca2+ 
uptake capacity is restricted by the sensitivity of mitochondria to the damaging effect of 
Ca2+, manifested in an induction of the permeability transition pore (PTP) (Chalmers and 
Nicholls 2003). PTP induction leads to mitochondrial depolarization and inhibition of 
potential-dependent processes such as oxidative phosphorylation and Ca2+ uptake 
(Bernardi et al. 1999). 
 
i. Evidence Supporting Mitochondrial Ca2+ Handling Defects in HD 
Several studies demonstrated mHtt-induced defects in mitochondrial Ca2+ uptake 
(defects in mitochondrial Ca2+ handling). An early paper by Panov et al. reported 
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bioenergetics abnormalities and a reduction in Ca2+ uptake capacity by mitochondria 
isolated from cells and tissues expressing mHtt (Panov et al. 2002). Mitochondria from 
lymphoblasts of patients with HD as well as brain nonsynaptic mitochondria from 
pathological YAC72 mice, expressing mHtt with a stretch of 72 Qs, had a diminished 
membrane potential and were depolarized at smaller Ca2+ loads compared with 
mitochondria from healthy YAC18 mice, expressing Htt with a stretch of 18 Qs. These 
defects appeared to be upstream of the onset of pathological or behavioral abnormalities 
and could be replicated by a fusion protein GST-Q62 containing expanded polyQ repeat. 
It is known that Ca2+ uptake capacity could be increased by a combination of ADP and 
cyclosporin A (CsA), efficient inhibitors of the PTP (Chalmers and Nicholls 
2003;Novgorodov et al. 1992). However, Panov et al. reported that the Ca2+ handling 
defect persisted even in the presence of these PTP inhibitors (Panov et al. 2002). Thus, 
the mechanism of the mitochondrial Ca2+ handling defect was not clarified in this study, 
but based on the fact that ADP and CsA failed to eliminate the difference between 
mitochondria from mutant and WT animals, PTP involvement could be excluded. 
Intriguingly, the effect of mHtt on mitochondrial Ca2+ uptake capacity appeared to be 
elusive, and in the next study, Panov et al. found that “the defect in Ca2+ handling in 
brain mitochondria was consistently observed only if brain mitochondria were isolated 
without bovine serum albumin (BSA)” (Panov et al. 2003). The authors proposed that 
BSA could displace mHtt from its binding sites on mitochondria, but did not provide 
experimental evidence supporting this hypothesis. 
 Soon after that, Choo et al. showed that liver mitochondria from homozygous 
knock-in Hdh150/150 mice had augmented predisposition to the Ca2+-induced PTP (Choo 
et al. 2004). The authors also found that GST-fused N-terminal truncated mHtt (GST-
exon1-Q65 or Htt65), containing 65 glutamines, and GST-Q62 fusion protein, containing 
62 glutamines, significantly increased mitochondrial susceptibility to Ca2+-dependent 
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PTP induction. Htt65 reduced Ca2+ threshold for PTP induction and could directly 
stimulate Ca2+-dependent PTP induction in mouse liver mitochondria (Choo et al. 2004). 
Later, Milakovic et al. showed that in mitochondria isolated from conditionally 
immortalized striatal progenitor cells STHdhQ111/Q111, mHtt with 111 glutamines, 
augmented mitochondrial sensitivity to Ca2+-induced decrease in ADP-activated 
respiration (State 3) and mitochondrial depolarization (Milakovic et al. 2006). In addition, 
mHtt reduced mitochondrial Ca2+ uptake capacity that could be salvaged by a 
combination of ADP and CsA, the inhibitors of the PTP (Novgorodov et al. 1992), thus 
linking PTP induction to the mHtt-induced Ca2+ handling defect. In line with this, Lim et 
al., using the same cell lines, demonstrated that mitochondria from the cells had reduced 
Ca2+ uptake capacity due to increased susceptibility to PTP induction (Lim et al. 2008). 
In support of these findings, Gizatullina et al. observed increased propensity of skeletal 
muscle mitochondria from R6/2 mice to Ca2+-induced PTP compared with mitochondria 
from WT mice (Gizatullina et al. 2006). In the following study, Gellerich et al. examined 
brain mitochondria isolated from transgenic HD rats expressing 727 amino acid 
fragments of mHtt with a 51Q stretch (Gellerich et al. 2008). The authors found that the 
mHtt fragments reduced membrane potential stability in response to Ca2+, decreased 
Ca2+ uptake capacity, and diminished Ca2+ threshold for PTP induction. 
 In addition to isolated mitochondria, neurons in culture have been used to study 
detrimental effects of mHtt on Ca2+ signaling and mitochondrial Ca2+ handling. 
Fernandes et al. reported that Ca2+ influx into cells mediated by the NMDA subtype of 
ionotropic glutamate receptors resulted in augmented mitochondrial depolarization in 
medium spiny neurons from YAC128 mice (Fernandes et al. 2007). This effect was 
paralleled by reduced clearance of elevated cytosolic Ca2+ following NMDA withdrawal. 
Suppression of the PTP by CsA or bongkrekic acid resulted in a decrease in cytosolic 
Ca2+ and diminished mitochondrial depolarization induced by NMDA in neurons from 
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YAC128 mice, but not from WT mice. Based on these observations, the authors 
concluded that mitochondria in medium spiny neurons from YAC128 mice have 
increased susceptibility to PTP induction by Ca2+ (Fernandes et al. 2007). In support of 
this view, Quintanilla et al. found that rat cortical neurons expressing a fragment of mHtt 
with 104 glutamines (Q104-GFP) are more susceptible to Ca2+ stress compared with 
neurons expressing a fragment of Htt with 25 glutamines (Q25-GFP) (Quintanilla et al. 
2013). The authors also reported that mitochondrial defects in mutant STHdhQ111/Q111 
cells and cortical neurons expressing Q104-GFP were attenuated by CsA, suggesting an 
important role for PTP in mitochondrial injury induced by Ca2+ stress in cells expressing 
mHtt. Overall, these data suggest that mHtt impairs mitochondrial Ca2+ uptake capacity 
by increasing susceptibility to PTP induction. Similar to studies aimed at elucidating mHtt 
effects on oxidative metabolism, the major remaining question is how does mHtt, a 350-
kDa cytosolic protein that binds to the outer mitochondrial membrane but does not cross 
it (Choo et al. 2004), affect mitochondrial Ca2+ handling and increase propensity to PTP 
induction, which are the processes mainly associated with the inner mitochondrial 
membrane.  
 
ii. Evidence Against Mitochondrial Ca2+ Handling Defects in HD 
Despite reported defects in mitochondrial Ca2+ handling, some investigators did 
not find evidence for mHtt-induced mitochondrial Ca2+ handling deficiency and increased 
propensity to PTP induction in the presence of mHtt. In an early study using striatal 
nonsynaptic mitochondria from HD mice (Q50, Q92, Q111, and R6/2 mice), there was 
no increased susceptibility to Ca2+-induced PTP induction in mitochondria from HD mice 
compared with mitochondria from respective WT animals (Brustovetsky et al. 2005a). 
Surprisingly, this study found increased resistance to Ca2+ in striatal mitochondria 
isolated from HD mice. In line with these findings, Oliveira et al. demonstrated that 
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nonsynaptic mitochondria from R6/2 and YAC128 mice had augmented Ca2+ uptake 
capacity compared with mitochondria from WT mice. Additionally, this study reported 
that mitochondria from Hdh150/+ and Hdh150/150 mice had similar Ca2+ uptake 
capacity compared with mitochondria from WT animals (Oliveira et al. 2007). The reason 
for the increased Ca2+ uptake capacity is not clear, but it may reflect compensatory 
adaptation to augmented Ca2+ influx via activated NMDA receptors and/or increased 
Ca2+ release from endoplasmic reticulum via abnormally activated IP3 receptors 
(Bezprozvanny and Hayden 2004). The lack of mHtt-induced impairment of 
mitochondrial Ca2+ handling argues against facilitated PTP induction in the presence of 
mHtt and, consequently, does not support involvement of the PTP in HD pathogenesis 
(Brustovetsky et al. 2005a;Oliveira et al. 2007). Additional evidence for the lack of 
mitochondrial Ca2+ handling defects came from experiments by Chang et al. who 
transiently exposed cortical neurons expressing N-terminal fragment of mHtt or full-
length mHtt to glutamate and used FCCP-induced mitochondrial depolarization to 
release Ca2+ accumulated in the mitochondrial matrix (Chang et al. 2006). In these 
experiments, the authors failed to find a significant effect of mHtt on the ability of 
neuronal mitochondria to accumulate Ca2+ following exposure of neurons to excitotoxic 
glutamate. Recently, Wang et al. evoked Ca2+ mobilization in medium spiny neurons by 
stimulating group I metabotropic glutamate receptors and eliciting inositol 1,4,5-
trisphospahe (InsP3) generation. They found significantly higher Ca2+ accumulation in 
mitochondria of neurons from YAC128 mice compared with neurons from WT mice 
(Wang et al. 2013). These data argue against mHtt-induced mitochondrial Ca2+ handling 
defects. However, even if these defects exist, their role in HD pathogenesis could be 
nonessential. Consistent with the dispensable role of mitochondrial Ca2+ handling 
defects in HD pathogenesis, Perry et al. demonstrated that R6/2 mice crossed with 
cyclophilin D knockout mice (cyclophilin D (CyD) is an important regulatory component 
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of the PTP that sensitizes the pore to Ca2+ (Tanveer et al. 1996;Basso et al. 2005) had 
augmented neuronal mitochondrial Ca2+ uptake capacity without any improvement in 
either behavioral or neuropathological characteristics (Perry et al. 2010). The authors 
reasoned that increased Ca2+ capacity of neuronal mitochondria is not advantageous for 
R6/2 mice. Altogether, these results cast doubt on the ability of mHtt to increase 
susceptibility to PTP induction and to decrease mitochondrial Ca2+ uptake capacity. 
Consequently, these data question the role of mitochondrial Ca2+ handling defects in HD 
pathogenesis. Thus, there are two distinct schools of thought, mHtt induces defects in 
mitochondrial Ca2+ uptake and increases susceptibility to PTP induction, versus no 
deleterious alterations in mitochondrial function associated with mHtt. The reason for this 
discrepancy is not clear, but it could be related to the use of different HD models and 
variations in methodological approaches.  
 
C. Hypothesis and Goals  
 The evidence presented in this introduction demonstrates that the main 
question of whether mHtt interaction with mitochondria leads to mitochondrial 
dysfunction remains unresolved, and a plethora of data exists to support both 
viewpoints: the presence or the lack of mitochondrial dysfunction induced by mHtt. 
Significant experience in both mitochondrial and HD studies accumulated over 30 years 
of research has prepared our lab to address the question whether mHtt causes 
mitochondrial dysfunction. Defects in bioenergetics and Ca2+ handling are considered by 
some investigators to be major contributing factors to neuronal dysfunction in HD (Beal 
et al. 1993). It has been shown that HD patients at early stages of the disease have 
impaired glucose metabolism (Kuhl et al. 1985). In postmortem brain tissue from HD 
patients, decreased respiratory activity of HD caudate mitochondria (Brennan, Jr. et al. 
1985) and defects in mitochondrial Complexes II, III and IV were found (Gu et al. 
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1996;Browne et al. 1997). Additionally, mitochondria in some HD models have shown 
alterations in Ca2+ uptake (Panov et al. 2007;Gellerich et al. 2008). However, other 
investigators failed to find definitive evidence for a deleterious effect of mHtt on energy 
metabolism or Ca2+ uptake. Guidetti et al. (Guidetti et al. 2001) and Olah et al. (Olah et 
al. 2008), for example, failed to find a difference in activity of mitochondrial Complexes I–
IV in brain mitochondria of HD mice compared with mitochondria from wild-type animals. 
Some groups have found no defect or even increased Ca2+ uptake capacity in certain HD 
models (Brustovetsky et al. 2005a;Oliveira et al. 2007). 
 The striatum is the brain region that is most susceptible to neurodegeneration in 
HD (Vonsattel et al. 1985). However, although the use of whole brain mitochondria for 
the study of mHtt-mediated dysfunction may provide evidence of mitochondrial 
dysfunction, it may also produce confounding results since mitochondria from other brain 
regions could obscure dysfunction that is present only in striatal mitochondria. For this 
reason, mitochondria isolated only from the striatal region may be better suited for 
evaluating the presence of respiratory or Ca2+ handling deficiencies. Consequently, I 
hypothesize that, if mitochondria isolated from the whole brain do not display 
measurable dysfunction, then such dysfunction may be observable in 
mitochondria isolated exclusively from striatum.      
It has been shown that mHtt is subject to cleavage by caspases, generating 
polyQ-containing fragments of the protein (Wellington et al. 2000;Wellington et al. 2002). 
Whether HD pathogenesis is mediated by full-length mHtt or fragments of mHtt remains 
not completely understood. Previous studies suggested that mHtt fragments might be 
more toxic than full-length mHtt (Kim et al. 1999;Li et al. 2000) and it was shown that 
reduction in mHtt fragment generation improved the phenotype of HD mice (Tian et al. 
2014;Wong et al. 2015). Based on the existing literature, I hypothesize that mHtt (full-
length, fragments, or both) impairs mitochondrial respiratory and/or Ca2+ uptake 
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functions. If full-length mHtt does not affect mitochondrial functions, then mHtt 
fragments could be more effective in damaging mitochondria.  
  
We will test our hypotheses by pursuing the following goals: 
Goal 1:  Using the transgenic YAC128 mouse model of HD, determine if full-
length human mHtt induces mitochondrial respiratory or Ca2+ handling 
deficiencies.  
Goal 2:  Using isolated striatal mitochondria from YAC128 mice, examine if 
human mHtt induces mitochondrial respiratory and/or Ca2+ handling defects.   
Goal 3:  Using the transgenic R6/2 mouse model of HD, determine if fragments 
of human mHtt induce mitochondrial respiratory or Ca2+ handling deficiencies.  
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II. Materials and Methods 
A. Materials 
 Pyruvate, malate, succinate, glutamate, glycine, EGTA, ADP, oligomycin, 
rotenone, antimycin A, 2,4-dinitrophenol, N-methyl-D-glucamine (NMDG) and 
carbonylcyanide-p-trifluorometh-oxyphenylhydrazone (FCCP) were purchased from 
Sigma (St. Louis, MO). Tetraphenylphosphonium chloride was from Fluka (Buchs, 
Switzerland). Percoll was from GE Healthcare Bio-Sciences (Pittsburgh, PA). Bovine 
serum albumin (BSA), free from free fatty acids, was from MP Biomedicals (Irvine, CA, 
USA). Fura-2FF-AM was from Teflabs (Austin, TX). Ionomycin was from LKT 
Laboratories (St. Paul, MN) 
 
B. Animals 
 All procedures with animals were performed in accordance with the Institutional 
Animal Care and Use Committee approved protocol. All efforts were made to minimize 
animal suffering, to reduce the number of animals used, and to utilize alternatives to 
in vivo techniques, if available. All animal experiments were carried out in accordance 
with the National Institutes of Health guide for the care and use of Laboratory animals 
(NIH Publications No. 80-23, revised 1978). YAC128 and R6/2 mice as well as 
respective wild-type (WT) lines were purchased from Jackson Laboratories (Bar Harbor, 
ME) and breeding colonies were established in the Laboratory Animal Resource Center 
at Indiana University School of Medicine, Indianapolis, IN. YAC128 mice express full-
length human mHtt containing 128 glutamines in the polyglutamine (polyQ) stretch, 
including upstream and downstream regulatory elements in addition to WT mouse Htt. 
Female FVB/NJ mice (background strain) were bred with male YAC128 mice. R6/2 mice 
express the N-terminal fragment of the human mHtt gene that encodes a pathologically 
expanded polyglutamine stretch with 144 glutamines (Mangiarini et al. 1996). R6/2 mice 
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and their WT littermates were generated by crossing WT CBAxC57Bl/6 F1 males with 
CBAxC57Bl/6 females that had ovary transplants from R6/2 mice. Mice were housed 
under standard conditions with free access to food and water. In our studies, mice of 
both sexes were used. 
 For our respiration and membrane potential experiments with YAC128 mice, we 
used early symptomatic 2-month-old YAC128 mice and their wild-type (WT) littermates 
(background: FVB/NJ) as well as 10-month-old YAC128 and age-matched WT 
littermates. To evaluate the expression of nuclear encoded mitochondrial proteins, we 
used 2- and 10-month-old YAC128 mice and their age-matched WT littermates. 
Previously, it was reported that YAC128 mice at 2 months of age begin to show 
behavioral abnormalities and are considered to be early symptomatic (Van Raamsdonk 
et al. 2005a;Van Raamsdonk et al. 2005b). A recent study using electron microscopy 
demonstrated a significant reduction in excitatory synapses of striatal neurons in 12-
month-old YAC128 mice (Singaraja et al. 2011). At 12 months of age, YAC128 mice 
show significant striatal loss and are considered to be at an advanced stage of HD 
pathology (Slow et al. 2003). Therefore, we were interested in assessing mitochondrial 
Ca2+ handling in mice at both ages. Consequently, in our experiments, we used early 
symptomatic 2-month-old and mature 12-month-old YAC128 mice, control age-matched 
YAC18 mice, and their age-matched wild-type FVB/NJ littermates. In experiments with 
isolated brain mitochondria from R6/2 mice, we used symptomatic 6- to 8-week-old mice 
and their WT littermates (background: B6CBA). 
 Every animal used for experiments was genotyped by PCR assay on tail DNA. 
PCR of tail DNA was carried out according to the protocol furnished by Jackson 
Laboratories. For YAC128 samples the oligonucleotide primers used were oIMR6533 
(GGCTGAGGAAGCTGAGGAG) and TmoIMR1594 (CCGCTCAGGTTCTGCTTTTA) 
(Invitrogen, Carlsbad, CA). The PCR reaction mixture was prepared with 1 μL DNA 
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template and 24 μL Platinum PCR SuperMix (Invitrogen) containing 0.39 μM of each 
primer for a total reaction volume of 25 μL. Cycling conditions were 5 min at 95 °C, 35 
cycles of 30 s at 95 °C, 30 s at 56 °C, 60 s at 72 °C, 10 min at 72 °C. For R6/2 samples 
oligonucleotide primers used were oIMR1594 (CCGCTCAGGTTCTGCTTTTA) and 
oIMR1596 (TTGAAGGACTTGAGGGACTC) obtained from Invitrogen. Oligonucleotide 
primers oIMR7338 (CTAGGCCACAGAATTGAAAGATCT) and oIMR7339 
(GTAGGTGGAAATTCTAGCATCATCC) (all from Invitrogen) were used as internal 
positive control. For R6/2 samples the PCR reaction mixture consisted of 1 µl DNA 
template and 23 µl Platinum PCR SuperMix (Invitrogen) supplemented with 0.5 µM of 
each primer (Invitrogen), total volume 25 µl. Cycling conditions were 2 min at 94°C, 10 
cycles for 20 s at 94°C followed by 15 s at 65°C with −0.5°C per cycle temperature 
decrease and 10 s at 68°C. Then, 28 cycles for 15 s at 94 °C followed by 15 s at 60 °C 
and 10 s at 72 °C, concluded by 1 min at 72°C (Jackson Laboratories, Bar Harbor, ME). 
For all samples, PCR reaction products were visualized on a 1.2% agarose gel run at 
100 V for 60 min with Tris–acetate–EDTA running buffer containing 1× GelRedTM 
Nucleic Acid Gel Stain (Biotium, Hayward, CA). 
 
C. Isolation and Purification of Mitochondria 
 Mitochondria were isolated in a mannitol-sucrose medium and purified on a 
discontinuous Percoll gradient as previously described (Brustovetsky et al. 2002). The 
isolation procedure is schematically depicted in Figure 3. Mitochondria were isolated 
from either three whole brains, two hearts, or two livers from each mouse line for each 
experiment. For isolated striatal mitochondria, nine mice were used in each experiment 
to prepare nonsynaptic striatal mitochondria and 15 mice were used in each experiment 
to prepare synaptic striatal mitochondria. Organs were removed according to an IACUC-
approved protocol, and, if necessary, striata were dissected. The tissue were immersed 
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into isolation medium containing 225 mM mannitol, 75 mM sucrose, 1 mM EGTA, and 
10mM HEPES, pH 7.4 that was chilled to 4°C. The tissue was washed with isolation 
medium, minced coarsely with scissors, and homogenized. Liver and heart tissue were 
first homogenized in a 50mL Potter-Elvehjem homogenizer with Teflon-coated pestle 
attached to an electric homogenizer. Then pre-homogenized heart or liver tissue or 
freshly dissected brain tissue was homogenized manually in a 15 mL glass Dounce 
homogenizer (10 strokes with pestle A, then 30 strokes with pestle B) on ice. 
Homogenate was then diluted with 40 mL of Isolation Buffer 1 (composition described 
below) and centrifuged for 10 minutes at 2,400 rpm in an Avanti J-26XP centrifuge 
(Beckman) outfitted with a JA-25.50 rotor (650 x g for 10 minutes) (1st centrifugation). 
Then, supernate was moved to a new tube and centrifuged for 10 minutes at 12,500 rpm 
(18,850 x g) in a Beckman Centrifuge Avanti J-26XP outfitted with a JA-25.50 rotor (2nd 
centrifugation). Supernate was discarded and pellet was re-suspended in 35 mL of 
Isolation Buffer 2 (composition described below) and centrifuged for 10 minutes at 
12,500 rpm (18,850 x g) in a Beckman Centrifuge Avanti J-26XP outfitted with a JA-
25.50 rotor (3rd centrifugation). For heart, liver, and unpurified brain mitochondria, the 
pellet was re-suspended in 0.5 mL of Isolation Buffer 3 (composition described below) 
and stored on ice. For brain purified brain mitochondria, the pellet was re-suspended in 5 
mL of Isolation Buffer 3. The suspension was then layered onto the top of discontinuous 
Percoll gradients (26%/40%) that were prepared in Beckman Ultra-Clear centrifuge 
tubes and centrifuged for 28 minutes at 15,500 rpm (41,100 x g) in a Beckman 
Ultracentrifuge Optima L100K, outfitted with a SW41Ti bucket rotor (4th centrifugation). 
Following this centrifugation, five layers were produced. In Figure 4, the layers are 
marked numerically and described as follows: 1 – clear (top); 2 – thick white with a 
yellowish hue, this layer contains synaptosomes; 3 – slightly cloudy thick layer; 4 – thin 
turbid layer, this layer contains nonsynaptic mitochondria; 5 – clear (bottom). At this 
43 
point, layers that contained synaptosomes and nonsynaptic mitochondria were collected 
into separate tubes. Nonsynaptic mitochondria were re-suspended in Isolation Buffer 3 
and momentarily set aside. 
 Synaptic mitochondria were isolated from synaptosomes by nitrogen cavitation 
using a nitrogen cell disruption bomb, model 4639 (Parr Instrument Company, Moline, 
IL), cooled on ice. Synaptosomes were transferred into an ice-cold 10 mL glass beaker 
and placed into the nitrogen bomb on ice under 1,100 psi for 13 minutes. Then, the 
ruptured synaptosomes were layered on top of a discontinuous Percoll gradient 
(24%/40%) and centrifuged for 28 minutes at 15,500 rpm (41,100 x g) in a Beckman 
Ultracentrifuge Optima L100K, outfitted with a SW41Ti bucket rotor (4’ centrifugation). 
The next two centrifugations (5th and 6th centrifugations were performed together with 
nonsynaptic mitochondria. The pellet of synaptic mitochondria was re-suspended in 
Isolation Buffer 3. Then, together with previously re-suspended nonsynaptic 
mitochondria, synaptic mitochondria were centrifuged for 20 minutes at 15,500 rpm 
(41,100 x g) in a Beckman Ultracentrifuge Optima L100K, outfitted with a SW41Ti bucket 
rotor (5th centrifugation). The pellets were re-suspended in Isolation Buffer 3 and 
centrifuged again for 20 minutes at 15,500 rpm (41,100 x g) in a Beckman 
Ultracentrifuge Optima L100K, outfitted with a SW41Ti bucket rotor (6th centrifugation). 
The pellets were collected, re-suspended in Isolation Buffer 3 (0.25-0.3 mL for 
nonsynaptic mitochondria and 0.1 mL for synaptic mitochondria), and stored on ice. 
These comprised the stock suspensions for nonsynaptic and synaptic mitochondria. All 
centrifugations, procedures, and solutions were maintained at 4°C throughout the 
protocol. Isolation Buffer 1: 225 mM mannitol, 75 mM sucrose, 1 mM EGTA, and 10mM 
HEPES, pH 7.4 adjusted with KOH. Isolation Buffer 2: 225 mM mannitol, 75 mM 
sucrose, 0.1 mM EGTA, and 10mM HEPES, pH 7.4 adjusted with KOH. Isolation Buffer 
3: 395 mM sucrose, 0.1 mM EGTA, and 10mM HEPES, pH 7.4 adjusted with KOH. 
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Percoll Buffer: 320 mM sucrose, 1 mM EGTA, 10 mM HEPES, pH 7.4 adjusted with 
KOH. It was previously proposed that BSA may preclude mHtt from binding to the 
mitochondrial outer membrane (Panov et al. 2003), therefore, unless indicated 
otherwise, BSA was omitted from solutions used in isolation procedures and from 
incubation medium. Only where indicated, isolation solutions and incubation medium 
were supplemented with 0.1% BSA (free from fatty acids; MP Biomedicals, cat. # 
150421). 
 
45 
 
 
Figure 3. Isolation and purification of brain nonsynaptic and synaptic 
mitochondria. 
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Figure 4. Separation of nonsynaptic mitochondria and synaptosomes on 
discontinuous Percoll gradient. After the fourth centrifugation, five layers are visible. 
From top: 1 – clear (top), Isolation Buffer 3; 2 – thick white-yellowish, synaptosomes; 3 – 
slightly cloudy thick layer, 26% Percoll; 4 – thin turbid layer, nonsynaptic mitochondria; 5 
– clear (bottom), 40% Percoll. 
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D. Western Blotting 
 Brain homogenates, cytosolic fractions, and isolated mitochondria that were 
previously treated with Protease Inhibitor Cocktail (Roche, Indianapolis, IN ref# 
04693124001) were solubilized by incubation in NuPAGE LDS sample buffer 
(Invitrogen) plus a reducing agent at 70 °C for 10 min. Either Bis-Tris Mops gels (4–12%, 
Invitrogen) or Tris-Acetate gels (3–8%, Invitrogen) were used to separate proteins by 
electrophoresis. Either 10 or 40 μg protein per lane was loaded. Following 
electrophoresis, proteins were transferred to Hybond-ECL nitrocellulose membrane 
(Amersham Biosciences, Piscataway, NJ). Blots were incubated for 1 h at room 
temperature in blocking solution of either 5% milk or 5% BSA dissolved in phosphate-
buffered saline, pH 7.2, and 0.15% Triton X-100. Then, where indicated, blots were 
incubated with one of the following primary antibodies: mouse monoclonal anti-Htt 2166 
(mAb 2166, 1:1000, Millipore, Temecula, CA), mouse monoclonal anti-polyQ 1C2 (mAB 
1574, 1:3000, Millipore), rabbit polyclonal anti-calnexin (1:1200, Abcam, Cambridge, 
MA), rabbit monoclonal anti-MEK1/2 (1:2000, Pierce, Rockford, IL), mouse monoclonal 
anti-Complex I 39 kDa subunit (1:1000, Invitrogen), mouse monoclonal anti-Complex II 
30 kDa subunit (1:1000, Invitrogen), mouse monoclonal anti-Complex II 70 kDa subunit 
(1:1000, Invitrogen), mouse monoclonal anti-aconitase 2 (1:1000, Abcam), rabbit 
polyclonal anti-manganese superoxide dismutase (MnSOD, 1:2000, Millipore), mouse 
monoclonal anti-ATP synthase α subunit (1:1000, Abcam), mouse monoclonal anti-CyD 
antibody (1:500, Calbiochem, San Diego, CA), mouse monoclonal anti-COX IV (1:2500, 
Invitrogen), rabbit polyclonal anti-VDAC1 (1:1000, Calbiochem). Blots were incubated 
with either goat anti-mouse or goat anti-rabbit IgG (1:25000 or 1:20000, respectively) 
coupled with horseradish peroxidase (Jackson ImmunoResearch Laboratories, West 
Grove, PA) and developed with Supersignal West Pico chemiluminescent reagents 
(Pierce). Molecular mass markers See Blue Plus 2 Standards (7 µl) (Invitrogen) and 
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HiMark Pre-stained High Molecular Weight Protein Standards (7 µl) (Invitrogen) were 
used for molecular mass determination. NIH ImageJ 1.48v software 
(http://rsb.info.nih.gov//ij) was used to quantify band densities. 
 
E. Mitochondrial Respiration  
 Mitochondrial respiration was measured under continuous stirring in 0.4 ml 
thermostated chamber at 37°C in the standard incubation medium containing 125 mM 
KCl, 0.5 mM MgCl2, 3 mM KH2PO4, 10 mM Hepes, pH 7.4, 10 µm EGTA supplemented 
either with 3 mM pyruvate plus 1 mM malate or 3 mM succinate plus 3 mM glutamate. 
The chamber was equipped with a Clark-type oxygen electrode and a tightly closed lid. 
The slope of the oxygen electrode trace corresponded to the respiratory rate. 
Experiments with succinate were supplemented with glutamate to prevent inhibition of 
succinate dehydrogenase by oxaloacetate (Wojtczak 1969;Brustovetsky and Dubinsky 
2000a).   
 
F. Mitochondrial Ca2+ Uptake  
 Mitochondrial Ca2+ uptake was measured with a miniature Ca2+-selective 
electrode in a 0.3 ml chamber at 37°C under continuous stirring. Uptake of Ca2+ by 
mitochondria is indicated by a decrease in external Ca2+ in the chamber. The standard 
incubation medium contained 125 mM KCl, 0.5 mM MgCl2, 3 mM KH2PO4, 10 mM 
Hepes, pH 7.4, 10 μM EGTA, and was supplemented either with 3 mM pyruvate plus 1 
mM malate or 3 mM succinate plus 3 mM glutamate. Succinate was used in combination 
with glutamate to prevent oxaloacetate inhibition of succinate dehydrogenase (Wojtczak 
1969;Brustovetsky and Dubinsky 2000a). Additionally, the incubation medium was 
supplemented with 0.1 mM ADP and 1 μM oligomycin as described previously 
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(Chalmers and Nicholls 2003). Ca2+ was delivered to mitochondria as 10 μM CaCl2 
pulses. Data were quantified as Ca2+ uptake capacity per mg of mitochondrial protein. 
 
G. Mitochondrial Membrane Potential and Swelling 
 Mitochondrial membrane potential was evaluated in 0.3 ml thermostated 
chamber at 37°C in the standard incubation medium containing 125 mM KCl, 0.5 mM 
MgCl2, 3 mM KH2PO4, 10 mM Hepes, pH 7.4, 10 µm EGTA supplemented either with 3 
mM pyruvate plus 1 mM malate or 3 mM succinate plus 3 mM glutamate. The chamber 
was outfitted with a tetraphenylphosphonium (TPP+) electrode that followed TPP+ 
distribution between the incubation medium and mitochondria (Kamo et al. 1979). A 
decrease in external TPP+ concentration corresponds to mitochondrial polarization, while 
an increase of TPP+ in the incubation medium corresponds to depolarization. 
Mitochondrial swelling was evaluated at 37°C and continuous stirring by following 
changes in light scattering of mitochondrial suspension at 525 nm with an incident light 
beam at 180° in a 0.3 ml chamber. The incubation medium for light scattering 
measurements contained 215 mM mannitol, 70 mM sucrose, 0.5 mM MgCl2, 3 mM 
KH2PO4, 10 mM Hepes, pH 7.4, 10 μM EGTA, 3 mM succinate, 3 mM glutamate. A 
decrease in light scattering of mitochondrial suspension indicated mitochondrial swelling. 
Maximal mitochondrial swelling was induced by alamethicin (30 μg/ml). Maximal swelling 
was taken as 100%. Ca2+-induced swelling was calculated as a percentage of maximal 
swelling (Brustovetsky et al. 2005b). 
 
H. Transmission Electron Microscopy 
 Prior to fixation, mitochondria were incubated for 10 min at 37°C in the standard 
incubation medium. Then, mitochondria or striatal neurons were fixed in 2.5% 
glutaraldehyde in either mitochondrial incubation medium or the standard neuron bath 
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solution at room temperature for 15 min. Samples were then centrifuged at 15,800 × g 
for 5 min, and the supernatant was discarded. The pellet was layered with a fresh 
solution of 2% paraformaldehyde plus 2% glutaraldehyde in 0.1 M phosphate buffer and 
left overnight at 4 °C. The samples were postfixed in 1% osmium tetroxide for 1 h and 
dehydrated through a series of graded ethyl alcohols before embedding in the resin 
Embed® 812 (Electron Microscopy Sciences, Fort Washington, PA). Thick sections were 
cut on an Ultracut UCT microtome (Leica, Bannockburn, IL), and then thin sections were 
cut using a diamond knife (Diatome, Electron Microscopy Sciences) at 70–90 nm and 
stained with uranyl acetate and lead citrate. Digital electron micrographs were taken 
using a Tecnai G12 BioTwin electron microscope (FEI, Hillsboro, OR) equipped with an 
AMT 2.6 × 2.6 K digital CCD camera. Mitochondrial morphology was analyzed in a blind 
manner as described previously. Mitochondrial populations were categorized into three 
classes: (i) condensed mitochondria with dark, shrunk matrices and distinct 
vacuolization, (ii) swollen mitochondria with light, expanded matrices and (iii) orthodox 
mitochondria with evenly spread grey matrices. Mitochondria were counted and 
morphological distribution was statistically analyzed using one-way analysis of variance 
followed by Bonferroni's post hoc test (GraphPad Prism® 4.0, GraphPad Software Inc., 
SanDiego, CA). This procedure was performed with the help of Caroline Miller at the 
Electron Microscopy Center, Indiana University School of Medicine. 
 
I. ATP and ADP Measurements 
 ADP and ATP were determined using a luciferin/luciferase-based ATP 
bioluminescent somatic cell assay (Sigma) and a GloMax 20/20 luminometer (Promega). 
Mitochondria were incubated for 10 min at 37°C in the standard incubation medium 
supplemented with 3 mM succinate plus 3 mM glutamate and then ADP and ATP were 
measured. Cultured striatal neurons (10 DIV) were lysed on ice with the Releasing 
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Reagent (Sigma) for 10 minutes. ATP was measured following precipitation of proteins 
by perchlorate (4%) and subsequent neutralization of extracts by KOH as measured by 
an esophageal pH electrode. ADP was converted to ATP using pyruvate kinase in the 
presence of phosphoenolpyruvate (Kimmich et al. 1975). 
 
J. Blue Native-PAGE and Western Blotting 
 Synaptic and nonsynaptic mitochondria from WT and YAC128 mice were 
solubilized in a sample buffer (Invitrogen) with 1% digitonin and Proteinase Inhibitor 
Cocktail (Roche) for 15 min on ice and then centrifuged at 100,000g for 30 min. 
Mitochondrial proteins (15 µg) were separated on NativePAGE™ 3–12% Bis–Tris gel. 
Following electrophoresis, protein bands were stained with SimplyBlue™ SafeStain. 
NativeMark™ was used as molecular weight marker. All reagents were from Invitrogen. 
For western blotting, the proteins were transferred on Immobilon™-FL PVDF membrane 
(EMD Millipore) and mitochondrial Complex I subunit Ndufa9 was detected using 
monoclonal antibodies against Ndufa9 (mAb 14713, Abcam). 
 
K. Cell Culture 
 Primary cultures of striatal and cortical neurons were prepared from individual 
dissected striata and cortices of postnatal day 1 mouse pups as previously described 
(Dubinsky 1993), but without pooling cells from different animals together. The striata or 
cortices were removed, coarsely minced, and incubated for 20 minutes at 37°C in L-15 
medium with 3 mg·ml−1 papain and 3 mg·ml−1bovine serum albumin (BSA). After gentle 
trituration in growth medium, the cell suspension was layered on L-44 with 100 mg·ml−1 
BSA and centrifuged at 500 rpm for 5 minutes. The pellet was then resuspended in 
growth medium. To inhibit proliferation of non-neuronal cells, 35 mg·ml−1 uridine plus 15 
mg·ml−1 5-fluoro-2′-deoxyuridine were added 24 h after plating. Neurons were 
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maintained in a 5% CO2 atmosphere at 37 °C in Neurobasal Medium with B27 
supplement (Life Technologies), and medium osmolality set to 280 mOsm. We used 
neuronal-glial co-culture derived from postnatal day 1 mouse pups because it is more 
physiologically relevant and allows for the study of more mature, better developed cells 
than pure neuronal culture derived from embryonic animals. 
 For respirometry experiments, neurons were plated on Seahorse plates that were 
previously coated with poly-L-lysine and without pre-plated glia. For fluorescence 
experiments and ATP measurements, neurons were plated onto glass bottom Petri 
dishes without pre-plated glia as previously described for calcium imaging experiments 
(Dubinsky 1993).  
 
L. Cell Respirometry 
 Oxygen consumption rates (OCRs) of cultured striatal and cortical neurons (9 
DIV) were measured using Seahorse XF24 flux analyzer (Seahorse Bioscience, 
Billerica, MA). Seahorse cell culture plates were coated for 1 hour with 20mg/mL poly-L-
Lysine prior to seeding cells. Neuronal cultures were grown in the assay plates at 105 
cells per well. Before performing measurements, the growth medium was replaced by 
the standard bath solution supplemented with 10 mM glucose and 15 mM pyruvate or 
2.5 mM glucose alone as indicated. The standard bath solution contained 139 mM NaCl, 
3 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 10 mM HEPES, pH 7.4. In experiments, in 
which 2.5 mM glucose was used, sucrose was supplemented to maintain osmolarity 
similar to that in the growth medium (300 mosm). Experiments consisted of 12 
measurement periods that each consisted of three functions. At the beginning of each 
measurement period, the medium was re-oxygenated with a three-minute mixing period, 
followed by a two-minute wait period to allow equal distribution of oxygen, then a three-
minute measurement period in which the rate of the decrease in oxygen concentration 
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was measured. Cellular respiration was measured under four conditions. Initially, three 
basal measurements were made with cells in the presence of only glucose and pyruvate, 
then cell respiration was assessed in the presence of the ATP-synthase inhibitor 
oligomycin (1 µM) , followed by evaluation of uncoupled respiration in the presence of  
2,4-dinitrophenol (60 µM), and finally non-mitochondrial respiration in the presence of 
mitochondrial respiratory complex inhibitors rotenone (1 µM) and antimycin A (1 µM). 
Measurements of extracellular acidification rate (ECAR) and OCR were made 
simultaneously during each experiment.     
 
M. Calcium Imaging 
 Cytosolic Ca2+ was assessed in striatal neurons (10–12 days in vitro, DIV) by 
loading neurons at 37 °C with 2.6 µM Fura-2FF-AM (Molecular Probes, Eugene, OR) in 
the standard bath solution containing 139 mM NaCl, 3 mM KCl, 0.8 mM MgCl2, 1.8 mM 
CaCl2, 10 mM NaHEPES, pH 7.4 and 5 mM glucose. Osmolarity of the bath solutions 
was measured with an Osmette II osmometer (Precision Systems Inc., Natick, MA) to 
ensure that it was similar to the osmolarity of the growth medium (280 mosm). A Nikon 
Eclipse TE2000-U inverted microscope using a Nikon CFI Plan Fluor 20× 0.45 NA 
objective and a back-thinned EM-CCD camera, Hamamatsu C9100-12 (Hamamatsu 
Photonic Systems, Bridgewater, NJ) controlled by Simple PCI software 6.1 (Compix Inc., 
Sewickley, PA) was used to take fluorescent images. A Lambda-LS system (Sutter 
Instruments, Novato, CA) was used to deliver excitation light. A Lambda 10-2 optical 
filter changer (Sutter Instruments, Novato, CA) was used to control excitation filters (340 
± 5 and 380 ± 7 nm). Fluorescence was recorded through a 505 nm dichoroic mirror at 
535 ± 25 nm. Images were taken every 15 seconds for the duration of the experiment. 
The exposure time was chosen that provided satisfactory image quality but minimal 
exposure. The ratio of F340/F380, calculated following background subtraction in both 
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channels, was used to monitor changes in cytosolic Ca2+ concentration ([Ca2+]c). After 90 
seconds of baseline fluorescence recording in standard bath solution, glutamate (25 µM) 
plus glycine (10 µM) was applied to the neuronal culture. At the end of the experiment, 
the glutamate-containing solution was replaced with a glutamate-, Ca2+- and Na+-free 
solution. The Na+ was replaced by equimolar N-methyl-D-glucamine (NMDG). Then 1 
µM FCCP was applied to the neurons, causing neuronal mitochondria to depolarize and 
leading to release of accumulated mitochondrial Ca2+ into the cytosol. The Grynkiewicz 
method (Grynkiewicz et al. 1985) was used for calculation of [Ca2+]c from Fura-2FF 
signals, using an assumed Kd for Fura-2FF of 5.5 µM. Fluorescence background was 
subtracted in every experiment. As has been suggested previously (Dietz et al. 
2007;Stanika et al. 2009), it should be noted that the Ca2+ binding and spectroscopic 
properties of fluorescent dyes can differ depending on the intracellular environment. 
Therefore calculations of [Ca2+]c should be considered estimates. 
 
N. Neuronal Transfection 
 To visualize mitochondria within live cells, cultured striatal neurons were 
transfected in suspension during plating using an electroporator BTX 630 ECM (Harvard 
Apparatus, Holliston, MA) with a plasmid encoding mitochondrially-targeted enhanced 
yellow fluorescent protein (mito-eYFP, generously provided by Dr. Roger Tsien, UCSD) 
(4 μg plasmid per 100μL of cell suspension, 5x106 cells). This procedure usually 
provided a 10–15% transfection rate in primary neuronal cultures. The transfected 
neurons were imaged 8–10 days after transfection. 
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O. Live-cell Laser Spinning-disk Confocal Microscopy 
 Mitochondrial morphology in live striatal neurons was analyzed by confocal 
microscopy. Serial images of neuronal mitochondria, visualized with mito-eYFP, were 
collected using spinning-disk confocal microscopy. A Nikon Eclipse TE2000-U 
microscope equipped with a Yokogawa spinning-disk confocal unit CSU-10, a back-
thinned EM-CCD camera Andor iXonEM+ DU-897 (Andor Technology, South Windsor, 
CT), and a motorized stage Prior H-117 (Prior Scientific, Rockland, MA) was employed. 
This setup was controlled by Andor iQ 1.4 software (Andor Technology, South Windsor, 
CT). To image mitochondria, neurons were exposed to excitation light at 488 nm using 
an air-cooled Kr/Ar laser T643-RYB-A02 (Melles Griot, Carlsbad, CA). The laser power 
was set to the minimum (<5%) to prevent photobleaching while maintaining excellent 
image quality. Fluorescence was collected through a 505 nm dichroic mirror and a 535 ± 
25 nm emission filter using a Nikon CFI Plan Apo 100× 1.4 NA objective. Serial images 
(z-stacks) were collected using the piezoelectric positioning device PIFOC P-721 (Physik 
Instrumente, Auburn, MA) with a z-step of 0.1 µm. The spatial resolution of the Andor 
iXonEM+ DU-897 camera was increased by installing a 2× extender lens in front of the 
camera. Three-dimensional blind deconvolution of z-stacks and 3D rendering were 
performed using AutoDeblur Gold CF 1.4.1 software (MediaCybernetics, Silver Spring, 
MD). Three-dimensional maximal projection reconstructions of the mitochondrial network 
in live neurons were performed using Imaris 6.4.0 (Bitplane Inc., St. Paul, MN). 
 
P. Calorimetric Analysis 
 Calorimetric analysis was performed to determine whole-animal metabolic 
activity. Oxygen consumption, CO2 release, energy expenditure, food consumption and 
motor activity were measured in 10-month-old YAC128 and WT mice with an Animal 
Monitoring System (LabMaster, TSE Systems, Midland, MI). The system consists of an 
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eight-cage open-circuit layout equipped with an air pump, a control unit, a sample switch 
unit to draw air samples from the cages and an air-drying unit. After 72 h acclimation in 
the calorimetric cages, the mice were recorded for 96 h for the previously mentioned 
parameters. The system measures O2 consumed and CO2 produced. These values were 
averaged to determine the hourly rate of each parameter. Energy expenditure was 
calculated by the Weir equation (Weir 1949) as modified by Bruss et al. (Bruss et al. 
2010): Energy expenditure (kcal/h) = [(3.815 + 1.232 × RER) × VO2]/1000, where VO2 is 
in milliliters/hour. 
 
Q. Mouse Body Composition 
 Fat mass and lean body mass of WT and YAC128 mice were estimated by dual-
energy x-ray absorptiometry (DEXA) scanning. A PIXImus II mouse densitometer (Lunar 
Corp., Madison, WI) was used in the Department of Cell Biology and Anatomy, Indiana 
University School of Medicine. During scanning, the mice were maintained in the 
anesthetized state by a constant flow of isoflurane gas (2% with oxygen at a rate of 1 
l/min) administered by a nose cone. The duration of the scan was 4–5 min. 
 
R. Statistics 
 Experimental data are shown as mean ± SEM of indicated number of 
independent experiments. Statistical analysis of the experimental results consisted of 
unpaired t-test or one-way ANOVA followed by Bonferroni's post hoc test (GraphPad 
Prism® 4.0, GraphPad Software Inc., San Diego, CA). Every experiment was performed 
using several different preparations of isolated mitochondria or several separate 
neuronal-glial platings. Power analysis was performed using G*Force software version 
3.1.9.2 (by Franz Faul, Universitat Kiel, Germany) to establish the sample size 
necessary to detect a 10% and 20% difference between mitochondria from WT and 
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YAC128 mice. The results of this analysis are shown in Tables 2 and 3. Based on this 
power analysis, the number of experiments that gives an 80% likelihood (the accepted 
level in statistical analysis) of detecting 10% difference between two means at the 
significance level of α = 0.05 is within the range of 6–10 experiments. Five to six 
experiments give an 80% likelihood of detecting 20% difference between two means at 
the significance level of α = 0.05. 
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Table 2. Calculation of a sample size using Power Analysis method for YAC128. 
 
            
Power analysis was performed using G*Force software version 3.1.9.2 (by Franz Faul, 
Universitat Kiel, Germany) to establish the sample size necessary to detect a 10% and 
20% difference between mitochondria from WT and YAC128 mice. Based on this power 
analysis, the number of experiments that gives an 80% likelihood (the accepted level in 
statistical analysis) of detecting 10% difference between two means at the significance 
level of α=0.05 is within the range of 6 to 10 experiments. The number of experiments 
suitable for statistical analysis was assumed to be 3 or higher. V3, respiratory rate in the 
presence of 200 μM ADP; VDNP, respiratory rate in the presence of 60 μM 2,4-DNP; Δψ, 
mitochondrial membrane potential; SD, standard deviation. Where indicated, the 
incubation medium was supplemented either with 3 mM pyruvate plus 1 mM malate or 
with 3 mM succinate plus 3 mM glutamate. 
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Table 3. Calculation of a sample size using Power Analysis method for R6/2. 
 
 
Power analysis was performed using G*Force software version 3.1.9.2 (by Franz Faul, 
Universitat Kiel, Germany) to establish the sample size necessary to detect a 10% and 
20% difference between mitochondria from WT and R6/2 mice. Based on this power 
analysis, the number of experiments that gives an 80% likelihood (the accepted level in 
statistical analysis) of detecting 10% difference between two means at the significance 
level of α=0.05 is within the range of 6 to 10 experiments. The number of experiments 
suitable for statistical analysis was assumed to be 3 or higher. V3, respiratory rate in the 
presence of 200 μM ADP; VDNP, respiratory rate in the presence of 60 μM 2,4-DNP; Δψ, 
mitochondrial membrane potential; SD, standard deviation. Where indicated, the 
incubation medium was supplemented either with 3 mM pyruvate plus 1 mM malate or 
with 3 mM succinate plus 3 mM glutamate. 
 
 
 
 
 
 
60 
III. Results 
A. Oxidative Metabolism and Ca2+ Handling in the YAC128 Mouse Model of HD. 
As mentioned previously, several reports have indicated that potential 
mitochondrial bioenergetic deficiency and mitochondrial Ca2+ handling defects may be 
important contributors to neuronal dysfunction in HD (Brennan, Jr. et al. 1985;Gu et al. 
1996;Browne et al. 1997). However, other reports have provided data that suggests 
mitochondrial functions may not be impaired by mHtt (Powers et al. 2007b); Powers et 
al. 2007b). The further evaluation of mHtt effects on mitochondrial functions is required 
to more clearly understand the role of potential mitochondrial dysfunction in HD. 
Impairment of mitochondrial bioenergetics by mHtt may result in decreased ATP 
production, potentially leading to neuronal degeneration (Lehninger et al. 1993;Wang 
and Youle 2009). Additionally, alterations to mitochondrial Ca2+ handling, such as 
insufficient Ca2+ uptake capacity or increased susceptibility to induction of the 
permeability transition pore, may result in excessively high cytosolic Ca2+ concentration 
or increased likelihood of mitochondrial damage (Lehninger et al. 1993;Wang and Youle 
2009). Therefore, if mHtt induces alterations to mitochondrial Ca2+ handling, it may also 
lead to neuronal degeneration.     
 
a. Clasping phenotype of YAC128 mice and genotyping. 
 In our initial experiments, we used YAC128 mice, which express full-length 
human mHtt with a 128-glutamine stretch near the N-terminus (Slow et al. 2003). At 2 
months of age, these mice begin to demonstrate a behavioral abnormality characterized 
by clasping of fore- and hind-limbs when suspended by the tail (Fig. 5A and B). This 
behavior is typical for transgenic HD mice (Reddy et al. 1999;Milnerwood et al. 2006). 
We regularly observed clasping behavior in 2-month-old YAC128 mice. Overall, out of 
288 2-month-old YAC128 mice of both sexes (162 males and 126 females) tested for 
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clasping behavior, clasping behavior was detected in 158 animals (96 males and 62 
females). Clasping behavior was never observed in WT mice. In our study, we used 
early symptomatic 2-month-old YAC128 mice and their WT littermates as well as 10-
month-old YAC128 mice at the later stage of pathology and their age-matched 
littermates to prepare isolated brain mitochondria. We used animals of both sexes. Every 
mouse used in our experiments was genotyped (Fig. 5C).  
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Figure 5. Behavioral phenotype of 2-month-old YAC128 mice and a representative 
genotyping. In A, the normal response of a wild-type (WT) FVB/NJ mouse to 
suspension by the tail with limbs extended out. In B, clasping behavior of a YAC128 
mouse that was usually observed within 15–45 s of suspension. In C, representative 
genotyping data of tail tissue from WT and YAC128 mice.  
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b. Expression of mHtt and morphological characterization of brain mitochondria 
isolated from YAC128 mice. 
 To confirm the presence of mHtt in isolated mitochondria fraction, western 
blotting was used. In immunoblotting experiments with brain homogenates, cytosolic 
fractions, and purified nonsynaptic (neuronal plus glial) and synaptic (neuronal) 
mitochondrial fractions from WT and YAC128 mice, we used two different antibodies for 
total Htt and mHtt: monoclonal anti-Htt antibody 2166 (mAb 2166, Millipore), which 
recognizes both mouse wild-type Htt and human mHtt, and monoclonal anti-polyQ 
antibody 1C2 (mAb 1574, Millipore), which recognizes mHtt. With mHtt-specific mAb 
1C2, a 350 kDa band, representing mHtt, was detected in homogenates, cytosolic and 
mitochondrial fractions from YAC128 mice, but not in samples from WT animals 
(Fig. 6A). Probing purified brain synaptic (neuronal) mitochondria with mAb 1C2 
produced a distinct band indicating that mHtt is associated with isolated mitochondria. 
Probing with anti-Htt mAb 2166, we detected a 350 kDa band, corresponding to wild-
type Htt, in both WT and YAC128 samples (Fig. 6B). In brain homogenates and cytosolic 
fractions from YAC128 mice, mAb 2166 detected an additional band with a slightly 
higher molecular weight that represents mHtt. The level of expression of human mHtt 
was similar to the expression of endogenous wild-type Htt (Fig. 6B), which is consistent 
with previously reported data for YAC128 mice (Slow et al. 2003;Pouladi et al. 2013). 
Similar results were obtained with nonsynaptic mitochondria isolated from WT and 
YAC128 mice (data not shown). α-Tubulin and cytochrome c oxidase subunit IV (COX 
IV) were used as cytosolic and mitochondrial markers, respectively. The weak α-tubulin 
bands seen in mitochondrial fractions were most likely due to tubulin binding to voltage-
dependent anion channel (VDAC1) in the outer mitochondrial membrane (Carre et al. 
2002). Interestingly, with mAb 2166, only wild-type Htt was easily detected in purified 
mitochondria from both WT and YAC128 mice, whereas the mHtt level in YAC128 
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mitochondria appeared to be much lower (Fig. 6B). This was not because of decreased 
sensitivity of mAb 2166 to mHtt.  In homogenates and cytosolic fractions, mAb 2166 
detected both Htt and mHtt with similar sensitivity (Fig. 6B). Only with increased protein 
loading (50 µg/lane) and extended film exposure, did a mHtt band become evident in 
mitochondrial fraction (Fig. 6C). The results of densitometry of wild-type mouse Htt and 
human mHtt bands are shown in Figure 6D. Similar results were obtained with 
nonsynaptic mitochondria isolated from WT and YAC128 mice (not shown).  
 In our experiments, we used Percoll gradient-purified synaptic and nonsynaptic 
brain mitochondria isolated from YAC128 and WT mice. Nonsynaptic mitochondria are 
derived from neuronal and glial cell bodies and use of these mitochondria will give 
information about total brain mitochondria. However, neurons are the cell type that is 
primarily affected in HD and the use of mitochondria from neurons and glia may obscure 
possible dysfunction that may be present only in neuronal mitochondria. Therefore, in 
our studies, we assessed the function of both nonsynaptic and synaptic mitochondria, 
which are derived from synaptic terminals, and thus are mitochondria of only neuronal 
origin. To characterize the isolated mitochondria, we performed transmission electron 
microscopy (TEM). The TEM did not reveal overt morphological differences in 
nonsynaptic (Fig. 7A and B) and synaptic (Fig. 7C and D) mitochondria isolated from 2-
month-old YAC128 (Fig. 7A and C) and WT mice (Fig. 7B and D). From these images, 
mitochondria were categorized into three distinct groups based on morphology (Fig. 7E): 
orthodox mitochondria with uniform, gray matrices, condensed mitochondria with 
compacted, dark matrices, and swollen mitochondria with light, vacuolarized matrices. A 
similar approach was used by our laboratory and others previously (Scorrano et al. 
2002;Shalbuyeva et al. 2006;Brustovetsky et al. 2010). In all cases, the majority of 
mitochondria appeared to be in a condensed state (Fig. 7F), consistent with previously 
reported morphology of isolated brain mitochondria (Shalbuyeva et al. 2006; 
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Brustovetsky et al. 2010). It has to be mentioned that it is very well known that isolated 
mitochondria do not retain native morphology typical for the organelles inside of the cell. 
Nevertheless, isolated mitochondria retain biochemical functions such as respiration, 
membrane potential generation, and ATP synthesis. This makes isolated mitochondria a 
valuable model to study the effects of different agents, in our case mHtt, under tightly 
controlled experimental conditions and easy access to the organelles. Thus, the purpose 
of Figure 7 is to illustrate the lack of overt morphological differences in synaptic and 
nonsynaptic mitochondria isolated from WT and YAC128 mice. This, however, does not 
imply the lack of morphological differences in vivo.  
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Figure 6. Detection of wild-type mouse 
huntingtin (Htt) and mutant human 
huntingtin (mHtt) in homogenates, and 
cytosolic and synaptic mitochondrial 
fractions from 2-month-old YAC128 and 
WT FVB/NJ mice. In A, mHtt was 
detected with anti-polyQ 1C2 antibody as a 
single band exclusively in samples from 
YAC128 mice. The bands with lower 
molecular weights (~200 kDa and 100 
kDa) are present in both WT and YAC128 
samples and most likely represent a result 
of non-specific cross-reaction with 
unidentified polyglutamine-containing 
proteins. In B, Htt and mHtt were detected 
using western blotting with 2166 antibody, 
which recognizes both Htt and mHtt. In 
homogenates and cytosolic fractions from 
WT and YAC128 mice, a 350 kDa band, 
belonging to wild-type Htt, was detected, 
whereas two bands, most likely 
representing both Htt and mHtt, were 
detected in homogenates and cytosolic 
fractions from YAC128 mice. Tubulin and 
COX IV were used as cytosolic and 
mitochondrial markers, respectively. In 
mitochondrial fractions from both WT and 
YAC128 mice, faint bands corresponding 
to Htt were detected, whereas amounts of 
mHtt attached to mitochondria were too 
low to be reliably detected with 2166 
antibody. Only after an increase in protein 
loading (50 µg/lane) and in exposure time 
of the film, did mHtt band become evident 
(C). In A–C: H, homogenate; C, cytosolic fraction; M, mitochondrial fraction. In D, the 
results of densitometry of mHtt and Htt bands obtained with 2166 antibody applied to 
mitochondrial samples. Data are mean ± SEM, N = 7, *p < 0.01 comparing band 
intensity for mHtt and wild-type Htt. 
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Figure 7. Representative electron 
micrographs of nonsynaptic (A, B) 
and synaptic (C, D) brain mitochondria 
isolated from YAC128 (A, C) and WT 
(B, D) mice. Prior to fixation with 2.5% 
glutaraldehyde, mitochondria were 
incubated for 10 min at 37°C in the 
standard incubation medium. In E, 
representative images of orthodox, 
condensed and swollen mitochondria. In 
F, morphometric analysis of isolated 
mitochondria: o, orthodox mitochondria; 
c, condensed mitochondria; s, swollen 
mitochondria. Data are expressed as a 
percentage of the total number of 
analyzed mitochondria. Mitochondria 
were analyzed in a blind manner as 
described previously (Shalbuyeva et al. 
2006; Scorrano et al. 2002). The total 
number of mitochondria analyzed from 
each type of animal and each type of 
mitochondria was 450–500. 
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c. Respiration of purified brain nonsynaptic and synaptic mitochondria from 2- 
and 10-month-old YAC128 mice as well as unpurified brain, liver, and heart 
mitochondria from YAC128 mice.    
 Next, we investigated the effect of mHtt expression on respiration of mitochondria 
isolated from brain (synaptic and nonsynaptic), heart, and liver of WT and YAC128 mice. 
Previously, it was hypothesized that bovine serum albumin (BSA), usually used to 
preserve mitochondrial integrity during isolation and purification of brain mitochondria 
(Lai and Clark 1989), might interfere with mHtt binding to mitochondria and hence could 
eliminate a functional difference between mitochondria from HD transgenic mice and WT 
animals (Panov et al. 2003). To avoid the possible confounding effect of BSA, we 
omitted BSA from all isolation and incubation media. We measured mitochondrial 
respiratory activity with either a combination of Complex I substrates malate (1 mM) and 
pyruvate (3 mM), or with the Complex II substrate succinate (3 mM). In the latter case, 
incubation medium was supplemented with 3 mM glutamate to remove oxaloacetate, an 
endogenous inhibitor of succinate dehydrogenase (Wojtczak 1969;Brustovetsky and 
Dubinsky 2000a), via a transaminase reaction (Oestreicher et al. 1969). We assessed 
basal respiration with only substrates present in the incubation medium (state 2 or V2), 
respiration stimulated by ADP (state 3 or V3), respiration after exogenous ADP was 
consumed by mitochondria (state 4 or V4) and maximal, uncoupled respiration in the 
presence of 2,4-dinitrophenol (2,4-DNP, VDNP). Under each condition, the slope of the 
line in the respiration trace can be quantified and converted to a respiratory rate. Purified 
brain nonsynaptic and synaptic mitochondria isolated from 2- (Figs. 8 and 9) or 10-
month-old YAC128 mice (Figs. 10 and 11) had similar respiratory rates under all tested 
conditions compared with mitochondria isolated from age-matched WT animals. KCN (5 
mM) completely inhibited respiration, indicating that mitochondria solely contributed to 
oxygen consumption (Fig. 12). Immunoblotting confirmed the presence of mHtt in 
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mitochondria isolated from YAC128 mice (Figs. 8E and 9E). Since nonsynaptic and 
synaptic mitochondria undergo Percoll-gradient purification, it is conceivable that the 
isolation procedure to obtain purified mitochondria may result in the loss of cellular 
components that are required for mHtt-induced mitochondrial dysfunction. To test this 
possibility we also evaluated the respiratory activity of unpurified (mixture of 
mitochondria and synaptosomes) brain mitochondria. Additionally, although neurons are 
the most vulnerable cell type in HD, mHtt is a ubiquitously expressed protein that may 
potentially affect mitochondrial functions in tissues other than the brain. Indeed, at least 
one study has reported altered mitochondrial structure in cardiomyocytes of a transgenic 
mouse model of HD (Mihm et al. 2007). For this reason we also assessed the respiratory 
rates of heart and liver mitochondria from YAC128 mice. Unpurified brain, liver, and 
heart mitochondria isolated from YAC128 and WT mice also had similar respiratory rates 
(Figs. 13–15). These results suggest that mHtt does not affect respiration of 
mitochondria isolated from YAC128 mice.  
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Figure 8. Respiratory activity of brain nonsynaptic mitochondria isolated from 2-
month-old WT (blue traces) and YAC128 (red traces) mice. In A and B, 
representative traces for mitochondrial O2 consumption. Where indicated, nonsynaptic 
mitochondria (Mtc), 200 μM ADP and 60 μM 2,4-dinitophenol (2,4-DNP) were added. 
The slope of the line following each addition corresponds to a respiratory rate. In A, 
incubation medium was supplemented with 3 mM pyruvate (pyr) and 1 mM malate (mal). 
In B, incubation medium was with 3 mM succinate (succ) and 3 mM glutamate (glut). In 
C and D, statistical analysis of respiratory rates. Data are mean ± SEM, N = 10. In E, 
western blot, indicating the presence of mHtt in nonsynaptic mitochondria from YAC128 
mice. VDAC1 was used as a loading control. 
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Figure 9. Respiratory activity of brain synaptic mitochondria isolated from 2-
month-old WT (blue traces) and YAC128 (red traces) mice. In A and B, 
representative traces for mitochondrial O2 consumption. Where indicated, synaptic 
mitochondria (Mtc), 200 μM ADP and 60 μM 2,4-dinitophenol (2,4-DNP) were added. In 
A, incubation medium was supplemented with 3 mM pyruvate (pyr) and 1 mM malate 
(mal). In B, incubation medium was supplemented with 3 mM succinate (succ) and 3 
mM glutamate (glut). In C and D, statistical analysis of respiratory rates. Data are mean 
± SEM, N = 10. In E, western blot, showing the presence of mHtt in synaptic 
mitochondria from YAC128 mice. VDAC1 was used as a loading control. 
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Figure 10. Respiratory activity of nonsynaptic mitochondria isolated from 10-
month-old WT (blue traces) and YAC128 (red traces) mice. In A and B, 
representative traces for mitochondrial O2 consumption. Where indicated, mitochondria 
(Mtc), 200 μM ADP, and 60 μM 2,4-dinitophenol (2,4-DNP) were added. In A, incubation 
medium was supplemented with 3 mM pyruvate (pyr) and 1 mM malate (mal). In B, 
incubation medium contained 3 mM succinate (succ) and 3 mM glutamate (glut). In C 
and D, statistical analysis of respiratory rates. Data are mean±SEM *p < 0.05 comparing 
V4 respiratory rates of mitochondria from WT and YAC128 mice, N =7. 
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Figure 11. Respiratory activity of synaptic mitochondria isolated from 10-month-
old WT (blue traces) and YAC128 (red traces) mice. In A and B, representative traces 
for mitochondrial O2 consumption. Where indicated, mitochondria (Mtc), 200 μM ADP, 
and 60 μM 2,4-dinitophenol (2,4-DNP) were added. In A, incubation medium was 
supplemented with 3 mM pyruvate (pyr) and 1 mM malate (mal). In B, incubation 
medium contained 3 mM succinate (succ) and 3 mM glutamate (glut). In C and D, 
statistical analysis of respiratory rates. Data are mean±SEM. *p < 0.05 comparing V4 
respiratory rates of mitochondria from WT and YAC128 mice, N =7. 
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Figure 12. KCN completely inhibits respiration of isolated brain mitochondria. In A 
and B, representative traces for mitochondrial O2 consumption by nonsynaptic 
mitochondria from WT and YAC128 mice. In C and D, representative traces for 
mitochondrial O2 consumption by synaptic mitochondria from WT and YAC128 mice. 
Where indicated, mitochondria (Mtc), 200 μM ADP, 60 μM 2,4-dinitophenol (2,4-DNP), 
and 5 mM KCN were added. In A and C, incubation medium was supplemented with 3 
mM pyruvate (pyr) and 1 mM malate (mal). In B and D, incubation medium was 
supplemented with 3 mM succinate (succ) and 3 mM glutamate (glut). 
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Figure 13. Respiratory activity of unpurified brain mitochondria isolated from 2-
month-old WT (blue traces) and YAC128 (red traces) mice. In A and B, 
representative traces for mitochondrial O2 consumption. Where indicated, mitochondria 
(Mtc), 200 μM ADP, 1 μM oligomycin (to inhibit ATP synthase) and 60 μM 2,4-
dinitophenol (2,4-DNP) were added. In A, incubation medium was supplemented with 3 
mM pyruvate (pyr) and 1 mM malate (mal). In B, incubation medium contained 3 mM 
succinate (succ) and 3 mM glutamate (glut). In C and D, statistical analysis of respiratory 
rates. Data are mean±SEM, N =7. In E, western blot, showing the presence of mHtt in 
unpurified brain mitochondria from YAC128 mice. VDAC1 was used as a loading control. 
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Figure 14. Respiratory activity of liver mitochondria isolated from 2-month-old WT 
(blue traces) and YAC128 (red traces) mice. In A and B, representative traces for 
mitochondrial O2 consumption. Where indicated, mitochondria (Mtc), 200 μM ADP, and 
60 μM 2,4-dinitophenol (2,4-DNP) were added. In A, incubation medium was 
supplemented with 3 mM glutamate (glut) and 1 mM malate (mal). In B, incubation 
medium was with 3 mM succinate (succ) and 3 mM glutamate (glut). In C and D, 
statistical analysis of respiratory rates. Data are mean±SEM, N = 6. In E, western blot, 
showing the presence of mHtt in liver mitochondria from YAC128 mice. VDAC1 was 
used as a loading control. 
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Figure 15. Respiratory activity of heart mitochondria isolated from 2-month-old 
WT (blue traces) and YAC128 (red traces) mice. In A and B, representative traces for 
mitochondrial O2 consumption. Where indicated, mitochondria (Mtc), 200 μM ADP, 1 μM 
oligomycin (to inhibit ATP synthase) and 60 μM 2,4-dinitophenol (2,4-DNP) were added. 
In A, incubation medium was supplemented with 3 mM pyruvate (pyr) and 1 mM malate 
(mal). In B, incubation medium was with 3 mM succinate (succ) and 3 mM glutamate 
(glut). In C and D, statistical analysis of respiratory rates. Data are mean±SEM, N = 6. In 
E, western blot, showing the presence of mHtt in heart mitochondria from YAC128 mice. 
VDAC1 was used as a loading control. 
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d. Protein expression in mitochondria from WT and YAC128 mice. 
 Consistent with our data, Yano et al. (Yano et al. 2014) did not find a difference 
in respiration of synaptic and nonsynaptic mitochondria from R6/2 mice compared with 
mitochondria from WT animals. However, the authors presented evidence for mHtt-
induced inhibition of protein import into mitochondria, and suggested that such an 
inhibition might affect mitochondrial functions later in the disease progression (Yano et 
al. 2014). According to the authors, this inhibition of mitochondrial protein import should 
result in a decreased amount of nuclear encoded mitochondrial proteins. However, the 
authors did not provide immunoblotting data supporting this hypothesis (Yano et al. 
2014). In an earlier study, Orr et al. (Orr et al. 2008) demonstrated that expression of 
nuclear encoded Mn-dependent superoxide dismutase (MnSOD) as well as 30 and 70 
kDa subunits of succinate dehydrogenase (Complex II) is similar in brain mitochondria 
isolated from 3- and 10-month-old heterozygous knock-in 150Q/7Q mice as well as in 3-
month-old wild-type 7Q/7Q mice. Milakovic and Johnson (Milakovic and Johnson 2005) 
also failed to find a difference in expression of 30 and 70 kDa subunits of Complex II in 
mutant STHdhQ111/Q111 striatal cells compared with wild-type STHdhQ7/Q7 cells. In the 
present study, we analyzed expression of several nuclear-encoded mitochondrial 
proteins, including 39 kDa subunit of Complex I, 30 and 70 kDa subunits of Complex II, 
aconitase 2, subunit IV of cytochrome oxidase (COX IV), MnSOD and α-subunit of ATP 
synthase in brain mitochondria isolated from 2- and 10-month-old YAC128 and WT 
mice. In these immunoblotting experiments, we did not find any evidence for decreased 
expression of the analyzed proteins in mitochondria of YAC128 compared with 
mitochondria from WT mice regardless of their age (Fig. 16). Although these 
experiments indicate that there is no decrease in protein expression, the denaturing 
process inherent in SDS-PAGE may prevent the observation of more subtle changes to 
proteins such as alterations in a protein’s secondary structure or its native charge 
79 
density. Therefore, we performed Blue Native–PAGE followed by western blotting 
analysis of expression of Ndufa9, a nuclear-encoded subunit of Complex I (Fig. 17). 
Using this approach, we confirmed no difference in expression of the Complex I subunit 
in mitochondria isolated from YAC128 and WT mice. These findings argue against mHtt-
induced inhibition of the mitochondrial protein import and its potential role in inhibition in 
mitochondrial respiration.  
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Figure 16. Expression of nuclear encoded mitochondrial proteins in nonsynaptic 
and synaptic mitochondria isolated from 2- and 10-month-old WT and YAC128 
mice. In A, representative western blots generated with antibodies against nuclear 
encoded mitochondrial proteins including 39 kDa subunit of Complex I, 30 and 70 kDa 
subunits of Complex II, aconitase 2, subunit IV of cytochrome oxidase (COX IV), 
MnSOD and α-subunit of ATP synthase. In B–E, the results of densitometry performed 
with NIH ImageJ 1.48v software. Data are mean ± SEM, N = 7. 
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Figure 17. Blue Native gel electrophoresis and western blotting with brain 
mitochondria lysates. Lysates were prepared with brain synaptic and nonsynaptic 
mitochondria from 10-month-old WT and YAC128 mice as described in Materials and 
Methods. In A, a representative Blue Native gel. In B, western blotting with anti-Ndufa9 
antibody. Molecular weight of Ndufa9 is 39 kDa. However, after Blue Native–PAGE 
Ndufa9 is detected in the Complex I with molecular weight above 720 kDa (38). In C, the 
results of densitometry performed with NIH ImageJ 1.48v software. Data are mean ± 
SEM, N = 6. 
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e. Membrane potential measurements in nonsynaptic and synaptic mitochondria 
from YAC128 mice. 
 In addition to respiration, we also evaluated mitochondrial membrane potential 
(Δψ) in brain nonsynaptic and synaptic mitochondria by measuring distribution of the 
lipophilic cation tetraphenylphosphonium (TPP+) across the inner mitochondrial 
membrane (Kamo et al. 1979;Brustovetsky et al. 2002). TPP+ accumulates in 
mitochondria and is distributed across the inner mitochondrial membrane according to 
membrane potential, therefore measurement of changes in [TPP+]ext outside of 
mitochondria provides a means for monitoring mitochondrial membrane potential. The 
basal mitochondrial membrane potential and responses to ADP were identical in 
mitochondria from YAC128 and WT mice (Fig. 18). BSA increased membrane potential 
to the same extent in both YAC128 and WT mitochondria (Fig. 19) most likely due to 
binding and removal of free fatty acids (Spector et al. 1969) thus decreasing free fatty 
acid-mediated proton permeability of the inner mitochondrial membrane and leading to 
more polarized mitochondria (Skulachev 1991). Mitochondrial membrane potential 
appeared to be similar in both nonsynaptic and synaptic mitochondria from YAC128 and 
WT mice, indicating the lack of dysfunction in mitochondria bound with mHtt.  
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Figure 18. Mitochondrial membrane potential in nonsynaptic (A, B) and synaptic 
(C, D) mitochondria isolated from 2-month-old WT (blue traces) and YAC128 (red 
traces) mice. In A–D, representative traces for TPP+ accumulation indicating changes in 
mitochondrial membrane potential (Δψ) in response to 200 μM ADP and 60 µM 2,4-
dinitrophenol. In A and C, incubation medium was supplemented with 3 mM pyruvate 
(pyr) and 1 mM malate (mal). In B and D, incubation medium was supplemented with 3 
mM succinate (succ) and 3 mM glutamate (glut). The initial part of each trace that 
resembles a “stair-step” pattern is the calibration which consists of six 0.3 μM TPP+ 
pulses and is used to convert [TPP+] to mV membrane potential according to Nernst 
equation (Kamo et al. 1979). The upward deflection of the line following addition of 
mitochondria indicates accumulation of TPP+ due to mitochondrial membrane potential. 
Downward deflections of the line indicate the movement of TPP+ out of mitochondria and 
is interpreted as depolarization. In E and F, statistical analysis of mitochondrial 
membrane potential measured 2 min prior to ADP addition. Data are mean ± SEM, N = 
7. 
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Figure 19. The effect of bovine serum albumin (BSA) on mitochondrial membrane 
potential in nonsynaptic (A, B) and synaptic (C, D) mitochondria isolated from 2-
month-old WT (blue traces) and YAC128 (red traces) mice. Representative traces for 
TPP+ accumulation indicating changes in mitochondrial membrane potential (Δψ) in 
response to 0.1% BSA (free from fatty acids) and 60 μM 2,4-dinitrophenol. In A and C, 
incubation medium was supplemented with 3 mM pyruvate (pyr) and 1 mM malate (mal). 
In B and D, incubation medium contained 3 mM succinate (succ) and 3 mM glutamate 
(glut). 
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f. Cellular respiration and extracellular acidification of neurons and ATP/ADP 
measurements in isolated mitochondria and primary neurons from YAC128 mice.  
 To further examine a possible effect of mHtt on oxidative metabolism, we 
evaluated the respiratory activity of striatal and cortical neurons at 9 days in vitro (DIV) 
derived from YAC128 and WT mice (Fig. 20). To measure cell respiration, we used 
Seahorse XF24 flux analyzer. Cellular respiration was evaluated by measuring oxygen 
consumption rate (OCR). Simultaneously with respiration, we measured glycolytic 
activity by following the extracellular acidification rate (ECAR). However, the medium 
conditions used in this experiment were chosen to accentuate cellular respiration to 
maximize the possibility that even small differences in respiration could be detected 
between HD and WT cells, as described previously (Gouarne et al. 2013). Moreover, the 
experimental protocol for measurements of glycolysis differs from the protocol used here 
for respiration. For these reasons, ECAR data should be considered preliminary and will 
require further assessment. Nevertheless, we believe that even preliminary ECAR data 
may provide valuable information. To accentuate mitochondrial respiration, in addition to 
10 mM glucose, the bath solution was supplemented with 15 mM pyruvate (Oliveira et al. 
2007). We measured basal respiratory activity, oligomycin-sensitive respiration coupled 
to ATP synthesis, and maximal, uncoupled respiration in the presence of 2,4-
dinitophenol (2,4-DNP). At the end of the experiment, cells were treated with a 
combination of rotenone and antimycin A (both in 1 µm), to assess non-mitochondrial 
respiration. The experiments with striatal and cortical neurons revealed no difference in 
respiratory rates between cells from YAC128 and WT mice (Fig. 20A and B). 
Interestingly, maximal respiratory activity of striatal neurons was considerably lower than 
maximal, uncoupled respiration of cortical neurons (Fig. 20A and B). It is possible that 
this contributes to increased vulnerability of striatal neurons in HD. 
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 Oligomycin inhibits oxidative phosphorylation and stimulates glycolysis that is 
manifested in increased ECAR (Wu et al. 2007;Ismailoglu et al. 2014). However, 
because 2,4-DNP increases proton permeability of membranes and increases proton 
extrusion from the cell, ECAR cannot be used as an indicator of glycolytic activity in the 
presence of protonophore (Gouarne et al. 2013). Therefore, similarly to Gouarne et al. 
(Gouarne et al. 2013), we did not analyze ECAR data obtained after 2,4-DNP injection. 
Consequently, Figures 20C and D and 21C and D show bar graphs that illustrate basal 
and oligomycin-stimulated ECARs in cultured striatal and cortical neurons from YAC128 
and WT mice. 
 In our experiments, basal as well as oligomycin-stimulated ECARs were similar 
in neurons from YAC128 and WT mice, suggesting similar glycolytic activities in YAC128 
and WT cells incubated in ‘high glucose medium’ (Fig. 20C and D). Recently, Gouarne 
et al. reported that neurons from BACHD rats have lower maximal respiratory rates 
compared to cells from WT animals, but only if neurons were incubated in the ‘low 
glucose medium’ (2.5 mM glucose, no pyruvate) (Gouarne et al. 2013). We therefore 
examined respiratory activities of striatal and cortical neurons from YAC128 and WT 
mice in the ‘low glucose medium’ and did not find a significant difference (Fig. 21A and 
B). However, following oligomycin application, striatal neurons from YAC128 mice 
demonstrated slight, but statistically significant decrease in oligomycin-stimulated ECAR 
compared with cells from WT animals, suggesting some decline in glycolytic activity 
under these conditions (Fig. 21C and D). This is consistent with previously reported data 
(Gouarne et al. 2013). Thus, measurements of respiratory and glycolytic activities with 
primary striatal and cortical neurons from YAC128 and WT mice revealed the lack of 
respiratory deficits in cells expressing mHtt and only a marginal decrease in oligomycin-
stimulated glycolytic rate when cells were incubated in the ‘low glucose medium’. 
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 Consistent with the lack of respiratory defects, we did not find a difference in ATP 
and ADP levels in isolated nonsynaptic and synaptic brain mitochondria isolated from 2- 
and 10-month-old animals or in primary striatal neurons (10 DIV) from YAC128 and WT 
mice (Fig. 22). These results support the lack of bioenergetic deficiency in brain 
mitochondria and cultured neurons from YAC128 mice.  
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Figure 20. OCR and ECAR of cultured neurons from YAC128 and WT mice: ‘high 
glucose conditions’. In these experiments, we used striatal and cortical neurons 
derived from postnatal Day 1 YAC128 and WT mice. The cells were grown for 9 days in 
vitro (9 DIV) before measurements. The bath solution contained 10 mM glucose and 15 
mM pyruvate to accentuate mitochondrial respiration (Oliveira et al. 2007). Where 
indicated, cells were treated with 1 µM oligomycin (Oligo), 60 µM 2,4-dinitrophenol (2,4-
DNP), 1 µM rotenone (Rot) and 1 µM antimycin A (Ant). In A and B, OCR of striatal and 
cortical neurons, respectively. In C and D, ECAR of striatal and cortical neurons. The 
OCR and ECAR were measured with Seahorse XF24 flux analyzer (Seahorse 
Bioscience, Billerica, MA, USA) at 37°C with 105 cells per well. Data are mean ± SEM, N 
= 7. 
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Figure 21. OCR and ECAR of cultured neurons from YAC128 and WT mice: ‘low 
glucose conditions’. In these experiments, we used striatal and cortical neurons 
derived from postnatal Day 1 YAC128 and WT mice. The cells were grown for 9 days in 
vitro (9 DIV) before measurements. The bath solution contained 2.5 mM glucose. Where 
indicated, cells were treated with 1 µM oligomycin (Oligo), 60 µM 2,4-dinitrophenol (2,4-
DNP), 1 µM rotenone (Rot) and 1 µM antimycin A (Ant). In A and B, OCR of striatal and 
cortical neurons, respectively. In C and D, ECAR of striatal and cortical neurons. The 
OCR and ECAR were measured with Seahorse XF24 flux analyzer (Seahorse 
Bioscience, Billerica, MA, USA) at 37°C with 105 cells per well. Data are mean ± SEM, N 
= 7. *p < 0.05 compared to ECAR produced by WT mitochondria.  
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Figure 22. ADP and ATP content in brain mitochondria (A–D) and cultured striatal 
neurons (E and F) derived from YAC128 and WT mice. Synaptic and nonsynaptic 
mitochondria were isolated from 2- (A and B) or 10-month-old (C and D) mice. 
Mitochondria (50µg protein) were incubated for 10 min at 37°C in the standard 
incubation medium supplemented with 3 mM succinate and 3 mM glutamate. In E and F, 
cultured striatal neurons (10 DIV) were lysed on ice with Releasing Reagent (Sigma). 
Then, ADP (A, C, E) and ATP (B, D, F) were measured with ATP bioluminescent 
somatic cell assay kit (Sigma) using Glomax 20/20 luminometer (Promega) as described 
in Materials and Methods. In A–D, data are mean ± SEM, N = 7. In E and F, data are 
mean ± SEM, N = 10–11 dishes from five platings. 
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g. Whole-animal metabolic activity of YAC128 mice. 
 Although we did not find any difference in respiration of isolated mitochondria or 
cultured neurons from YAC128 and WT mice, these results could not exclude an effect 
of mHtt on mitochondrial respiration in vivo. Considering this, we tested oxidative 
metabolism of YAC128 and WT mice in vivo. In these experiments, we chose to use 10-
month-old animals, an age that HD mice have previously been found to show evidence 
of neurodegeneration (striatal atrophy) (Slow et al. 2003). Mice were kept in metabolic 
cages (Animal Monitoring System, Lab Master, TSE Systems, Midland, MI) for 72 h for 
acclimation and then for the following 96 h, animal OCR, CO2 release rate and motor 
activity were monitored. Because adipose tissue does not significantly contribute to 
overall O2 consumption, the lean body mass was determined for each mouse by dual-
energy X-ray absorptiometry (DEXA) scanning and the OCRs and CO2 release rates 
were normalized to animal lean body mass (DePaoli-Roach et al. 2012). Our 
experiments revealed that YAC128 mice and WT littermates have similar motor activity 
and comparable in vivo OCRs and CO2 release rates (Fig. 23). This finding suggests 
that there are no significant changes in energy metabolism in YAC128 mice. 
Additionally, we measured food consumption and fasted blood glucose in YAC128 and 
WT mice and found no difference in these parameters. However, YAC128 mice were 
heavier compared with age-matched WT mice and had larger percentage of body fat 
(Table 4). Thus, whole animal respirometry with YAC128 and WT mice confirmed the 
lack of respiratory deficiency and supported the conclusion that respiratory activity in 
YAC128 mice is not affected by mHtt.  
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Figure 23. Oxygen consumption (A), CO2 release (B), energy expenditure (C), and 
total physical activity (D) of 10-month-old YAC128 and WT mice. The animals were 
analyzed by indirect calorimetry in metabolic cages. Oxygen consumption, CO2 release, 
and energy expenditure were normalized to lean mouse body mass determined by 
DEXA scanning. The shaded areas correspond to the 12-h dark cycles. Data are mean ± 
SEM, N = 8. 
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Table 4. Body composition of YAC128 and WT mice. 
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h. Ca2+ uptake capacity of nonsynaptic and synaptic mitochondria from YAC128 
mice. 
Mitochondrial Ca2+ uptake plays an essential role in removal of excessive Ca2+ 
from the cytosol (Bernardi et al. 1999) and therefore is required for maintenance of Ca2+ 
homeostasis in the cell and for cell survival (Bernardi and Rasola 2007). Ca2+ 
accumulation in mitochondria is restricted by induction of the mitochondrial PTP that 
depolarizes mitochondria and thereby limits their ability to accumulate additional Ca2+ 
(Bernardi et al. 1999). We tested the effect of mHtt on Ca2+ uptake capacity of 
mitochondria isolated from YAC128 mice and compared it with Ca2+ uptake capacity of 
mitochondria from wild-type FVB/NJ mice. A possible decrease in mitochondrial Ca2+ 
uptake capacity could serve as an indicator of mitochondrial impairment in HD such as 
increased propensity to induction of PTP. Conversely, unchanged or augmented Ca2+ 
uptake capacity suggests that there are no defects in mitochondrial Ca2+ handling. In our 
hands, Ca2+ uptake capacity of nonsynaptic mitochondria from 2- and 12-month-old 
YAC128 mice was slightly, but statistically significantly increased compared with 
mitochondria from FVB/NJ mice (Fig. 24). This result is consistent with data previously 
reported by Oliveira et al. (2007). The slight increase in Ca2+ uptake capacity was 
observed with both Complex I substrates pyruvate/malate and the Complex II substrate 
succinate used in combination with glutamate to prevent accumulation of oxaloacetate 
and inhibition of succinate dehydrogenase (Wojtczak 1969;Brustovetsky and Dubinsky 
2000a). Synaptic mitochondria from 2-month-old YAC128 mice also had a slight, but 
statistically significant increase in Ca2+ uptake capacity compared with mitochondria from 
age-matched FVB/NJ mice regardless of oxidative substrates (Fig. 25A and D). BSA 
(Fig. 25B) considerably increased Ca2+ uptake capacity in synaptic mitochondria from 
both WT and YAC128 mice. Interestingly, Ca2+ uptake capacity of synaptic mitochondria 
95 
from 12-month-old YAC128 mice was noticeably increased compared with mitochondria 
from 2-month-old YAC128 mice and age-matched 12-month-old FVB/NJ mice 
(Fig. 25C). 
Earlier, some investigators reported an increased propensity to PTP induction in 
mitochondria exposed to mHtt (Choo et al. 2004;Fernandes et al. 2007;Lim et al. 
2008;Quintanilla et al. 2013). However, in a previous study no evidence was found for 
increased susceptibility to PTP induction in striatal and cortical mitochondria from HD 
mice compared with mitochondria from wild-type mice (Brustovetsky et al. 2005a). In this 
earlier study, investigators studied PTP induction in nonsynaptic mitochondria. In the 
present study, we for the first time tested synaptic (neuronal) mitochondria from YAC128 
and WT mice (Fig. 26). Mitochondrial swelling and depolarization are the major 
manifestations of PTP induction (Bernardi et al. 1999). Consequently, we investigated an 
induction of the PTP by simultaneously monitoring a decrease in light scattering of the 
mitochondrial suspension, indicative of swelling of the organelles, and a release of TPP+ 
from mitochondria, indicative of mitochondrial depolarization. Ca2+, in a concentration-
dependent manner, induced swelling and depolarization of synaptic mitochondria (Fig. 
26). To quantify swelling of mitochondria, at the end of the experiment we applied 
alamethicin (AL), an antibiotic that causes maximal mitochondrial swelling (Brustovetsky 
and Dubinsky 2000b). Maximal swelling was taken as 100% and mitochondrial swelling 
following 15 minutes incubation with Ca2+ was calculated as a percentage of maximal 
swelling. Both mitochondrial swelling and depolarization in response to Ca2+ were 
comparable in mitochondria isolated from YAC128 and wild-type mice. Thus, in our 
experiments mHtt failed to increase propensity to PTP induction in synaptic (neuronal) 
mitochondria from YAC128 mice. 
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Figure 24. Ca2+ uptake capacity of brain nonsynaptic mitochondria isolated from 
YAC128 and wild-type FVB/NJ mice. Mitochondria were incubated at 37°C in the 
standard incubation medium supplemented either with 3 mM succinate plus 3 mM 
glutamate or with 3 mM pyruvate plus 1 mM malate as indicated in the Figure. In all Ca2+ 
uptake experiments, 100 μM ADP and 1 μM oligomycin were present in the incubation 
medium. When Ca2+ is added to the chamber, there is a downward deflection of the 
trace, indicating an increase in the external [Ca2+]. The trace goes up as Ca2+ is removed 
from the external medium due to uptake by mitochondria. In A and B, mitochondria were 
isolated from 2-month-old mice. In C, mitochondria were isolated from 12-month-old 
mice. In A–C, where indicated 10 μM Ca2+ pulses were applied to mitochondria until 
mitochondria fail to uptake additional Ca2+. In D, statistical analysis of Ca2+ uptake 
capacity of mitochondria from YAC128, and wild-type FVB/NJ mice. Data are 
mean ± SEM, *p < 0.05 compared with mitochondria from FVB/NJ, N = 9. 
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Figure 25. Ca2+ uptake capacity of brain synaptic mitochondria isolated from 
YAC128 and wild-type FVB/NJ mice. Mitochondria were incubated at 37°C in the 
standard incubation medium supplemented either with 3 mM succinate plus 3 mM 
glutamate or with 3 mM pyruvate plus 1 mM malate as indicated in the Figure. In all Ca2+ 
uptake experiments, 100 μM ADP and 1 μM oligomycin were present in the incubation 
medium. In B, incubation medium was additionally supplemented with 0.1% bovine 
serum albumin (BSA) (free from fatty acids). In A, B, and D, mitochondria were isolated 
from 2-month-old mice. In C, mitochondria were isolated from 12-month-old mice. In A–
D, where indicated 10 μM Ca2+ pulses were applied to mitochondria until mitochondria 
fail to uptake additional Ca2+. In E, statistical analysis of Ca2+ uptake capacity of 
mitochondria from YAC128 and wild-type FVB/NJ mice. Data are mean ± SEM, 
*p < 0.05 comparing with FVB/NJ mitochondria; **p < 0.01 compared with mitochondria 
from 12-month-old FVB/NJ mice, N = 9. 
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Figure 26. Ca2+-induced mitochondrial swelling and depolarization in synaptic 
mitochondria from WT (A, C, E) and YAC128 (B, D, F) mice. Mitochondrial swelling 
was evaluated by following a decline in light scattering of mitochondrial suspension (red 
traces). A decrease in light scattering indicates mitochondrial swelling. Changes in 
mitochondrial membrane potential were evaluated by following distribution of 
tetraphenylphosphonium (TPP+) between incubation medium and mitochondrial matrix 
(black traces). The decrease in TPP+ concentration in the incubation medium ([TPP+]ext) 
indicates TPP+ accumulation in mitochondria and high membrane potential. The release 
of TPP+ from mitochondria indicates a decrease in membrane potential. Mitochondrial 
swelling and membrane potential were evaluated simultaneously at 37°C. Where 
indicated 25, 50, or 100 μM Ca2+ was applied to mitochondria (Mtc). At the end of the 
experiments, 60 μM 2,4-dinitrophenol (2,4-DNP) was applied to completely depolarize 
mitochondria and, then, 30 μg/ml alamethicin (AL) was added to induce maximal 
mitochondrial swelling, taken as 100%. The amount of Ca2+-induced swelling was 
determined as percentage of maximal swelling (shown in A as X%). In G, percentage of 
Ca2+-induced mitochondrial swelling. Data are mean ± SEM, N=8. 
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B. Respiration and Ca2+ uptake capacity in striatal nonsynaptic and synaptic 
mitochondria isolated from YAC128 mice. 
 Earlier findings suggested abnormalities in mitochondrial respiration and defects 
in Ca2+ handling in mitochondria from HD mouse and cell models (Tabrizi et al. 
2000;Panov et al. 2002;Choo et al. 2004;Lim et al. 2008;Aidt et al. 2013;Damiano et al. 
2013). However, in the previous section, we tested the possible deleterious effects of 
mHtt on mitochondrial oxidative metabolism and Ca2+ handling using isolated 
nonsynaptic and synaptic mitochondria from the whole brain of YAC128 mice. 
However, no evidence was found for mitochondrial dysfunction using mitochondria 
isolated from the whole brain of YAC128 mice. In HD, different brain regions have 
different susceptibility to degeneration with striatum being most vulnerable (Vonsattel 
and DiFiglia 1998). Consequently, it is conceivable that isolation of mitochondria from 
the whole brain could be a reason for our failure to detect mitochondrial dysfunction in 
HD mice. In the present section, the respiratory activity and Ca2+ handling in 
mitochondria isolated exclusively from the striatal tissues of YAC128 mice were 
assessed.  
a. Clasping phenotype of early symptomatic YAC128 mice. 
 In this section, the YAC128 mice used ranged in age from 8 to 10 weeks and 
already showed signs of motor dysfunction manifested as clasping of the fore- and hind-
limbs when suspended by the tail (see Fig. 5A and B). Since the mice exhibited this 
phenotype, it suggests that if altered mitochondrial respiration or Ca2+ handling 
contributed to such behavioral aberrations, we should be able to detect such defects in 
brain mitochondria isolated from these mice. For all experiments, age-matched genetic 
background FVB/NJ mice were used as control. Before all experiments, every mouse 
was genotyped by PCR on tail DNA to confirm the presence or absence of the transgene 
as described in the first section (see Fig. 5C). 
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b. Expression of mHtt in striatal mitochondria and purity of mitochondrial 
preparations. 
 Nonsynaptic mitochondria were derived from neuronal somata and glial cells 
whereas synaptic mitochondria were isolated from neuronal synaptic terminals and, 
therefore, were of exclusively neuronal origin. Fig. 27A and B shows the absence of 
MEK1/2, a cytosolic marker, and calnexin, an endoplasmic reticulum (ER) marker, in 
mitochondrial fractions, suggesting the absence of cytosolic and ER contaminations. On 
the other hand, mitochondrial fractions contained augmented levels of Complex II, 
70 kDa subunit (CII, 70) indicating mitochondrial enrichment in these fractions. 
Mitochondria from YAC128, but not FVB/NJ mice, contained mHtt detected with mouse 
monoclonal mHtt-specific antibody 1C2 (1:1000, mAb 1574, Millipore, Temecula, CA) 
that recognizes the polyglutamine stretch of the protein (Fig. 27C). This is consistent 
with our previous data (Fig. 6) and with results from others (Choo et al. 2004). Huntingtin 
protein and its mutated form, mHtt, reside in the cytosol (Bates et al. 2015) and, 
therefore, the presence of mHtt in the mitochondrial fraction could be due to cytosolic 
contamination. However, because mitochondrial fractions did not contain detectable 
amounts of cytosolic contamination, mHtt present in mitochondrial fractions (Fig. 27C) 
was unlikely to be the result of cytosolic contamination (Fig. 27A and B). Thus, in our 
study we used striatal nonsynaptic and synaptic mitochondria which were essentially 
free from cytosolic and ER contaminations and contained mHtt attached to mitochondria. 
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Figure 27. Purity of striatal nonsynaptic (Nonsynap) and synaptic (Synap) 
mitochondria isolated from FVB/NJ (A) and YAC128 (B) mice and detection of 
mHtt in mitochondrial fractions (C). In A and B, purity of striatal mitochondrial fraction 
was assessed by western blotting. Homogenates (Homogen), cytosolic, and 
mitochondrial fractions were analyzed using antibodies against calnexin (ER marker), 
MEK1/2 (cytosolic marker), and the 70 kDa subunit of Complex II (mitochondrial 
marker). In C, mHtt was detected as a single band exclusively in samples from YAC128 
mice using the mouse monoclonal anti-polyQ antibody 1C2. The 70 kDa subunit of 
Complex II was used as a mitochondrial marker and a loading control.  
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c. Respiration of nonsynaptic and synaptic striatal mitochondria from YAC128 
mice. 
 In our experiments, we used striatal nonsynaptic mitochondria fueled with 3 mM 
pyruvate and 1 mM malate, a combination of Complex I-linked substrates. Mitochondrial 
respiratory rates were measured under various conditions: basal mitochondrial 
respiration in the presence of only substrates (V2), ADP-stimulated respiration (V3, 300 
μM ADP), respiration following ADP depletion (V4), and maximal, 2,4-dinitrophenol (2,4-
DNP)-stimulated respiration (VDNP, 60 μM 2,4-DNP). Earlier, it was reported that the 
functional difference between mitochondria from HD and wild-type animals could be 
reliably detected only in the absence of BSA (Panov et al. 2003). In the aforementioned 
study, BSA eliminated the difference and it was proposed that BSA displaces mHtt from 
the mitochondrial outer membrane. Consequently, BSA was omitted from all isolation 
and incubation solutions in our experiments shown in Fig. 28. In these experiments, 
striatal mitochondria isolated from YAC128 and FVB/NJ mice had similar respiratory 
rates under every experimental condition.  
 Previously, it was shown that inhibition of Complex II with 3-nitropropionic acid 
recapitulated HD pathology in animals (Brouillet et al. 1999) and it was demonstrated 
that activity of Complex II is decreased in striatum of HD patients and in HD mouse 
striatal neurons (Benchoua et al. 2006). Correspondingly, in our experiments, we used 
3 mM succinate as a mitochondrial substrate in combination with 3 mM glutamate to 
remove oxaloacetate via transamination reaction and thus prevent oxaloacetate-
mediated inhibition of Complex II (Wojtczak 1969;Brustovetsky and Dubinsky 2000a). In 
addition, the incubation medium was supplemented with 0.1% BSA (free from fatty 
acids) to preserve mitochondrial integrity and improve mitochondrial functionality (Lai 
and Clark 1989). In our previous study, we found that incubation of isolated mitochondria 
with 0.1% BSA failed to displace mHtt from the organelles (Pellman et al. 2015) and, 
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therefore, we expected to detect mHtt effects on mitochondria despite the presence of 
BSA. In these experiments, we used nonsynaptic and synaptic mitochondria isolated 
from striata of YAC128 and FVB/NJ mice. Similar to our previously described 
experiments (Fig. 28), we did not find any difference in respiratory activity between 
mitochondria from YAC128 and wild-type FVB/NJ mice (Fig. 29). 
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Figure 28. Respiratory activity of striatal nonsynaptic mitochondria isolated from 
2-month-old FVB/NJ (blue trace) and YAC128 (red trace) mice. In A, representative 
traces of oxygen consumption by striatal nonsynaptic mitochondria. Where indicated, 
mitochondria (30 μg protein), 300 μM ADP, or 60 μM 2,4-dinitrophenol (2,4-DNP) were 
added. The incubation medium was supplemented with the Complex I substrates 
pyruvate (3 mM) plus malate (1 mM). In B, the pooled group results demonstrating 
respiratory rates of striatal nonsynaptic mitochondria. Data are mean ± SEM, N = 5. 
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Figure 29. Respiratory activity of striatal nonsynaptic and synaptic mitochondria 
isolated from 2-month-old FVB/NJ (blue traces) and YAC128 (red traces) mice. 
Representative traces of oxygen consumption by either striatal nonsynaptic (A) or 
striatal synaptic (B) mitochondria. Where indicated, mitochondria (30 μg protein), 200 
μM ADP, or 60 μM 2,4-dinitrophenol (2,4-DNP) were added. The incubation medium 
was supplemented with the Complex II substrate succinate (3 mM) plus glutamate 
(3 mM). Additionally, incubation medium was supplemented with 0.1% BSA (free from 
fatty acids) to maintain mitochondrial integrity (Lai and Clark 1989). The pooled group 
results demonstrating respiratory rates are shown for striatal nonsynaptic (C) and striatal 
synaptic (D) mitochondria. Data are mean ± SEM, N = 5 (nonsynaptic), N = 4 (synaptic). 
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d. Expression of nuclear-encoded proteins in mitochondria from YAC128 and WT 
mice. 
 Recently, inhibition of protein import machinery in mitochondria from HD mice 
was reported and suggested to be a possible cause of bioenergetic deficit in HD (Yano 
et al. 2014). The decrease in the levels of nuclear-encoded mitochondrial proteins 
seems to be a logical consequence of inhibition of mitochondrial import into 
mitochondria. However, this was not tested in the recent study (Yano et al. 2014). In the 
previous section with mitochondria isolated from the whole brain of YAC128 and wild-
type FVB/NJ mice no difference was found in expression of nuclear-encoded proteins in 
mitochondria isolated from the whole brains. In the present section, the levels of protein 
expression in striatal nonsynaptic and synaptic mitochondria from YAC128 and FVB/NJ 
mice were evaluated using immunoblotting followed by densitometry (Fig. 30). In these 
experiments, we did not find a difference in expression of randomly chosen nuclear-
encoded proteins located in the inner membrane or matrix of mitochondria from YAC128 
and FVB/NJ mice. We also did not find a difference in expression of VDAC1, a protein of 
the mitochondrial outer membrane. 
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Figure 30. Expression of nuclear encoded mitochondrial proteins in nonsynaptic 
and synaptic striatal mitochondria derived from FVB/NJ and YAC128 mice. In A 
and C, are representative western blots of nonsynaptic and synaptic striatal 
mitochondria isolated from FVB/NJ and YAC128 mice probed with various antibodies 
against nuclear-encoded mitochondrial proteins including 39 kDa subunit of Complex I, 
30 and 70 kDa subunits of Complex II, Aconitase 2, Mn-dependent superoxide 
dismutase (Mn-SOD), a subunit of ATP synthase, cyclophilin D (CyD), and cytochrome 
oxidase subunit IV (COX IV). Voltage-dependent anion channel isoform 1 (VDAC1) was 
used as a loading control. In B and D, the results of densitometry performed with NIH 
ImageJ 1.48v software. Data are mean ± SEM, N = 6. 
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e. Ca2+ uptake capacity of striatal nonsynaptic and synaptic mitochondria from 
YAC128 and WT mice.  
 Earlier, it was reported that mitochondria from HD mouse and cell models have 
decreased Ca2+ uptake capacity compared with mitochondria from wild-type animals and 
cells (Panov et al. 2002;Milakovic et al. 2006;Gellerich et al. 2008;Lim et al. 2008). 
However, in the previous section, we assessed Ca2+ uptake capacity in mitochondria 
isolated from the whole brains of YAC128 and did not find a difference compared to 
mitochondria from age-matched WT animals. In the present section, Ca2+ uptake 
capacity in striatal mitochondria from YAC128 and their genetic background FVB/NJ 
mice was evaluated. Nonsynaptic mitochondria incubated without BSA and fueled with a 
combination of 3 mM pyruvate and 1 mM malate or with a combination of 3 mM 
succinate and 3 mM glutamate (Fig. 31A and B) were used. In both cases, Ca2+ uptake 
capacities of mitochondria from YAC128 and FVB/NJ mice were similar. In the latter 
case, supplementing incubation medium with BSA significantly increased Ca2+ uptake 
capacity of mitochondria from both YAC128 and FVB/NJ mice without revealing any 
difference between mitochondria from these animals (Fig. 31C). Fig. 31D shows 
statistical analysis of these experiments.  
 Next, we tested striatal synaptic mitochondria from YAC128 and FVB/NJ mice 
(Fig. 32). Mitochondria were fueled with a combination of 3 mM succinate and 3 mM 
glutamate and incubated without BSA. We did not find a difference in Ca2+ uptake 
capacity in striatal synaptic mitochondria from YAC128 and FVB/NJ mice (Fig. 32A). 
Addition of BSA to the incubation medium significantly increased Ca2+ uptake capacity in 
mitochondria from both YAC128 and FVB/NJ mice (Fig. 32B). Interestingly, under these 
conditions striatal synaptic mitochondria from YAC128 mice accumulated even more 
Ca2+ than mitochondria from WT animals. Fig. 32C shows statistical analysis of these 
experiments. Taken together, evaluation of mitochondrial Ca2+ uptake capacity did not 
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provide evidence for defects in Ca2+ handling by striatal mitochondria from YAC128 
mice. 
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Figure 31. Ca2+ uptake capacity of brain nonsynaptic mitochondria isolated from 
the striatum of FVB/NJ (blue traces) and YAC128 (red traces) mice. Mitochondrial 
Ca2+ uptake capacity was measured in the standard incubation medium supplemented 
with the Complex I substrates pyruvate (3 mM) and malate (1 mM) (A), or the Complex II 
substrate succinate plus glutamate (both in 3 mM) (B). In C, in addition to succinate plus 
glutamate, the incubation medium was supplemented with 0.1% BSA (free from fatty 
acids). In all experiments, the incubation medium was also supplemented with 100 µM 
ADP and 1 µM oligomycin (Chalmers and Nicholls 2003). Where indicated, 10 µM Ca2+ 
pulses (delivered as CaCl2) were applied to mitochondria until mitochondria were unable 
to accumulate additional Ca2+ and released previously accumulated Ca2+. In D, the 
pooled group results demonstrating Ca2+ uptake capacity of striatal nonsynaptic 
mitochondria from FVB/NJ and YAC128 mice. Data are mean ± SEM, N = 4. 
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Figure 32. Ca2+ uptake capacity of brain synaptic mitochondria isolated from the 
striatum of FVB/NJ (blue traces) and YAC128 (red traces) mice. Mitochondrial Ca2+ 
uptake capacity was measured in the standard incubation medium supplemented with 
the Complex II substrate succinate (3 mM) plus glutamate (3 mM) in the absence (A) or 
presence of 0.1% BSA (B). In all experiments, the incubation medium was also 
supplemented with 100 µM ADP and 1 µM oligomycin (Chalmers and Nicholls 2003). 
Where indicated, 10 µM Ca2+ pulses (delivered as CaCl2) were applied to mitochondria 
until mitochondria were unable to accumulate additional Ca2+ and released previously 
accumulated Ca2+. In C, the pooled group results showing Ca2+ uptake capacity of 
striatal synaptic mitochondria from FVB/NJ and YAC128 mice. Data are mean ± SEM, *p 
< 0.05 comparing mitochondria from YAC128 and FVB/NJ mice in the presence of 0.1% 
BSA, N = 5. 
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C. Oxidative metabolism and Ca2+ handling in the R6/2 mouse model of HD. 
 In the previous sections, the effect of human full-length mHtt on respiratory 
activity and Ca2+ uptake capacity in brain synaptic and nonsynaptic mitochondria as well 
as striatal and cortical neurons from transgenic YAC128 mice was investigated. Despite 
significant effort, no evidence was found for mHtt-induced alterations in respiration and 
Ca2+ uptake capacity of mitochondria from wild-type (WT) and YAC128 mice. Whether 
HD pathogenesis is mediated by full-length mHtt or fragments of mHtt remains not 
completely understood. Previous studies suggested that mHtt fragments might be more 
toxic than full-length mHtt (Kim et al. 1999;Li et al. 2000) and it was shown that reduction 
in mHtt fragment generation improved the phenotype of HD mice (Wellington et al. 
2000;Tian et al. 2014;Wong et al. 2015). Here, we hypothesized that fragments of 
human mHtt, contrary to full-length human mHtt, are more deleterious and exert a 
detrimental effect on mitochondrial respiration and Ca2+ handling. Consequently, in 
the present section, the effect of mHtt fragments on mitochondrial respiratory activity and 
Ca2+ handling in synaptic and nonsynaptic brain mitochondria and striatal neurons from 
the R6/2 mouse model of HD was assessed. In our experiments, we used the R6/2 
mouse model of HD because it expresses an exon 1 fragment of human mHtt 
(Mangiarini et al. 1996). These mice exhibit a behavioral phenotype that manifests by 6 
weeks of age as limb clasping when suspended by the tail (Mangiarini et al. 1996;Stack 
et al. 2005). The presence of this phenotype is consistent with previous reports 
describing this and other mouse models of HD (Mangiarini et al. 1996;Reddy et al. 
1999). 
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a. Clasping phenotype of R6/2 mice and respiration of nonsynaptic and synaptic 
mitochondria derived from R6/2 and WT mice. 
 To assess the effect of mHtt fragments on mitochondrial respiration, we used 
Percoll gradient-purified brain nonsynaptic (neuronal plus glial) and synaptic (pure 
neuronal) mitochondria isolated from 6- to 8-week-old R6/2 and background B6CBA 
(WT) mice. Each R6/2 mouse demonstrated clasping behavior and each animal was 
genotyped to confirm the presence of the mutation in the Htt gene (Fig. 33). Overall, out 
of 267 6- to 8-week-old R6/2 mice of both sexes (144 males and 123 females) tested for 
clasping behavior, clasping behavior was detected in 191 animals (106 males and 85 
females). WT mice did not display clasping behavior. Previously, it was hypothesized 
that bovine serum albumin (BSA) may displace mHtt from the outer mitochondrial 
membrane and hence preclude it from exerting deleterious effects on mitochondrial 
functions (Panov et al. 2003). Therefore, although BSA is commonly used during 
mitochondrial isolation and purification to maintain integrity of brain mitochondria (Lai 
and Clark 1989), we omitted BSA from all of our experiments involving isolated 
mitochondria unless stated otherwise. We assessed mitochondrial respiratory activity in 
both nonsynaptic (Fig. 34) and synaptic (Fig. 35) mitochondria using either a 
combination of the Complex I substrates pyruvate (3 mM) and malate (1 mM) or the 
Complex II substrate succinate (3 mM). In experiments with succinate, the incubation 
medium was supplemented with glutamate (3 mM) to remove oxaloacetate by 
transaminase reaction and prevent oxaloacetate-mediated inhibition of succinate 
dehydrogenase (Wojtczak 1969;Brustovetsky and Dubinsky 2000a). For all experiments, 
basal respiration of mitochondria was measured in the presence of substrates only (V2), 
followed by ADP-stimulated respiration (V3), controlled respiration after ADP-depletion 
(V4), and, finally, maximal, uncoupled respiration stimulated by 2,4-dinitrophenol (VDNP). 
In these experiments, we found that under all tested conditions nonsynaptic and synaptic 
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mitochondria from R6/2 animals had similar respiratory rates compared with 
mitochondria from WT animals (Figs. 34 and 35).  
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Figure 33. Comparison of motor phenotype of 6-week-old R6/2 and WT mice and 
representative genotyping. In A, typical posture of a WT mouse following suspension 
by the tail with fore- and hind-limbs extended away from the body (B) the usual feet-
clasping posture adopted by an R6/2 mouse within 10 s of suspension by the tail. In C, 
representative genotyping data of tail tissue from WT and R6/2 mice. In D, internal 
positive control. 
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Figure 34. Respiratory activity of brain nonsynaptic mitochondria isolated from 6- 
to 8-week-old WT (blue traces) and R6/2 (red traces) mice. In A and B, 
representative traces of mitochondrial O2 consumption for mitochondria at 37 °C in 
incubation medium supplemented with pyruvate (3 mM) plus malate (1 mM) or succinate 
(3 mM) plus glutamate (3 mM), respectively. Arrows indicate the addition of either 
nonsynaptic mitochondria (Mtc), 200 µM ADP, or 60 µM 2,4-DNP. In C and D, statistical 
analyses of respiratory rates. Data are presented as mean ± SEM from 5 separate 
experiments. Here and in all other experiments with isolated mitochondria, three WT and 
three transgenic R6/2 mice were used in each experiment. 
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Figure 35. Respiratory activity of brain synaptic mitochondria isolated from 6- to 
8-week-old WT (blue traces) and R6/2 (red traces) mice. In A and B, representative 
traces of mitochondrial O2 consumption for mitochondria at 37 °C in incubation medium 
supplemented with pyruvate (3 mM) plus malate (1 mM) or succinate (3 mM) plus 
glutamate (3 mM), respectively. Arrows indicate the addition of either synaptic 
mitochondria (Mtc), 200 µM ADP, or 60 µM 2,4-DNP. In C and D, statistical analyses of 
respiratory rates. Data are presented as mean ± SEM from five separate experiments. 
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b. Expression of nuclear-encoded proteins in mitochondria from R6/2 mice. 
 In line with our data, Yano et al. (Yano et al. 2014) did not find a difference in 
respiratory activity of synaptic and nonsynaptic mitochondria from R6/2 mice compared 
with mitochondria from WT animals. On the other hand, the authors found evidence for 
mHtt-induced inhibition of protein import into mitochondria, and proposed that such an 
inhibition might alter mitochondrial functions at later stages of HD (Yano et al. 2014). We 
analyzed expression of several nuclear-encoded mitochondrial proteins, including a 39 
kDa subunit of Complex I, 30 and 70 kDa subunits of Complex II, aconitase 2, Mn-
dependent superoxide dismutase (MnSOD), cyclophilin D (CyD) and α-subunit of ATP 
synthase in brain nonsynaptic and synaptic mitochondria isolated from 8-week-old R6/2 
and WT mice. VDAC1, (voltage-dependent anion channel 1 or mitochondrial porin), a 
protein in the outer mitochondrial membrane, was used as a loading control. In these 
experiments, we did not find any evidence for decreased expression of the analyzed 
proteins in mitochondria from R6/2 compared with mitochondria from WT mice (Fig. 36). 
These findings argue against mHtt-induced inhibition of mitochondrial protein import and 
its potential role in inhibition of mitochondrial respiration.  
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Figure 36. Expression of nuclear encoded mitochondrial proteins in nonsynaptic 
and synaptic mitochondria isolated from 8-week-old WT and R6/2 mice. In A and C, 
representative western blots of nonsynaptic (A) or synaptic (C) mitochondria generated 
with antibodies against nuclear encoded mitochondrial proteins including 39 kDa subunit 
of Complex I, 30 and 70 kDa subunits of Complex II, aconitase 2, MnSOD, CyD, and α-
subunit of ATP synthase (ATP synthase, α). VDAC1 was used as a loading control. In B 
and D, the results of densitometry performed with NIH ImageJ 1.48v software. Data are 
mean ± SEM from six separate experiments. 
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c. Cellular respiration and extracellular acidification of striatal neurons from R6/2 
mice.  
 Although mitochondria isolated from brains of R6/2 and WT mice had similar 
respiratory activities, we could not rule out the effect of mHtt fragments on mitochondrial 
respiration under more physiological conditions. Striatum is the most vulnerable region 
of the brain in HD (Zuccato et al. 2010). Consequently, we examined the respiratory 
activities of cultured striatal neurons derived from R6/2 and WT mice using the Seahorse 
XF24 extracellular flux analyzer. Additionally, in these experiments we evaluated 
glycolytic activities in striatal neurons. OCR was used to evaluate cellular respiration and 
extracellular acidification rate (ECAR) was used to assess glycolytic activity. Each 
experiment followed the same protocol with sequential measurements of basal 
respiratory activity, oligomycin-sensitive respiration coupled to ATP synthesis, and 2,4-
DNP-stimulated, maximal respiration. At the end of the experiment, neurons were 
treated with rotenone and antimycin A to completely inhibit mitochondrial respiration. It 
was previously suggested that supplementing the bath solution with 15 mM pyruvate in 
addition to 10 mM glucose would accentuate mitochondrial respiration (Oliveira et al. 
2007). Under these ‘high glucose plus pyruvate’ conditions, we did not find any 
difference in respiration and glycolytic activities of striatal neurons from R6/2 and WT 
mice (Fig. 37A and C).  
 Recently, it was proposed that impaired respiratory activity may become 
apparent in mHtt-expressing neurons when the cells are incubated in a ‘low glucose’ 
medium that contained no pyruvate (Gouarne et al. 2013). Under these conditions, 
neurons from BACHD rats had decreased FCCP-stimulated maximal respiratory rates 
compared with neurons from WT animals. We assessed OCR and ECAR of striatal 
neurons from R6/2 and WT animals in ‘low glucose’ medium (2.5 mM glucose, no 
pyruvate) and did not find any statistically significant difference in respiratory and 
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glycolytic activities of these cells (Fig. 37B and D). Consistent with the lack of 
impairment in respiratory and glycolytic activities in striatal neurons, ATP levels in 
neurons from R6/2 mice (17.9 ± 1.1 nmol ATP/mg protein, N = 5) were not statistically 
different compared with ATP levels in neurons from WT mice (18.7 ± 1.0 nmol ATP/mg 
protein, N = 5). 
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Figure 37. OCR and ECAR of cultured striatal neurons from WT and R6/2 mice in 
‘high’ and ‘low’ glucose medium conditions. Striatal neurons from post-natal day 1 
R6/2 and WT mice were grown in culture for 8 DIV before measurements. Where 
indicated, the bath solution contained either ‘high glucose’ (10 mM glucose, 15 mM 
pyruvate) or ‘low glucose’ (2.5 mM glucose). Where indicated, cells were treated with 1 
µM oligomycin (Oligo), 60 µM 2,4-DNP and 1 µM rotenone (Rot) plus 1 µM antimycin A 
(Ant). In A and B, OCR of striatal neurons in ‘high glucose’ or ‘low glucose’ medium 
conditions, respectively. In C and D, ECAR of striatal neurons in ‘high glucose’ or ‘low 
glucose’ medium conditions, respectively. A Seahorse XF24 flux analyzer (Seahorse 
Bioscience, Billerica, MA, USA) was used to measure both OCR and ECAR at 37 °C, 
seeded at 105 cells per well. Data are mean ± SEM from five to nine separate 
experiments. 
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d. Ca2+ uptake capacity of nonsynaptic and synaptic mitochondria from R6/2 mice. 
 Next, we compared the Ca2+ uptake capacity in synaptic and nonsynaptic 
mitochondria isolated from 6- to 8-week-old R6/2 and WT mice. Mitochondria were 
subjected to 10 µM Ca2+ pulses every 2 min (Figs. 38 and 39). The Ca2+ uptake 
capacities in synaptic and nonsynaptic mitochondria from R6/2 and WT mice appeared 
to be similar. In experiments with synaptic mitochondria, Ca2+ uptake capacity was lower 
than in experiments with nonsynaptic mitochondria (Fig. 39). To improve Ca2+ uptake 
capacity in synaptic mitochondria, we used BSA, which increases Ca2+ uptake capacity, 
as shown in the previous section. In this study, BSA increased Ca2+ uptake capacity of 
synaptic mitochondria. Importantly, BSA similarly increased Ca2+ uptake capacity in 
synaptic mitochondria from both R6/2 and WT mice (Fig. 39B and C).  
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Figure 38. Ca2+ uptake capacity of brain nonsynaptic mitochondria isolated from 6-
to 8-week-old WT (blue traces) and R6/2 (red traces) mice. Ca2+ uptake was 
assessed in mitochondria incubated at 37 °C in the standard incubation medium 
supplemented with either 3 mM succinate plus 3 mM glutamate (A) or 3 mM pyruvate 
plus 1 mM malate (B). In all Ca2+ uptake experiments, incubation medium was 
additionally supplemented with 100 µM ADP and 1 µM oligomycin. In C, statistical 
analysis of Ca2+ uptake capacity of mitochondria from R6/2 and WT mice. Data are mean 
± SEM, N = 5–6 separate experiments. 
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Figure 39. Ca2+ uptake capacity of brain synaptic mitochondria isolated from 6- to 
8-week-old WT (blue traces) and R6/2 (red traces) mice. Ca2+ uptake was assessed 
in mitochondria incubated at 37 °C in the standard incubation medium supplemented 
with 3 mM succinate plus 3 mM glutamate either without (A) or with (B) 0.1% BSA in the 
incubation medium. In all Ca2+ uptake experiments, incubation medium was additionally 
supplemented with 100 µM ADP and 1 µM oligomycin. In C, statistical analysis of Ca2+ 
uptake capacity of mitochondria from R6/2 and WT mice. Data are mean ± SEM from 5 
separate experiments. 
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e. Mitochondrial Ca2+ accumulation in striatal neurons from R6/2 mice.
We also assessed mitochondrial Ca2+ accumulation in striatal neurons derived 
from R6/2 and WT mice. For these measurements, we stimulated Ca2+ influx into 
neurons and subsequently into mitochondria by briefly exposing cells to glutamate (25 
µM glutamate plus 10 µM glycine) (Fig. 40). Changes in cytosolic Ca2+ were monitored 
by following fluorescence of Fura-2FF. After glutamate removal and return of cytosolic 
Ca2+ to near resting level, the release of mitochondrial Ca2+ into the cytosol was triggered 
by mitochondrial depolarization with 1 µM FCCP (Fig. 40). The magnitude of cytosolic 
Ca2+ elevation following depolarization was taken as a measure of mitochondrial Ca2+ 
accumulation in situ as described previously (Chang et al. 2006). To avoid Ca2+ influx 
into cells from the extracellular medium, Ca2+ was omitted from the bath solution. To 
prevent Ca2+ extrusion from the cell via the Na+/Ca2+ exchanger during FCCP-induced 
increase in cytosolic Ca2+, external Na+ was replaced with equimolar N-methyl-D-
glucamine (NMDG) during FCCP application (Li and Van 1995). NMDG is a bulk organic 
cation that cannot be transported by the Na+/Ca2+ exchanger and, therefore, precludes 
the extrusion of Ca2+ via this mechanism. In these experiments, neurons from R6/2 and 
WT mice showed comparable transient increases in cytosolic Ca2+ during glutamate 
application (Fig. 40C). The increase in cytosolic Ca2+ triggered by FCCP was also not 
different between neurons from R6/2 and WT mice (Fig. 40D). This result, similar to the 
results obtained with Ca2+ uptake capacity in isolated mitochondria (Figs. 38 and 39), 
argues against mHtt fragment-mediated alterations in mitochondrial Ca2+ accumulation in 
the R6/2 mouse model of HD.  
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Figure 40. Mitochondrial Ca2+ accumulation following transient glutamate-induced 
elevations in cytosolic Ca2+ in striatal neurons derived from WT and R6/2 mice. In 
A and B, the averaged fluorescence signals (mean ± SEM) from the representative 
experiments are shown. Cytosolic Ca2+ was followed by monitoring Fura-2FF F340/F380 
fluorescence ratio at 37 °C. In these experiments, striatal neurons (10–13 DIV) were 
exposed to 25 µM glutamate with 10 µM glycine for 2 min as indicated. Then, glutamate 
and glycine were removed to let cytosolic Ca2+ concentration ([Ca2+]c) recover. After 
[Ca2+]c reached near resting level (7 min after glutamate removal) neurons were treated 
with 1 µM FCCP to depolarize mitochondria and release accumulated Ca2+. To avoid 
ambiguity concerning possible Ca2+ influx from the outside of the cell, external Ca2+ was 
removed simultaneously with glutamate and glycine. In addition, to prevent Ca2+ 
extrusion from the cell by Na+/Ca2+ exchanger, the external Na+ was replaced by 
equimolar NMDG as indicated. In C and D, the areas under the curve (AUC) for the 
averaged fluorescence signals are shown. The AUC for glutamate-induced increase in 
[Ca2+]c (Glu AUC) was calculated for the 120-s period beginning with glutamate 
application. The AUC for FCCP-induced increase in [Ca2+]c (FCCP Glu) was calculated 
for the 300-s period following FCCP application. Data are mean± SEM from five to six 
separate experiments with 20–25 individual neurons analyzed in each experiment. 
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f. Morphological characterization of mitochondria in striatal neurons from R6/2 
mice.  
 Despite the lack of respiratory deficiency and mitochondrial Ca2+ handling defect 
in mitochondria from R6/2 mice, we cannot rule out possible alterations in mitochondrial 
morphology in HD. In neurons, altered mitochondrial morphology could lead to, for 
example, impaired trafficking of mitochondria to distant processes, resulting areas of 
local energy deficiency within the neuron (Li et al. 2010). Previously, morphological 
imbalance and a shift toward augmented fission was reported in mouse and cell models 
of HD (Wang et al. 2009;Costa et al. 2010;Song et al. 2011;Shirendeb et al. 2012). In 
addition, a dramatic enlargement of mitochondria in neurons (Tellez-Nagel et al. 
1974;Bayram-Weston et al. 2012a;Bayram-Weston et al. 2012b) and peripheral cells 
(Squitieri et al. 2010;Brustovetsky 2016) expressing mHtt was reported. In our 
experiments, we used live-cell laser spinning-disk confocal microscopy and 3D 
reconstruction of the mitochondrial network in neurons from WT and R6/2 mice. In 
parallel experiments, we employed transmission electron microscopy to substantiate 
data obtained with confocal microscopy. In all analyzed striatal neurons from WT mice 
(142 neurons), mitochondria had a normal worm-like appearance whereas in about 24% 
of neurons from R6/2 mice (35 out of 148 analyzed neurons) most of mitochondria were 
fragmented while some mitochondria were enlarged (Fig. 41). Yet, despite altered 
mitochondrial morphology in this subpopulation of neurons, the entire neuronal 
population from R6/2 mice had similar respiratory activities and Ca2+ handling compared 
with neurons from WT mice. Whether neurons with abnormal mitochondrial morphology 
observed in our study have alterations in oxidative metabolism and mitochondrial Ca2+ 
handling is not clear yet.  
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 Taken together, our results show no difference in respiratory activities and Ca2+ 
handling in isolated brain mitochondria and cultured striatal neurons from R6/2 mice 
compared with mitochondria and neurons from WT animals. 
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Figure 41. Representative 3D reconstructions of mitochondrial networks and 
electron micrographs of cultured striatal neurons from WT (A, C) and R6/2 (B, D) 
mice. In A and B, the representative 3D maximal fluorescence intensity projection 
images of the mitochondrial network in live cultured striatal neurons (9 DIV) from WT 
and R6/2 mice, respectively (total number of neurons analyzed in these experiments—
142 neurons from WT mice and 148 neurons from R6/2 mice). Cells were analyzed in a 
blind manner. The scales are in µm. In C and D, representative electron micrographs of 
cultured striatal neurons (9 DIV) from WT and R6/2 mice, respectively. Arrowheads point 
to small-size, normal-looking mitochondria; the arrow points to enlarged mitochondrion. 
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IV. Discussion and Future Directions 
A. Oxidative metabolism and mitochondrial Ca2+ handling in the YAC128 mouse 
model. 
 In the present work, we, for the first time, evaluated the effect of mHtt on 
oxidative metabolism of YAC128 mice using a combination of three different 
experimental models: (i) isolated, whole brain mitochondria, (ii) neurons in culture and 
(iii) whole YAC128 and WT animals. All three models produced consistent results 
strongly arguing against a noteworthy deleterious effect of mHtt on mitochondrial 
oxidative metabolism, mitochondrial Ca2+ handling, and neuronal glycolysis in YAC128 
mice. The lack of respiratory defects suggests that mHtt does not impair mitochondrial 
oxidative metabolism in YAC128 mice. Consequently, mitochondrial respiratory 
deficiency most likely does not contribute to HD pathology in YAC128 mice, and if it 
occurs later in disease progression, it most likely represents a consequence of HD 
pathology rather than its cause. 
 In the study with YAC128 mice, we confirmed that mHtt is present in cultured 
neurons from these mice and that mHtt is associated with mitochondria isolated from 
transgenic animals. We invariably performed genotyping with every animal and 
immunoblotting with every sample of isolated mitochondria and cultured neurons to 
confirm the presence of mHtt in biological materials from YAC128 mice. Consistent with 
previously reported data (Slow et al. 2003;Pouladi et al. 2013), in western blotting 
experiments performed with brain homogenates and cytosolic fractions from YAC128 
mice, it was found that human mHtt was expressed at the same level as wild-type 
mouse Htt. Using mAb 2166, which recognizes both wild-type Htt and mHtt, we detected 
wild-type Htt associated with mitochondria from both WT and YAC128 mice (Fig. 6B). 
With mAb 2166, mHtt associated with mitochondria from YAC128 mice was also 
detected. Surprisingly, the amount of mHtt associated with mitochondria was four times 
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lower than the amount of mitochondria-bound wild-type Htt. Keeping in mind that similar 
amounts of mHtt were detected with mAb 2166 in homogenates and cytosolic fractions 
from YAC128 mice, this suggests that mHtt has lower affinity for mitochondria compared 
with wild-type Htt. This also suggests that a considerable amount of wild-type Htt is 
associated with mitochondria, and presumably, wild-type Htt plays some role in 
regulation of mitochondrial functions. Indeed, a recent study with mouse embryonic stem 
cells (mESC) revealed that the lack of wild-type Htt in htt−/− mESCs results in extensive 
metabolic aberrations (Ismailoglu et al. 2014). On the other hand, mESCs expressing 
mHtt with an expanded poly-Q stretch (Htt-Q140/Q7 mESCs) were bioenergetically 
indistinguishable from mESCs expressing wild-type Htt (Htt-Q7/Q7 mESCs) (Ismailoglu 
et al. 2014), which is, again, consistent with our results. This study (Ismailoglu et al. 
2014), as well as our finding regarding the association of wild-type Htt with brain 
mitochondria, supports a potential role of wild-type Htt in regulation of mitochondrial 
function since lack of Htt results in mitochondrial functional changes. However, many 
questions concerning the relationship between wild-type Htt and mitochondria remain to 
be answered. Is wild-type Htt located on the outer side of the outer mitochondrial 
membrane, in the intermembrane space, or in the mitochondrial matrix? Is it inserted into 
the outer membrane or only peripherally attached to the membrane like mHtt? How does 
wild-type Htt affect mitochondrial respiration, Ca2+ uptake, and PTP induction? Does 
mHtt interfere with wild-type Htt-mediated regulation of mitochondrial functions? These 
and many other questions need to be answered to gain insight into the role of wild-type 
Htt in the regulation of mitochondrial functions and to better understand possible 
deleterious effect of mHtt on mitochondria or reasons for the lack of such an effect. 
 In our experiments, we chose to use both early symptomatic, 2-month-old 
YAC128 mice as well as 10-month-old YAC128 mice at a more advanced HD stage, 
expecting to see overt alterations in mitochondrial functions. The 2-month-old YAC128 
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mice used in our experiments already demonstrated clasping, a clear sign of HD-
associated behavioral abnormalities reported previously with other mouse models of HD 
(Reddy et al. 1999;Milnerwood et al. 2006). This observation assured us that if 
mitochondrial respiratory dysfunction plays a role in neuronal alterations leading to 
behavioral abnormalities, then at this stage of HD progression, we should be able to 
detect this change in mitochondrial respiratory activity. This would allow for the further 
investigation of the mechanism of respiratory deficiency induced by mHtt. Even more so, 
we expected to see mitochondrial dysfunction with 10-month-old YAC128 mice. 
However, despite all our efforts, we found no indication of mitochondrial dysfunction.  
 In the present study, we found a minute but statistically significant decline in 
oligomycin-stimulated ECAR in striatal neurons from YAC128 mice incubated with 2.5 
mM glucose. This suggested a decreased glycolytic activity in striatal neurons from 
YAC128 mice potentially indicating energy deficiency. Previously, oligomycin-stimulated 
extracellular acidification was interpreted as an indicator of glycolysis activation under 
conditions of inhibition of oxidative phosphorylation (Wu et al. 2007;Ismailoglu et al. 
2014). However, under these conditions, cellular respiration is significantly suppressed 
and, consequently, we cannot correlate respiratory rate and glycolytic activity based on 
the data obtained in the presence of oligomycin. 
 Since the discovery of a link between the mutation in huntingtin and HD 
pathogenesis (MacDonald et al. 1993), numerous hypotheses concerning the 
mechanism of detrimental mHtt action have been put forward, and numerous studies 
have been performed to untangle these mechanisms. The studies regarding possible 
defects in oxidative metabolism can be divided into two groups: one of which generated 
experimental data indicating impairment of mitochondrial functions either in animal or 
cell models of HD (Brennan, Jr. et al. 1985;Kuhl et al. 1985;Gu et al. 1996;Browne et al. 
1997;Kim et al. 2011;Siddiqui et al. 2012;Damiano et al. 2013;Napoli et al. 2013), and 
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another group that produced data arguing against defects in oxidative metabolism 
(Higgins et al. 1999;Guidetti et al. 2001;Milakovic and Johnson 2005;Lee et al. 
2007;Oliveira et al. 2007;Olah et al. 2008;Gouarne et al. 2013;Boussicault et al. 2014). 
The reasons for these contradictory data are not clear, but it might be related to 
methodological differences and the use of different experimental models of HD. 
Interestingly, recent studies with HD patients revealed that oxidative metabolism remains 
properly operating despite expression of mHtt (Gaba et al. 2005;Powers et al. 
2007b;Turner et al. 2007). These observations support the point of view that mHtt does 
not directly and severely affect mitochondrial functions. This is also in line with the lack 
of alterations in oxidative metabolism in YAC128 mice examined in the present study. 
 In earlier studies, a decreased ability of mitochondria to accumulate Ca2+ has 
been proposed to contribute to HD pathogenesis (Panov et al. 2002;Choo et al. 
2004;Milakovic et al. 2006). On the other hand, in experiments with nonsynaptic 
mitochondria, we and other investigators failed to find an increase in sensitivity to 
deleterious Ca2+ and instead observed an increase in resistance to Ca2+ that was 
manifested in augmented Ca2+ uptake capacity (Brustovetsky et al. 2005a). In this study, 
we did not find evidence of impaired Ca2+ uptake capacity in either synaptic or 
nonsynaptic mitochondria from YAC128 mice. On the contrary, both types of 
mitochondria had increased Ca2+ capacity, especially, synaptic mitochondria from 12-
month-old YAC128 mice. The mechanism underlying augmented Ca2+ uptake capacity 
of mitochondria from YAC128 mice remains unknown, and, at the moment, we can only 
speculate about possible scenarios. The increased Ca2+ uptake capacity of mitochondria 
from YAC128 mice may be indicative of compensatory response to augmented Ca2+ 
influx via over-activated NMDA receptors and/or increased Ca2+ release from 
endoplasmic reticulum normally activated via IP3 receptors, but increased Ca2+ uptake 
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capacity is not considered a direct result of intrinsic mitochondrial damage or dysfunction 
(Bezprozvanny and Hayden 2004).  
 The lack of deficiencies in oxidative metabolism and mitochondrial Ca2+ uptake in 
YAC128 mice suggests that mHtt in these mice does not directly and acutely affect 
mitochondria. Therefore, mHtt neurotoxicity may likely be mediated by mechanisms 
unrelated to mitochondria, such as oxidative stress associated with elevated NAD(P)H 
oxidase activity (Valencia et al. 2013) and/or alterations in cholesterol metabolism 
(Trushina et al. 2014). Therefore, mitochondrial bioenergetics or Ca2+ uptake 
impairment, if it can be detected, most likely lies downstream of mHtt-induced alterations 
in other neuronal functions. However, it is also possible that in other cell or animal HD 
models, full-length or truncated mHtt with different levels of expression and different 
Htt/mHtt ratio does influence mitochondrial functions. Consequently, further 
investigations with alternative HD models and cell lines derived from HD patients are 
necessary to demonstrate and clarify possible deleterious effects of mHtt on oxidative 
metabolism. 
 
B. Oxidative metabolism and Ca2+ handling in striatal mitochondria from YAC128 
mice. 
 In the previous section (section A), it was shown that nonsynaptic and synaptic 
mitochondria isolated from whole brains of YAC128 mice have similar respiratory rates 
and Ca2+ uptake capacities compared to mitochondria from WT mice. However, the 
experiments in the previous section (A) utilized mitochondria isolated from the whole 
brain to assess respiratory rates and Ca2+ uptake capacity. In HD, the striatum is the 
most vulnerable brain region whereas hippocampus and cerebellum remain practically 
intact (Vonsattel and DiFiglia 1998). The use of mitochondria isolated from whole brains 
was a limitation of the results obtained in the previous section because contribution from 
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mitochondria from unaffected brain regions may have obscured deficiencies of striatal 
mitochondria. In this section (section B), we will discuss the results obtained with 
nonsynaptic and synaptic mitochondria isolated exclusively from striata of 8- to 10-week-
old YAC128 and FVB/NJ mice. The results produced with striatal mitochondria are 
consistent with the data obtained with mitochondria isolated from the whole brain. We 
did not find evidence for alterations in expression of nuclear-encoded mitochondrial 
proteins and for impairment of mitochondrial respiration and Ca2+ uptake capacity in 
striatal mitochondria from YAC128 mice compared to mitochondria from FVB/NJ mice. 
These findings argue against mitochondrial bioenergetics and Ca2+ handling dysfunction 
as a contributing factor in HD pathogenesis. 
 In addition to the data obtained with isolated mitochondria, we sought to confirm 
our findings by using cultured primary neurons. In addition to measuring respiration and 
Ca2+ uptake capacity in striatal nonsynaptic and synaptic mitochondria isolated from 
YAC128 and FVB/NJ mice, we examined oxidative metabolism and mitochondrial Ca2+ 
handling in cultured striatal neurons from these animals.  Although, two-month-old 
YAC128 mice already demonstrate clasping behavior, an early symptom associated with 
mHtt expression (Mangiarini et al. 1996;Reddy et al. 1999), our data obtained with 
cultured neurons and isolated mitochondria from YAC128 mice provide no evidence for 
mitochondrial impairment, suggesting that the motor dysfunction, which most reliably 
manifests as clasping, may not be associated with mitochondrial alterations. 
 Mitochondrial respiration generates an electrochemical proton gradient across 
the mitochondrial inner membrane which is utilized to synthesize ATP in the process of 
oxidative phosphorylation and to transport Ca2+ into the mitochondrial matrix. 
Consequently, impairment of mitochondrial respiration may affect both oxidative 
phosphorylation and Ca2+ uptake. In this current study, we did not find a difference in 
ADP-stimulated respiration and in uncoupled respiration stimulated by 2,4-DNP. This 
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suggests that the oxidative phosphorylation system and electron transport chain are not 
affected by mHtt in YAC128 mice. Similar respiratory activities were observed with both 
malate plus pyruvate, Complex I substrates, and with succinate, a Complex II substrate. 
This suggests that Complex I and Complex II of the electron transport chain are not 
impaired by mHtt. These findings are consistent with previously reported data. In early 
studies, Guidetti et al. did not detect alterations in activity of the electron transport chain 
in the striatum and cerebral cortex of HD48 and HD89 mice, expressing full-length mHtt 
with 48 or 89 glutamines, respectively, compared to wild-type mice (Guidetti et al. 2001). 
In experiments with cultured striatal neurons from 15- to 17-week-old heterozygous 
Hdh150 mice, cell respiratory activities were found to be similar (Oliveira et al. 2007). 
Olah et al. found that the activities of Complexes I–IV in brain mitochondria from 20-
week-old transgenic N171-82Q mice were not diminished compared to mitochondria 
from wild-type animals (Olah et al. 2008). Gouarne et al. did not find a difference in 
respiration of cultured striatal neurons from heterozygous transgenic BACHD rats 
compared to wild-type neurons, when cells were incubated in the presence of 25 mM 
glucose and 1 mM pyruvate (Gouarne et al. 2013). In experiments with STHdhQ111/Q111 
cells, mitochondrial pathways were not significantly altered and the obtained data 
uniformly refuted a view of direct deleterious mHtt effect on mitochondria (Lee et al. 
2007). The direct measurements of oxidative metabolism in striatum of HD patients and 
age-matched controls using positron emission tomography failed to find a difference, 
which argues against a defect in mitochondrial oxidative phosphorylation and 
mitochondrial electron transport chain activity (Powers et al. 2007b). Finally, Ismailoglu 
et al. studied mouse embryonic stem cells expressing wild-type and 140Q-mHtt and 
found no difference in cellular bioenergetics of these cell lines (Ismailoglu et al. 2014). 
Collectively, these results suggest no overt respiratory defects in HD mitochondria. 
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 In the previous section (A), we discussed expression of nuclear-encoded proteins 
in brain mitochondria isolated from whole brains. It had previously been reported that 
mitochondrial protein import machinery might be impaired by mHtt (Yano et al. 2014). 
Despite finding no alteration in protein expression in whole brain mitochondria, we 
reasoned that if striatal mitochondria exposed to mHtt had decreased protein expression 
and other brain regions have no change in expression, such an alteration may not have 
been detectable in our previous experiments.  Although we did not directly assess 
activity of protein import machinery in striatal mitochondria from YAC128 mice, our data 
unequivocally demonstrate the lack of respiratory deficits and show the absence of 
alterations in protein expression in striatal mitochondria from YAC128 mice. Therefore, 
although we cannot directly confirm that import is not inhibited in mitochondria from 
these animals using this experiment, having similar mitochondrial protein levels strongly 
supports the lack of difference seen in functions of mitochondria from WT and HD mice.  
Taken together, these data suggest that if protein import in mitochondria of HD mice is 
suppressed, this, nevertheless, does not affect the level of expression of mitochondrial 
nuclear encoded proteins and, consequently, does not affect mitochondrial respiration. 
 Mitochondria possess Ca2+ channels, historically known as “calcium uniporter”, 
that allows Ca2+ influx into the mitochondrial matrix driven by high membrane potential, 
negative inside of the organelle (Bernardi et al. 1999). Inside of mitochondria, elevated 
Ca2+can interact with inorganic phosphate and precipitate in the form of hydroxyapatite 
(Chalmers and Nicholls 2003). This allows for the large Ca2+ accumulation in 
mitochondria. The ability of mitochondria to accumulate significant amounts of Ca2+ is 
important for maintenance of Ca2+ homeostasis in the cell (Bernardi and Rasola 2007). 
Ca2+ accumulation in mitochondria is limited by induction of the mitochondrial 
permeability transition pore that depolarizes mitochondria and prevents further 
Ca2+uptake (Bernardi et al. 1999). In early studies, decreased Ca2+ uptake capacity in 
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mitochondria isolated from HD mouse and cell models was reported, and it was 
proposed to contribute to HD pathogenesis by affecting Ca2+ homeostasis in neurons 
(Panov et al. 2002;Milakovic et al. 2006;Gellerich et al. 2008;Lim et al. 2008) However, 
other investigators failed to find a decrease in mitochondrial Ca2+ uptake capacity in 
mitochondria exposed to mHtt with an elongated polyQ stretch (Oliveira et al. 2007;De et 
al. 2016). In these studies, the authors either did not find a difference between 
mitochondria from HD and wild-type animals or they found a paradoxical increase in 
Ca2+ accumulation in mitochondria from HD mice. In line with these findings that suggest 
no impairment of mitochondrial Ca2+ handling, the results from section A with 
nonsynaptic and synaptic mitochondria isolated from the whole brain of YAC128 mice 
and with cultured neurons from these animals substantiate these observations. The 
results presented in this section (B) demonstrate no deficiency in Ca2+ handling in 
nonsynaptic and synaptic mitochondria isolated from striata of YAC128 mice and 
support previous findings indicating no Ca2+ accumulation defect in mitochondria from 
HD mice. 
 The experiments with isolated mitochondria and cultured neurons provide 
valuable information about possible effects of mHtt. However, in vivo measurements of 
brain respiratory activity may further enhance our understanding of potential defects in 
oxidative metabolism in HD. A recent paper by Lou et al. described elegant experiments 
with the use of 17O magnetic resonance spectroscopy aimed at assessing cerebral 
mitochondrial respiratory activity in R6/2 mice in vivo (Lou et al. 2016). In this study, the 
authors did not find a difference in basal striatal oxygen consumption rate in 
symptomatic R6/2 mice at rest. Inhibition of oxidative phosphorylation with oligomycin 
resulted in a similar decrease in respiration, suggesting similar phosphorylation capacity 
and coupling of oxidative phosphorylation in HD and wild-type mice. Yet, after injection 
of the uncoupler 2,4-DNP, the authors found a negligible (about 15%), but statistically 
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significant, decrease in respiratory responses in both striatum and cortex of R6/2 mice 
compared with respiratory responses of corresponding brain tissues in wild-type animals 
(Lou et al. 2016). The physiological significance of this difference is not evident but it is 
clear that such conditions (2,4-DNP-induced stimulation) do not take place in a 
physiological scenario. The ambiguity of the small difference in uncoupled respiration is 
supported by the fact that natural, sensory stimulation-induced elevation in respiration 
measured with photoacoustical microscopy (Yao et al. 2015) is weaker than 2,4-DNP-
induced increase in oxygen consumption. Thus, importance and relevance of small 
decreases in 2,4-DNP stimulated respiration of mitochondria from HD mice is not 
obvious. However, such in vivo measurements of mitochondrial functions in HD models 
may provide new insights toward uncovering the role, or lack thereof, of mitochondria in 
HD pathogenesis 
 Overall, the data from this section (B) obtained with striatal nonsynaptic and 
synaptic mitochondria from YAC128 mice and data from previous section (A) with whole-
brain mitochondria and cultured striatal and cortical neurons from YAC128 mice do not 
provide evidence for mitochondrial respiratory deficiency and defects in mitochondrial 
Ca2+ handling.  
 Our data are consistent with anecdotal evidence from individuals who tested 
positive for the mutation in the huntingtin gene, further suggesting a lack of mitochondrial 
deficits. Although these individuals express mHtt in all tissues beginning from an 
embryonic stage, they do not begin to show symptoms of the disease until adulthood 
and instead, during the intervening pre-symptomatic period, they engage in everyday life 
as cognitively and physically capable individuals. Some individuals with HD even ascend 
to the highest levels of athletic competition. For example, a British rower, Sarah 
Winckless, tested positive for the mutation in the huntingtin gene in the late 1990s and 
went on to win two world championships in rowing and to compete in three Olympics, 
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winning a bronze medal at the Athens Olympic Games in 2004 (English 2014). Since 
then, she has climbed Mt. Kilimanjaro and biked from London to Paris. Other 
testimonials abound of patients who capably compete in similarly rigorous sports. Since 
mitochondria are responsible for the production of energy in the form of ATP, proper 
mitochondrial function would be essential for individuals to engage in activities that 
expend large amounts of energy. The observation that pre-symptomatic HD patients can 
excel in physically strenuous activities raises the question of how mitochondria could 
support such energy demand if mHtt interferes with the normal mitochondrial functioning. 
These observations, coupled with our results, support the idea that mHtt per se does not 
induce mitochondrial dysfunction.  This conclusion reinforces the necessity to continue 
exploring the potential, non-mitochondrial mechanisms of HD pathogenesis.           
 
C. Oxidative metabolism and mitochondrial Ca2+ handling in the R6/2 model. 
 In the previous sections (A and B), we discussed the effect of full-length mHtt on 
mitochondrial functions and did not find evidence for detrimental alterations in 
mitochondria from YAC128 mice. In this section (C), we will discuss our results obtained 
with isolated mitochondria and cultured neurons from R6/2 mice expressing mHtt 
fragments. It remains unclear whether full-length mHtt or mHtt fragments mediate HD 
pathogenesis. However, some studies suggest that mHtt fragments might be more prone 
to aggregation and therefore might be more toxic for neurons (Kim et al. 1999; 
Wellington et al. 2000). We demonstrated no mitochondrial respiratory or Ca2+ handling 
defects in mitochondria and cultured neurons from YAC128 mice, which express human 
full-length mHtt. Next, we hypothesized that fragments of mHtt might be more harmful to 
mitochondria than full-length mHtt. If this would be the case, we might expect to detect 
mitochondrial functional abnormalities induced by mHtt fragments. 
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 In these experiments, two model systems were used: isolated brain mitochondria 
and primary cultured striatal neurons. It is conceivable that there might be some 
difference in the results produced with these two model systems. Mitochondria isolated 
from adult brains may better reflect changes that take place in HD over time. However, 
isolated mitochondria taken away from their natural intracellular environment may lead to 
unwanted artifacts (e.g. loss of association with mHtt) and, consequently, to inaccurate 
interpretations. On the other hand, mitochondria in young, post-natal neurons are 
immersed within their natural intracellular environment, but they might be too young for 
developing overt functional defects. The use of both, mitochondria isolated from adult 
brains and mitochondria in post-natal neurons, complement each other and allows for 
improved assessment of possible effects of mHtt on the organelles. 
 Earlier studies reported mitochondrial respiratory dysfunction and a decreased 
ability of mitochondria to accumulate Ca2+ in HD mouse models expressing full-length or 
fragments of mHtt (Panov et al. 2002; Lim et al. 2008; Kim et al. 2011; Damiano et al., 
2013). On the other hand, results from this section (C), from sections A and B, and from 
other investigators (Guidetti et al. 2001;Chang et al. 2006;Olah et al. 2008) suggest that 
there are no defects in respiration and Ca2+ uptake in mitochondria isolated from brains 
of HD mice compared with mitochondria from brains of WT animals. Consistent with 
these previous findings in other mouse models of HD, the data presented here indicate 
no defects in respiration and Ca2+ uptake capacity in brain mitochondria isolated from 
R6/2 mice compared with brain mitochondria from WT mice. Similarly, experiments with 
cultured striatal neurons demonstrate no difference in cellular respiratory activity and 
Ca2+ handling between neurons from R6/2 and WT mice. 
 In this study, we used isolated brain mitochondria from symptomatic 6- to 8-
week-old R6/2 mice and age-matched WT mice. The R6/2 mice used in these 
experiments displayed a clasping phenotype typical for HD animals (Mangiarini et al. 
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1996). The presence of clasping behavior assured us that if mitochondrial respiratory 
abnormalities and aberrant Ca2+ handling by mitochondria were involved in neuronal 
dysfunction leading to these behavioral deviations, then it should be possible to detect 
such changes in respiration, Ca2+ handling, or both. The lack of difference between 
mitochondria from WT and R6/2 mice suggests that fragments of mHtt do not impair 
mitochondrial respiratory and Ca2+ uptake activities. Accordingly, our data argue against 
defects of mitochondrial functions as a contributing factor to HD pathogenesis in R6/2 
mice. 
 It was recently reported that inhibition of protein import into mitochondria might 
result in defects in mitochondrial function and it was suggested that impaired 
mitochondrial protein import could result in decreased expression of nuclear-encoded 
mitochondrial proteins (Yano et al. 2014). Our data with mitochondria isolated from R6/2 
mice indicate no difference in expression of several randomly selected nuclear-encoded 
mitochondrial proteins, suggesting no defects in mitochondrial protein import. This is 
consistent with the study by Orr et al. that found that expression of nuclear encoded 
MnSOD as well as 30 and 70 kDa subunits of succinate dehydrogenase (Complex II) is 
similar in brain mitochondria isolated from 3- and 10-month-old heterozygous knock-in 
150Q/7Q mice as well as in 3-month-old WT 7Q/7Q mice (Orr et al. 2008). Milakovic and 
Johnson also failed to demonstrate a difference in expression of 30 and 70 kDa subunits 
of Complex II in mutant STHdhQ111/Q111striatal cells compared with WT STHdhQ7/Q7 cells 
(Milakovic and Johnson 2005). 
 Previously, Rosenstock et al. reported a significant increase in cytosolic Ca2+ 
induced by 1 mM glutamate in cortical and striatal slices of 9 month-old R6/1 transgenic 
mice. Following glutamate removal, FCCP-mediated mitochondrial depolarization led to 
Ca2+ release from mitochondria and resulted in an increase in cytosolic Ca2+ that was 
similar in slices from both R6/1 and WT animals. This suggests that there are no defects 
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in mitochondrial Ca2+ accumulation in brain slices from R6/1 mice (Rosenstock et al. 
2010). 
The lack of defects in Ca2+ uptake by nonsynaptic mitochondria isolated from 
brains of R6/2 mice was also found by David Nicholls’ group (Oliveira et al. 2007). 
Contrary to expectations, they found a moderate but statistically significant increase in 
Ca2+ uptake capacity of mitochondria isolated from brains of R6/2 mice compared with 
mitochondria from WT animals. Although we did not find a statistically significant 
increase in Ca2+ uptake capacity in isolated brain mitochondria from R6/2 mice, we 
confirm that Ca2+ uptake capacity in brain mitochondria from R6/2 mice is not impaired. 
The authors also found an increase in Ca2+ uptake capacity in nonsynaptic mitochondria 
from YAC128 mice, which express full-length mHtt, and found no difference in 
mitochondria from knock-in Hdh150/+ mice (Oliveira et al. 2007). In addition, the authors 
did not find a significant difference in respiratory activity of striatal neurons from 
Hdh150/+ and WT mice. 
 The reason for the increased Ca2+ uptake capacity in mitochondria from HD mice 
is not clear but might be related to compensatory changes in mitochondria and 
alterations in susceptibility to induction of the permeability transition pore (PTP), which 
determines mitochondrial Ca2+ uptake capacity (Chalmers and Nicholls 2003). 
Interestingly, Choo et al. reported a significantly increased level of glutathione in cortical 
and striatal mitochondria from R6/2 mice (Choo et al. 2005). The authors interpreted this 
finding as an indication of compensatory reaction (i.e. preconditioning) to protect cells 
against an increase in mitochondrial oxidative stress. An increase in mitochondrial 
glutathione may also suggest increased resistance to Ca2+-induced damage that 
manifests as induction of the PTP. Indeed, glutathione was found to be protective 
against Ca2+-induced PTP in liver, heart, and brain mitochondria (Chernyak and Bernardi 
1996;Heales and Bolanos 2002;Aon et al. 2007). Consequently, the same mechanism 
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might contribute to the lack of difference in Ca2+ uptake capacity in this study of 
mitochondria from R6/2 and WT mice. 
Mitochondrial CyD is a component of the mitochondrial PTP that sensitizes it to 
Ca2+ (Rasola and Bernardi 2007). Genetic ablation of CyD inhibits PTP induction and 
significantly increases Ca2+ uptake capacity in brain mitochondria (Baines et al. 2005;Li 
et al. 2009). Considering this, it was logical to propose that if mitochondria from HD mice 
have increased propensity to PTP induction and, concomitant decrease in Ca2+ uptake 
capacity and if this defect in Ca2+ handling plays an important role in HD pathology, then 
CyD deletion should protect mitochondria, increase Ca2+ uptake capacity, and rescue 
behavioral deficits in R6/2 mice. Perry et al. reported elegant experiments in which the 
authors crossed R6/2 with CyD-knockout mice (CyD−/−) and evaluated mitochondrial 
Ca2+ uptake capacity in mitochondria from cerebral cortex of crosses of CyD−/− and R6/2 
mice (Perry et al. 2010). The authors found a significant increase in Ca2+ uptake capacity 
in mitochondria from R6/2:CyD−/− mice but no indication of behavioral improvement or 
alleviation of HD neuropathological features. From these results, the authors concluded 
that increasing neuronal mitochondrial Ca2+ uptake capacity is not beneficial in the R6/2 
model of HD. Unfortunately, in this study the authors failed to compare Ca2+ uptake 
capacity of brain mitochondria from R6/2 and WT mice. Based on our data and results 
from David Nicholls’ group, Ca2+ uptake capacities of isolated brain mitochondria and 
mitochondria in cultured neurons from R6/2 mice are not decreased compared with Ca2+ 
capacity of mitochondria from WT animals (Oliveira et al. 2007). Consequently, 
alterations in Ca2+ uptake capacity most likely do not play a role in HD pathogenesis and 
one should not expect significant improvement in HD pathology due to an increase in 
mitochondrial Ca2+ uptake capacity. 
 Overall, the full body of data presented here and studies from other investigators 
(Guidetti et al. 2001;Chang et al. 2006;Olah et al. 2008) show no significant differences 
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in respiratory activity and Ca2+ handling in mitochondria exposed to human full-length or 
truncated mHtt. Consequently, based on our results and data from other groups, the 
dearth of defects in bioenergetics and Ca2+ handling makes their contribution to HD 
pathology unlikely. However, this does not rule out the potential contribution of 
mitochondria to HD pathogenesis. One caveat of the results with isolated mitochondria 
used in this and the previous section (sections A and C) is that these data were obtained 
with mitochondria derived from the whole brain of mice. Since the striatum, the most 
severely affected brain region in HD, comprises a relatively small fraction of total brain 
volume, it may be possible that use of whole brain mitochondria could mask 
mitochondrial deficiencies present in only mitochondria from the striatum. Alternatively, 
the neurotoxic effect of mHtt or its fragments may be due to mechanisms that are not 
directly related to mitochondrial bioenergetics or Ca2+ transport but may indirectly affect 
these functions. In addition, numerous reports indicate alterations in mitochondrial 
morphology and trafficking in cell and mouse models of HD (Trushina et al. 
2004;Shirendeb et al. 2011;Song et al. 2011). Our observations of alterations in 
mitochondrial morphology in neurons from R6/2 mice made with spinning-disk confocal 
and electron microscopy are consistent with previously reported mitochondrial 
morphological abnormalities found in cells expressing mHtt (Tellez-Nagel et al. 
1974;Squitieri et al. 2006;Wang et al. 2009;Costa et al. 2010;Squitieri et al. 2010;Song 
et al. 2011;Bayram-Weston et al. 2012b;Shirendeb et al. 2012). It is conceivable that 
these alterations in mitochondrial morphology as well as in non-mitochondrial 
mechanisms may play a significant role in neuronal dysfunction and over time may lead 
to the neuronal loss and behavioral deficits seen in HD. 
Although the causes and significance of alterations in mitochondrial morphology 
are not entirely clear, impairment of trafficking and deficits in the mitochondrial 
fission/fusion cycle have been reported to accompany morphological changes (Li et al. 
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2010). It is still unclear whether trafficking and fission/fusion impairment are causes or 
consequences of mitochondrial morphological changes. In our experiments, the 
observation of both fragmented and enlarged mitochondria in cultured striatal neurons 
from R6/2 mice indicated a potential impairment of proper fusion and fission, resulting in 
a non-uniform mitochondrial population. Fragmentation of mitochondria in HD neurons 
could be the result of direct interaction of mHtt with proteins involved in fission/fusion 
dynamics, as has been previously suggested (Li et al. 2010). Alternatively, increased 
mitochondrial fragmentation could be the result of an attempt to sequester and remove 
portions of mitochondria that have been somehow damaged by mHtt (Chen and Chan 
2009). Although the mechanism leading to increased fragmentation in mHtt-expressing 
cells remains unclear, a recent study has indicated that inhibition of mitochondrial 
fragmentation may attenuate neuronal degeneration (Guo et al. 2013a). 
 Alterations to mitochondrial morphology may also be associated with aberrant 
mitochondrial trafficking (Chen and Chan 2009). Increased fragmentation of 
mitochondria has been shown to decrease mitochondrial motility (Li and Conforti 2013). 
On the other hand, changes to the shape of mitochondria as they become fragmented 
may impede their entry into neuronal processes, thus precluding mitochondria from 
efficiently moving to locations of high energy demand, such as synaptic terminals (Li et 
al. 2010). It has been reported that mitochondria in cells expressing mHtt move at a 
slower rate and stop more frequently (Trushina et al. 2004;Shirendeb et al. 2011;Song et 
al. 2011), which could partially explain the neuronal degeneration seen in HD if 
mitochondria are not present in sufficient numbers at neuronal terminals to support local 
energy demand. Though the mechanism of mHtt-induced mitochondrial motility 
impediment is not entirely resolved, some evidence suggests that a potential interaction 
of mHtt with tubulin could block the passage of motor proteins loaded with mitochondria 
(Smith et al. 2009). Thus, the interplay among altered mitochondrial morphology, 
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impaired trafficking, and aberrant mitochondrial fission/fusion may play an important role 
in neuronal dysfunction and ultimately the neuronal loss seen in HD.         
 
D. Future Directions 
 Despite an immense and ongoing effort, the mechanisms responsible for HD 
pathology remain not completely understood nearly 25 years after the discovery of the 
mutation linked to HD. Animal models have enabled researchers to gain some 
understanding regarding the aberrant function of neurons in the presence of mHtt, but 
the fundamental underlying processes that mediate striatal neuron loss have not been 
identified. Additionally, it is unclear whether mHtt may affect mitochondrial functions 
differently in human neurons compared to neurons derived from animal models of HD. 
Due to the genetic manipulations that are required to generate HD animal models, there 
could be unintended functional consequences that may obscure an understanding of the 
mechanisms by which mHtt leads to neuronal degeneration in humans (Mattis et al. 
2012). Models expressing multiple copies of the mutated allele, transgenes that become 
randomly inserted into the genome or lack of human mHtt may all complicate 
interpretation of experimental results with animals (Ramaswamy et al. 2007;Pouladi et 
al. 2013). Symptom manifestation and disease progression in animals may also be 
incongruent with disease development in humans. Moreover, expression levels of Htt 
and mHtt and the ratio of expression between the two proteins can differ from one 
animal model to another and, importantly, can differ from the expression of both proteins 
in humans (Pouladi et al. 2013). Since mHtt and Htt are believed to be implicated in 
regulation of transcription, differing expression of these proteins may result in larger 
scale alterations in gene expression. Indeed, Buck et al recently reported that 
expression of sirtuins, proteins involved in the regulation of mitochondrial functions, was 
different between HD patients and transgenic mouse models of HD (Buck et al. 2017). 
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Although animal models have helped to improve our understanding of the mechanisms 
of HD, they are imperfect and different models may yield conflicting data.    
  However, new technologies have allowed for the study of neurons from human 
HD patients. The development of a process for somatic cell reprogramming into 
pluripotent stem cells and the generation of differentiation protocols now permits 
researchers to investigate disease processes in cell types that had been previously 
unattainable from living humans. Although HD iPSC lines were first established by Park 
et al in 2008, then subsequently by other groups, it was not until after the HD iPSC 
Consortium generated and characterized 14 additional iPSC lines from HD patients and 
controls that reprogrammed neurons from human HD patients began to be studied more 
intensely (Park et al. 2008;Zhang et al. 2010;Camnasio et al. 2012;Mattis et al. 2012). 
Studies with human iPSCs from HD patients have suggested alterations in the lysosomal 
pathway, alterations in protein expression, and the presence of mHtt aggregates 
(Castiglioni et al. 2012;Chae et al. 2012;Nekrasov et al. 2016). GABAergic neurons 
derived from iPSCs of HD patients display increased mitochondrial fragmentation and 
increased expression of the mitochondrial fission protein dynamin-related protein 
(DRP1) compared to neurons from control iPSCs (Guo et al. 2013b). Mattis et al. 
showed that, following prolonged exposure to glutamate, iPSC-derived neurons from HD 
patients demonstrated increased propensity to Ca2+ dysregulation compared to control 
neurons (Mattis et al. 2012). Additionally, neural stem cells derived from human HD 
iPSCs displayed lower basal and FCCP-induced maximal respiration compared to 
control iPSCs (An et al. 2012). However, in these latter two studies, experiments were 
performed with cells that were not completely differentiated to DARPP-32 expressing 
striatal-like neurons, leaving unaddressed the extent of potential mitochondrial 
alterations in striatal-like neurons derived from HD iPSCs. For these reasons, we have 
endeavored to establish and characterize HD iPSCs in our lab with the intent of 
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differentiating these cells into putative striatal neurons and assessing neuronal and 
mitochondrial functions. 
 Cultures of undifferentiated human iPSCs derived from fibroblasts of HD and 
control patients were established at Harvard University by Dr. George Daley. Initially one 
HD and one control line was established from previously reprogrammed cells that were 
obtained from the Harvard Stem Cell Institute. Each line was characterized by 
morphology and the presence of specific markers throughout the differentiation process. 
Undifferentiated cells from HD and control lines were organized into tightly packed 
colonies with clearly demarcated edges and each colony displayed a uniform thickness 
(Fig. 42A). The presence of characteristic gene expression of the undifferentiated state 
were first demonstrated using reverse transcription PCR followed by cDNA amplification. 
The pluripotency genes OCT4, NANOG, and SOX2 were expressed. However, 
BRACHURY (BRACH), α-Fetoprotein (AFP), and PAX6, markers of the mesoderm, 
endoderm, and ectoderm, respectively were not yet being expressed (Fig. 42B). 
Immunocytochemistry of the pluripotency markers NANOG, SOX2, and OCT4 further 
indicated their expression in both control and HD undifferentiated colonies. Furthermore, 
immunocytochemical analysis demonstrated the expression of Tra1-60, Tra1-81, and 
SSEA4 which are indicative of human pluripotent stem cells (Fig. 42C).  
 Induction of human PSCs to a primitive anterior neuroepithelial fate commences 
with the detachment of undifferentiated colonies and the maintenance of embryoid 
bodies in suspension during the first stage of differentiation. After seven days in 
suspension, embryoid bodies are re-plated. Following reintroduction to attached culture, 
nascent progenitor colonies display a rounded, thicker center and a more flat periphery 
characterized by less tightly packed cells and less sharply defined edges (Fig. 43A). RT-
PCR analysis demonstrates the expression of the neural markers PAX6 and SOX1. The 
anterior neural fate is further indicated by expression of OTX2, RAX, and LHX2. The 
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expression of these neural-associated genes is present in colonies from control and HD 
colonies (Fig. 43B). Immunocytochemistry demonstrates that PAX6 and OTX2 are 
widely expressed in control and HD colonies (Fig. 43C).  
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Figure 42.Characterization of undifferentiated WT and HD hiPSCs. In A, phase 
contrast images of undifferentiated WT or HD colonies displaying typical round, tightly-
packed colonies with sharply defined edges.  In B, DNA gels using cDNA generated by 
RT-PCR from WT or HD undifferentiated colonies show the expression of the 
pluripotency markers OCT4, NANOG, and SOX2. The lack of Brachyury (mesoderm 
marker) and PAX6 (ectoderm marker) expression indicate colonies have yet to establish 
germ layers.  GAPDH is a constitutively expressed control. In C, immunocytochemistry 
demonstrates the expression of cell surface markers (green) and pluripotency-
associated transcription factors (red). In D, proportion of WT and HD cells that stained 
positive for Nanog, SOX2, and OCT4 (normalized to DAPI). Data are mean ± SEM.  
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Figure 43. Characterization of hiPSCs induced to a neural progenitor fate. In A, 
Phase contrast images of WT and HD hPSC colonies after 10 days of differentiation 
show a thicker, 3-dimensional center and less defined, flatter periphery. In B, DNA gels 
using cDNA generated by RT-PCR from WT or HD colonies display the expression of 
neural markers PAX6 and SOX1. RAX and LHX2 expression indicate differentiation to 
the anterior neural fate. GAPDH is a constitutively expressed control. In C, 
Immunocytochemstry further demonstrates the expression of neural-associated 
transcription factors. In D, Proportion of WT and HD cells that stained positive for Nanog, 
SOX2, and OCT4 (normalized to DAPI). Data are mean ± SEM.     
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 Once the primitive anterior neural fate has been established, colonies are 
detached from the culture surface and maintained in suspension. Floating colonies will 
adopt either a neural lineage or a retinal fate that are morphologically distinguishable 
from each other. The culture is manually enriched for colonies of the neural fate by 
removing all retinal-fated colonies. Neurospheres fated for neuronal differentiation are 
characterized by a dark and rounded appearance (Figure 44A). The neural-associated 
transcription factors PAX6, NEUROD1, and FABP7 are expressed in neurospheres from 
control and HD lines. Expression of forebrain-associated transcription factors SOX1, 
DLX1, and EMX1 further indicate the refinement of the neurospheres to the neural 
lineage and the divergence of cells from the retinal fate. Importantly, cells from the 
enriched neurosphere population do not express RAX, a marker of the retinal fate (Fig. 
44B). Immunocytochemistry indicates the expression of forebrain-associated markers 
OTX2, SOX1, and DLX5. Nascent neurons are indicated by expression of MAP2 (Fig. 
44C). 
 After being maintained in suspension for 15-20 days, the neurospheres are 
carefully dissociated by brief incubation in accutase followed by gentle trituration yielding 
aggregates that are 200-400 μm in diameter. Aggregates are re-plated in the presence 
of growth factors and maintained for an additional 14 days to generate cortical neurons. 
Human PSC-derived cortical neurons display typical neuronal morphology, including 
axonal outgrowth and branching, and stain for the neuronal markers MAP2 and 
Neurofilament. Supplementation of the culture medium with purmorphamine induces the 
differentiation of lateral ganglion eminence progenitors, resulting in expression of 
gamma-aminobutyric acid (GABA)-ergic neurons (Fig. 45).      
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Figure 44. Characterization of cortical progenitors derived from WT and HD 
hiPSCs. In A, phase contrast images of neural-fated WT and HD neurospheres in 
suspension after 40 days of differentiation appear as uniformly round and dark spheres. 
In B, DNA gels using cDNA generated by RT-PCR from WT or HD cortical progenitors 
display expression of neural-associated transcription factors PAX6, NeuroD1, and 
FABP7. SOX1, DLX1, and EMX1 more specifically indicate differentiation toward the 
forebrain fate. Lack of RAX expression indicates a divergence from the retinal lineage. In 
C, immunocytochemistry demonstrates expression of the neural marker SOX1 and 
markers of the emerging forebrain neurons, OTX2, DLX5, and MAP2.   
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Figure 45. Characterization of neurons derived from cortical progenitors from WT 
and HD hiPSCs. Following 14 days of directed neuronal differentiation, cells display 
typical neuronal morphologies under phase contrast microscopy and express the 
neuronal markers MAP2 and Neurofilament-L (Neurofil). Supplementation of the culture 
medium with purmorphamine, drives the expression of GABAergic neurons.  
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 The method for generation of striatal-like neuron progenitors diverges from that 
of cortical progenitors following the establishment of the primitive anterior neural fate. In 
order to guide cells toward the striatal lineage, previously plated embryoid bodies are 
maintained in medium supplemented with FGF-8, Shh, valpromide, purmorphamine, and 
DKK1 until neural rosettes, which are the in vitro analog to the neural tube, are formed. 
Neural rosettes are then selectively removed and re-plated for further growth to generate 
an enriched culture. Rosettes grow into tightly packed clusters and express neural 
associated transcription factors as well as forebrain-associated transcription factors (Fig. 
46A,B). Immunocytochemistry indicates that nearly all cells express the neural markers 
OTX2 and SOX1 (Fig. 46C,D). Additionally, these cells express Nestin a marker of 
neural progenitor cells and Ki-67 a marker indicating that these progenitors are 
proliferative (Fig. 46C).   
 After 19 total days in culture, the rosettes are detached from the culture surface 
and gently dissociated with accutase. Dissociated striatal-like rosettes are re-plated in 
the presence of BDNF and GDNF as well as purmorphamine, valpromide, and FGF-8 to 
drive differentiation toward the striatal neuronal fate. The cells are maintained in culture 
for an additional 14 days to generate MSN-like neurons (Fig. 47). After 14 days, the cells 
express neuronal markers (MAP2 and Neurofiliment) and are GABA-ergic. Moreover, 
the neurons express the MSN-specific marker DARPP-32 (Fig. 47).   
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Figure 46. Characterization of striatal-like progenitors derived from WT and HD 
hiPSCs. In A, phase contrast images of neural rosette clusters from WT and HD striatal 
progenitors after 18 days of differentiation. In B, DNA gels using cDNA generated by RT-
PCR from WT or HD striatal progenitors indicate expression of neural-associated 
transcription factors (PAX6, NeuroD1, and FABP7) and transcription factors associated 
with the forebrain lineage (SOX1, DLX1, EMX1). Lack of RAX expression indicates 
divergence from the retinal fate. Expression of LMX1A and NR4A2 (Nurr1) indicate the 
potential for these progenitors to differentiate into dopaminergic neurons. In C, 
immunocytochemistry of striatal progenitors demonstrates the expression of neural-
associated markers SOX1 and OTX2 as well as Nestin, a marker of progenitor cells, and 
Ki-67, a proliferation marker. In D, proportion of WT and HD cells that stained positive for 
OTX2 and SOX1 (normalized to DAPI). Data are mean ± SEM.   
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Figure 47. Characterization of neurons derived from striatal-like progenitors from 
WT and HD hiPSCs. Following 14 days of directed neuronal differentiation, cells display 
typical neuronal morphologies under phase contrast microscopy and express the 
neuronal markers MAP2 and Neurofilament-L (Neurofil). Supplementation of the culture 
medium with purmorphamine, valpromide, and FGF-8 results in neurons that are GABA-
ergic, DARPP-32-positive and tyrosine hydroxylase (TH)-positive.  
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To verify the presence of the expanded CAG repeat sequence in cells from the 
iPSCs from human patients, we performed PCR to amplify the CAG repeat tract (Fig. 
48A). Progenitors derived from iPSCs from HD patients possessed one mutated allele 
with an expansion of 72 CAG repeats, as described previously (Park et al. 2008;Zhang 
et al. 2010;An et al. 2012). Since the patient from whom these cells were originally taken 
possessed a CAG expansion with 72 repeats in the mutated allele, this finding indicates 
that the CAG expansion has not spontaneously contracted or expanded, which has been 
previously suggested to occur (Duyao et al. 1993). To confirm the presence of mHtt in 
progenitor cell lysates derived from human HD iPSCs, we performed immunoblotting 
experiments using two different antibodies for total Htt and mHtt: monoclonal anti-Htt 
antibody 2166 (mAb 2166, Millipore), which recognizes both WT Htt and mHtt, and 
monoclonal anti-polyQ antibody 1C2 (mAb 1574, Millipore), which recognizes mHtt (Fig. 
48B). With mHtt-specific mAb 1C2, a 350 kDa band, representing mHtt, was detected in 
cell lysates from HD patient-derived cells, but not in cells from controls. Probing with 
anti-Htt mAb 2166, we detected a 350 kDa band, corresponding to WT Htt, in both WT 
and HD samples. In cell lysate from HD iPSCs, mAb 2166 detected an additional band 
with a slightly higher molecular weight that represents mHtt. In HD samples, the level of 
expression of Htt and mHtt was similar. 
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Figure 48. Genotypic analysis of CAG repeat expansion and expression of mHtt in 
progenitors derived from human HD iPSCs. In A, DNA gel displaying PCR 
amplification of the CAG trinucleotide repeat tract from WT and HD samples showing 
one allele with an expanded CAG stretch in DNA of progenitor cells derived from human 
HD iPSCs. In B, expression of mHtt was detected with anti-polyQ 1C2 antibody as a 
single band exclusively in samples from HD patients. Htt and mHtt were detected using 
western blotting with 2166 antibody, which recognizes both Htt and mHtt. In cell lysates 
from WT and HD progenitors, a 350 kDa band, belonging to WT Htt, was detected, 
whereas an additional, slightly heavier band representing mHtt was detected in 
progenitors differentiated from HD patient-derived iPSCs.     
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 Previous studies have indicated Ca2+ handling defects by mitochondria in 
cultured neurons from transgenic mouse models of HD. Fernandes et al. reported that 
Ca2+ influx into cells mediated by NMDA-subtype of ionotropic glutamate receptors 
resulted in augmented mitochondrial depolarization in MSNs from YAC128 mice and that 
withdrawal of NMDA resulted in reduced clearance of cytosolic Ca2+ (Fernandes et al. 
2007) . We assessed the vulnerability of human iPSC-derived striatal-like neurons from 
HD patient to excitotoxic insult by monitoring NMDA-induced changes in cytosolic Ca2+ 
concentration ([Ca2+]c) (Fig. 49). Cultured human neurons were loaded with the Ca2+-
sensitive dye, Fura-2FF-AM, and then recorded for 40 minutes in the presence of 100 
µM NMDA (plus 10 µM glycine). In human WT neurons, application of NMDA resulted in 
a brief spike in [Ca2+]c that returned to nearly baseline level within 3 minutes and 
remained stable for the duration of the experiment (Fig. 49A). Human HD neurons 
exposed to NMDA showed an initial increase in [Ca2+]c, but there was no return of [Ca2+]c 
to a basal level. After 20 minutes, human HD neurons underwent delayed Ca2+ 
dysregulation, indicated by sustained increase in [Ca2+]c (Fig. 49B).  
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Figure 49. Ca2+ dynamics in response to NMDA in striatal neurons derived from 
WT (blue trace) and HD (red trace) human iPSCs. Striatal neurons (14 DIV) were 
loaded with Ca2+-sensitive dye Fura-2FF-AM to monitor changes in cytosolic Ca2+ 
concentration ([Ca2+]c). Blue and red traces represent average [Ca2+]c  ± SEM from 
experiments with neurons derived from iPSCs from a healthy individual and HD patient, 
respectively (N = 20-25 neurons per experiment). Where indicated, 100 µM NMDA plus 
10 µM glycine was applied to neurons.  
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These results demonstrate our ability to direct the differentiation of human iPSCs 
derived from HD patients into both cortical and striatal neurons. Functional studies 
indicate that these striatal neurons are responsive to NMDA and that there may be some 
difference in Ca2+ signaling between human WT and HD neurons.  In future studies, 
human striatal neurons will be used to assess the effect of mHtt on their functions. 
Initially, mitochondrial functions of neurons from HD patients will be evaluated by 
analyzing their respiratory activity, glycolytic activity, and further evaluating mitochondrial 
Ca2+ handling functions. If, in experiments with cultured human neurons, we will find 
signs of mitochondrial dysfunction, then we will use mitochondria isolated from these 
cells to more stringently evaluate the mechanisms underlying mitochondrial dysfunction. 
Through the study of iPSC lines from HD patients, we may yet begin to answer the 
vexing questions that still pervade the field and potentially provide insights about 
mechanisms of pathology that could ultimately lead to the development of new 
therapeutics for HD that address underlying causes of the disease.      
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